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ABSTRACT
Adoptive cell transfer (ACT) immunotherapy using genetically modified antigen (Ag)specific T cells is a rapidly evolving field. Although evidence from pre-clinical and clinical
studies suggests the use of Ag-specific T cells can be effective treating different malignancies,
several challenges remain in order to improve these therapeutics. Host factors that can affect Agspecific T cells during ACT immunotherapy remain understudied. Evidence of this lack in
research includes characterizing the effects of sex and sex hormone receptor signaling on Agspecific T cell function. Males and females have great differences in their circulating T cell
populations and subset phenotypes. While some of these sex-differences in T cell phenotype are
genetically and environmentally mediated, many of these differences heighten or decrease with
puberty and reproductive senescence indicating a sex hormone receptor involvement. Estrogen
was shown to modulate the development and differentiation of T cells. The effect of estrogen on
T cell function remains controversial and incompletely understood. With most of the important
aspects concerning the role of estrogen on T cells previously investigated in autoimmunity
models and at hormone concentrations limited to physiological and pregnancy estrogen levels,
the role of estrogen signaling through its canonical receptors, estrogen receptor  and  (ER
and ER) at other ranges of estrogen dosage need to be investigated. Knowing that sex and
estrogen have direct effects on T cell differentiation and function, it is important to carefully
characterize their effects on Ag-specific T cells for immunotherapy in order to identify possible

xx

mechanisms that can be targeted to enhance T cell anti-tumor immune responses and
immunotherapy efficacy.
The effects of sex and estrogen signaling on T cells and other immune cells result in
differences on pathogenesis of malignancies including hepatocellular carcinoma (HCC). HCC is
significantly more prevalent in males and post-menopausal females not undergoing estrogen
hormone replacement therapy compared to pre-menopausal females, demonstrating a protective
role of estrogen against HCC. The role of estrogen signaling was investigated in transformed
hepatocytes and infiltrating innate immune cells but was not reported in tumor infiltrating T
cells. ACT immunotherapy using genetically modified T cells showed some success on treating
HCC in pre-clinical and clinical studies but the efficacy of ACT fighting HCC remains
unsatisfactory. In this study, it was hypothesized that the protective role of estrogen against HCC
is partially due to the estrogen-mediated enhancement of the T cell anti-tumor immune
responses. Thus, if the T cell anti-tumor immune response is enhanced by estrogen, then estrogen
signaling can be used to increase the efficacy of adoptive T cell transfer immunotherapy.
The work performed in this dissertation was aimed to characterize the role of estrogen
signaling on T cell function in vitro, and during ACT immunotherapy against HCC in vivo.
Using human male and female Ag-specific T cells, the effect of estrogen receptor signaling on
overall T cell function and anti-tumor immunity was determined. Estrogen signaling through
ER was shown to enhance the expression and secretion of Type I effector cytokines including
interferon  (IFN), tumor necrosis factor  (TNF), and Granzyme B in male and female Agspecific T cells activated with their cognate tumor Ag. Estrogen signaling through ER was also
shown to modulate the overall expression of the Type 2 cytokine interleukin 4 (IL-4) in male and
xxi

female Ag-specific T cells. These results indicated that estrogen signaling through ER mediates
the balance between Type I and Type II Ag-specific T cell responses. Estrogen signaling through
ER enhanced the polyfunctionality, or the ability of a T cell to express several markers
simultaneously upon activation, of male and female Ag-specific T cells activated with their
cognate Ag. T cell polyfunctionality is correlated with enhanced T cell receptor (TCR) signaling,
indicating that estrogen signaling through ER enhances TCR downstream signaling pathways.
These results demonstrated for the first time that estrogen signaling through ER and ER can
enhance the function of human Ag-specific T cells. Using an HCC mouse model treated using
ACT immunotherapy, the effect of estrogen on the Ag-specific T cell anti-tumor immune
response was measured. The presence of estrogen resulted in reduced tumor burden through
higher Ag-specific T cell tumor infiltration, survival, activation state, and cytokine expression.
Removal of physiological estrogen during ACT immunotherapy reduced the survival of CD4+
Ag-specific T cells resulting in reduced tumor infiltration. Lack of physiological estrogen during
ACT also caused hindered cytokine production and polyfunctionality of CD4+ Ag-specific T
cells. These results revealed for the first time that estrogen signaling can enhance the survival
and function of CD4+ Ag-specific T cells which results in enhanced anti-tumor responses and
reduced tumor burden.
In summary, estrogen signaling enhances male and female Ag-specific T cell cytokine
expression and secretion, and polyfunctionality which lead to enhanced tumor infiltration,
survival, activation state, and function during ACT immunotherapy. This indicates that inducing
estrogen signaling on Ag-specific T cells can enhance the efficacy and therapeutic outcome of
ACT immunotherapy.
xxii

CHAPTER I
LITERATURE REVIEW
Immunotherapy
The immune system has the ability to recognize and destroy tumor cells without affecting
normal cells through a mechanism called immune surveillance, and thus functions as a primary
anti-cancer defense mechanism [1]. The immune system can also prevent cancer through
generating long-term memory T cell responses [1]. Immunotherapy involves the enhancement of
immune responses in cancer patients to increase tumor recognition and initiation of anti-tumor
responses [2]. Because of the success obtained in recent years treating specific cancers with this
therapeutic approach, immunotherapy has become the fourth pillar of cancer treatment together
with surgery, radiation, and traditional chemotherapy. Most clinically approved immunotherapies
have T cells central to their mechanism and fall broadly into two categories: first, agents that
directly target and modulate endogenous T cell responses; and, second, cellular therapies where
genetically modified T cells are used as treatment. T cells are immune cells that can be activated
by tumor antigens, they can specifically destroy tumor cells in response to tumor antigen
stimulation, and further generate memory responses that last long periods of time. While
immunotherapy enhances the anti-tumor immune response, tumors can avoid it and still develop
in the presence of an active immune system through a mechanism called immune tolerance.
Therefore, the focus of ongoing immunotherapy research is on not only the recognition and
destruction of specific tumor cells but also toward overcoming immune tolerance posed by the
1

2

tumor microenvironment (TME), and finally in discovering new host pathways that can be
targeted to enhance its efficacy. The work performed in this dissertation was aimed at identifying
novel roles of host factors present in the TME, like the sex hormone estrogen, that can be
modulated in order to enhance T cell-based immunotherapy. In the upcoming paragraphs, T cell
function and subsets are described as well as the different current types of T cell-based
immunotherapies and the challenges that immunotherapy is faced with in the clinic.
T cell Signaling and Function
T cells play a central role in mediating cellular immunity. T cells are multi-functional
effector cells that protect humans from disease throughout their entire lives with their ability to
recognize bacterial, viral, and cancer antigens. The specificity of T cells is mediated by the T cell
receptor (TCR), a surface receptor that facilitates target antigen recognition in the context of a
major histocompatibility complex (MHC) molecule. Cell surface expression of the TCR requires
its association with the CD3 complex (Figure 1) [3]. The CD4 and CD8 co-receptors enhance the
binding of the TCR to MHC class II and I respectively and promote downstream signaling by
localizing the lymphocyte-specific protein tyrosine kinase (lck) to the TCR/CD3 complex
(Figure 1) [3, 4]. Upon recognition and binding to the antigen-bearing MHC, a signaling cascade
begins downstream from the TCR consisting on phosphorylation of immunoreceptor tyrosinebased activation motifs (ITAMs) by lck in the CD3 chain and recruitment of -chain associated
protein (Zap70), which induces assembly of the remaining signaling components (Figure 1) [5].
Several signaling pathways are triggered downstream from the TCR including the activation of
phospholipase C  (PLC) which hydrolyzes membrane-bound phosphatidylinositol 4, 5biphosphate (PIP2) into inositol-3-phosphate (IP3) and diacylglycerol (DAG). IP3 triggers the

3

activation of the calcium (Ca+2)-dependent nuclear factor of activated T cells (NFAT) signaling
pathway [6]. DAG activates several major signaling pathways including the mitogen activated
kinase (MAP kinase) pathway, and the nuclear factor kappa-light-chain-enhancer of activated B
cells (NFB) pathway induced by protein kinase C (PKC) activation [6]. Activation of these
signaling pathways induce intracellular Ca2+ release, actin polymerization, integrin activation, T
cell proliferation, cytokine secretion, and degranulation [7]. This T cell functional response
varies depending on the subset of activated T cell. Naïve T cells can differentiate into various
subsets depending on the activating stimulus and the cocktail of cytokines present during Ag
recognition [8, 9]. T cell subsets are identified by cell surface markers, transcription factors
expression, and cytokines secreted.
A well characterized example of T cell subsets being distinguished by cytokine secretion
and transcription factor expression is the Th1 and Th2 CD4+ helper T cell subsets. Th1 CD4+ T
cells express the transcription factor T-Bet and secrete mainly interferon  (IFN), interleukin-2
(IL-2), and tumor necrosis factor  (TNF) upon activation [9]. Th1 mediate pro-inflammatory
cell mediated immunity and were shown to induce delayed-type hypersensitivity and mediate the
response to some protozoa. On the other hand, Th2 CD4 + T cells express the transcription factor
GATA3 and secrete mainly IL-4, -5, -6, -10, and -13 [9]. Th2 cells promote non-inflammatory
immediate immune responses and are essential in B cell production of immunoglobulin G (IgG),
IgA, and IgE [9]. Th1 and Th2 development routes are mutually antagonistic, giving rise to the
model of polarization of the T cell immune response. Other CD4 + helper T cells subsets that
differentiate based on transcription factor expression and cytokine production are the Th17
subset which expresses RORt and produces IL-17a and IL-22, the regulatory T cells (Tregs)
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subset which expresses forkhead box P3 (FoxP3) and secretes IL-10 and transforming growth
factor  (TGF), and the Th9 subset which produces IL-9 [9].

Figure 1. T Cell Receptor (TCR) Mediated Target Recognition and T Cell Activation. Depicted
is a target cell, such as a tumor cell, presenting an antigen in the context of the MHC to a T cell’s
TCR. The TCR  and  chains form a complex with CD3 components and the CD8 or CD4 coreceptors stabilize the TCR-MHC interaction. Upon antigen recognition and TCR ligation, Lck
phosphorylates the ITAMs on the CD3 chains which recruit Zap70 which facilitates TCR
downstream signaling which results in T cell activation. MHC: major histocompatibility complex,
Lck: lymphocyte-specific protein tyrosine kinase, ITAM: immunoreceptor tyrosine-based activation
motif, Zap70: -chain associated protein.
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CD8+ cytotoxic T lymphocytes (CTLs) are derived from naïve CD8+ T cells, proliferate
in the presence of IL-2, and can expand their number by a thousand-fold upon activation at the
peak of a primary immune response [9]. Rapid expansion and the ability of CD8+ CTLs to
destroy more than one target while sparing bystander cells, make CTLs very efficient Agspecific effector cells [9]. Destruction of target cells by CTLs requires Ag recognition which
initiates the release of cytotoxic granules such as perforin and Granzyme B into the
immunological synapse between CTL and target cells, or the initiation of Fas/Fas-ligandmediated apoptosis. Similarly to CD4+ T cells, cytotoxic CD8+ effector T cells fall into two
subpopulations based on cytokine secretion. Type I CD8+ T cells secrete IFN, whereas Type II
CD8+ T cells secrete IL-4, IL-5, and IL-10 [10]. Both Type I and Type II CD8+ T cells were
shown to provide strong immunity against tumors and differentiate into CD8 + memory T cells.
Long-lasting protection by Type I and Type II CD8+ effector cells was dependent on IL-4, IL-2,
and INF production indicating both subsets are required for the generation of superior antitumor responses [10]. Overall, the immunology field generally accepts that T cells are
functionally restricted by the subset into which they differentiate, each CD4+ and CD8+ T cell
subset has different functions based on the cytokines and factors they secrete upon TCR
activation [9].
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Types of Immunotherapy
Immune Checkpoint Blockade
Upon Ag encounter, to ensure robust T cell activation, two independent signaling
pathways are involved. The first signal requires recognition of the Ag-bearing MHC on the
surface of antigen presenting cells (APCs) or tumor cells by the corresponding TCR. The second
signal, which is Ag independent, is delivered by the engagement of co-stimulatory molecules
[11, 12]. Positive co-stimulation is mainly mediated by CD28 receptors expressed on T cells
binding to B7.1 (CD80) and B7.2 (CD86) on APCs [13]. This interaction leads to a cascade of
intracellular signal transducers and regulators, and results in T cell activation and proliferation,
as well as the production of various cytokines, including IL-2, thus avoiding anergy [11, 14].
CD4+ and CD8+ T cells have severely impaired proliferation and produce reduced levels of
effector cytokines in the absence of CD28 [15, 16]. T cells can also express several inhibitory costimulatory factors, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and
programmed cell death protein-1 (PD-1) which are denominated immune checkpoints. Binding
of these negative co-stimulatory factors to their ligands antagonizes T cell activation. T cell
immunosppression by immune checkpoints is relevant in order to avoid T cell responses against
self Ag which can promote autoimmunity. In the TME, the expression of immune checkpoints by
TILs results in T cell hyporesponsiveness and immune exhaustion contributing to tumor immune
scape. Blocking the interactions of TIL inhibitory co-stimulatory molecules results in sustained
activation of the anti-tumor immune response thereby making checkpoint blockade an
efficacious immunotherapy.
Activated T cells express CTLA-4 which binds to ligands B7.1 (CD80) and B7.2 (CD86)
with much higher affinity than CD28 [17]. Binding of CTLA-4 to B7.1 or -2 induces powerful
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inhibitory signaling that dampens T cell activation, leading to decreased cell cycle progression,
proliferation, and IL-2 secretion [17]. CTLA-4 inhibition with monoclonal antibodies prevents
the binding of CTLA-4 to B7.1, 2, thereby promoting T cell activation and successful anti-tumor
immune responses. Several CTLA-4 blocking monoclonal antibodies such as Ipilimumab and
Tremelimumab were approved by the Food and Drug Administration (FDA) to treat melanoma.
Although CTLA-4 blockade was successful for some patients, the objective response rates
(ORR) for stage III or IV melanoma patients treated with Ipilimumab was 15-20%, and only
11% for those treated with Tremelimumab [18-21]. Progression free survival rates (SR) for
melanoma patients treated with CTLA-4 inhibitors were around 2.8 months.
The surface receptor PD-1, which is homologous to CD28, is also expressed in activated
T cells and it is primarily involved in inhibitory immune signaling. PD-1 binds to the
programmed cell death ligand 1 (PD-L1) and elicits intracellular signaling that results on the
dephosphorylation of TCR proximal components such as CD28 [22-24]. Interfering with CD28
signaling, PD-1 signaling therefore results in reduced cytokine production, reduced T cell
proliferation and survival, and reduced expression of T cell effector functions such as T-Bet and
Eomes [23-25]. PD-L1 expression is observed in both cancer cells and tumor-infiltrating immune
cells such as macrophages. PD-L1 expression on the cells present in the TME is upregulated in
response to IFN signaling [26]. PD-L1 expression therefore indicates an active anti-tumor
immune response and it is a way for the tumor cells to escape it through immunosuppression.
Blockade of PD-1 and PD-L1 using monoclonal antibodies was approved by the FDA as a
therapy for cancers including melanoma, renal cell carcinoma, squamous cell carcinoma, and
non-small cell lung cancer (NSCLC). PD-1 inhibitors such as Nivolumab and Pembrolizumab
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showed encouraging ORR of over 40% on stage III or IV melanoma patients with progression
free survival rates of over 7 months [18, 21]. PD-1 inhibitors were also used to treat NSCLC
(ORR of 20% and SR of 3 months), renal carcinoma (ORR of 25% and SR of 5 months),
Hodgkin’s lymphoma (ORR of 87%), ovarian cancer (ORR of 15% and SR of 4 months), and
metastatic colorectal cancer (ORR of 40% and SR of 5 months) [27-31]. PD-L1 inhibitor
Atezolizumab was found to be successful in solid tumors with ORR of 16% and 23% in NSCLC
and urothelial carcinoma respectively [32, 33]. Better outcome was observed when both
Nivolumab and Ipilimumab were used to treat stage III and IV melanoma (ORR of 57% and SR
of over 11 months) indicating that blocking both PD-1 and CTLA-4 simultaneously can induce
stronger anti-tumor immune responses [21, 34].
Immune checkpoint blockade treatment proves to be initially effective but unfortunately
many patients eventually relapse. Due to the selection pressure caused by checkpoint blockade
monoclonal antibody therapy, resistant tumor cells can arise. These checkpoint blockade
immunotherapy resistant tumor cells upregulate or downregulate pathways that allow them to
evade immune recognition and T cell anti-tumor immune responses. Tumor cells from relapsing
anti-PD-1 treated patients were shown to downregulate IFN response elements including MHC
class I through deactivating mutations to avoid T cell recognition [35]. Also, immune cells in
anti-PD-1 treated melanoma or prostate cancer patients exhibited upregulation of other immune
checkpoints like TIM-3 [36]. Tumor-associated macrophages (TAMs) present in the TME of
relapsing patients were shown to be able to phagocytize the therapeutic monoclonal antibody
bound to the surface of T cells, rendering them again susceptible to PD-1 inhibitory signaling
[37]. A better understanding of these immune escape mechanisms in the TME limiting the
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effectiveness of immune checkpoint blockade immunotherapy will therefore allow for
improvement of cancer treatment.
Adoptive T cell Transfer Immunotherapy
Adoptive T cell therapy (ACT) consists on generating robust T cell anti-tumor immune
responses by the ex vivo manipulation of patients’ endogenous T cells. ACT has multiple
advantages compared to other forms of immunotherapy that rely on generating enough numbers
of functionally active and tumor reactive T cells in vivo. For use in ACT, large numbers of antitumor T cells can be readily generated and selected for high-avidity recognition of the tumor, as
well as for the effector functions required to mediate tumor destruction. In addition, these antitumor T cells are generated from the patient’s own circulating T cells so there is no risk of graftversus-host disease. The first type of ACT was generated by isolating autologous Ag-specific
tumor infiltrating lymphocytes (TILs) from resected melanomas [38]. Melanoma Ag-specific
TILs were expanded in vitro and transferred into the patient in combination with IL-2 to enhance
T cell activation and function. Using TILs for ACT immunotherapy, the ORR of metastatic
melanoma patients reached 50% and durable remissions were achieved [38-41]. Even if TILs can
be grown in vitro from many tumor types, only melanomas consistently give rise to TILs with
effective tumor reactivity [42]. In order to develop ACT for other tumor types, techniques were
developed to genetically introduce anti-tumor receptors into normal T cells that could be used for
therapy. The specificity of T cells can be redirected by the integration of genes encoding either
conventional  TCRs or CARs.
The first successful clinical application of ACT using genetically engineered T cells
treated melanoma patients using autologous T cells transduced with a human TCR recognizing
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the MART-1 melanoma-melanocyte differentiation antigen [43]. These initial studies
demonstrated that TCR gene-modified T cells were generally tolerated by patients and safe to
use as cancer therapeutics. Then, this approach was expanded to larger metastatic melanoma
patient numbers who received T cells modified with high-avidity TCRs recognizing MART-1
(ORR of 30%) and gp100 (ORR of 19%) [44]. Even if this treatment was efficacious it showed
severe off-tumor on-target toxicity in the skin, eyes and ears due to melanocyte presence in these
organs. Fortunately, in this case such toxicities resolved naturally or with administration of
topical steroids. These earliest studies suggested TCR gene-modified T cells could reach clinical
benefit, but that the choice of TCR was important in order to limit toxicities. Since the early
studies, numerous TCR genes capable of recognizing tumor antigens were identified, and
improvements in TCR gene transfer have allowed for recognition of a variety of other antigens
and malignancies. These include, but are not limited to, carcinoembryonic antigen (CEA)
expressed in epithelial cancers like colorectal cancer [45], cancer-testis antigens such as NYESO-1 and MAGE expressed in breast, bladder, colon, lung, ovarian, thyroid cancers and
myeloma [46-48], and viral proteins expressed in cancers derived from viral infections. The use
of these TCR engineered T cells to treat patients showed some limitations especially regarding
severe side effects. Colorectal cancer patients treated with CEA-specific T cells experienced life
threatening colitis and colonic hemorrhage which prevented further use of this TCR even if
partial response on liver metastases was achieved [45]. Unexpected brain toxicity and gray
matter destruction were observed when using MAGE-specific T cells to treat melanoma patients
[43]. TCR engineered T cells that are specific for viral proteins include targets such as
cytomegalovirus (CMV) [49], human immunodeficiency virus (HIV) [50], hepatitis C virus
(HCV) [51, 52], and human papilloma virus (HPV) [53]. No clinical reports have yet been
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published testing virus-specific TCR expressing T cells in humans, however this is a good
approach to avoid off-tumor on-target effects since viral proteins are not expressed by noninfected human tissues.
Chimeric antigen receptors (CARs) are assembled by linking the variable regions of the
antibody heavy and light chains, specifically reactive to a tumor antigen, to intracellular
signaling molecules such as CD3 CARs often include the sequences of co-stimulatory domains
including but not limited to CD28 or CD137 (4-1BB) in order to fully activate T cells [54-56].
The antibody part of the CAR is specific for an antigen expressed in the tumor providing nonMHC-restricted recognition of cell surface components. CARs can be introduced into T cells
with high efficiency using viral vectors [42]. Tumor antigens that are shared with nonessential
organs represent potential targets for ACT immunotherapy. A prominent example is the
molecule CD19 expressed in more than 90% of B cell malignancies and differentiating B cells
excluding plasma cells. Administration of autologous T cells expressing the anti-CD19 CAR to
patients with follicular lymphoma, large-cell lymphomas, chronic lymphocytic leukemia, and
acute lymphocytic leukemia was shown to successfully reject the tumors with ORRs from 80 to
100% [55, 57-59]. Anti-CD19 CAR ACT immunotherapy not only elicits dramatic regression of
lymphomas and leukemia but also provides patients lifelong protection since CAR T cells can
become memory T cells detectable on circulation years after ACT [60]. Due to its success, antiCD19 CAR T cell immunotherapy was approved by the FDA to treat B cell lymphoblastic
leukemia and certain types of non-Hodgkin’s lymphoma in 2017. A wide variety of other CARs
were designed to target several antigens showing promise as potential cancer immunotherapies.
Other targets that were pre-clinically evaluated include but are not limited to CD33 and CD123
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for myeloid leukemia [61, 62], GD2 for neuroblastoma (ORR of 27%) [63], HER-2 and MUC-1
for breast cancer [64, 65], and MUC16 for ovarian cancer [66].
There are some limitations using CAR T cells for immunotherapy. For example, CARs
target surface antigens, rendering them ineffective against intracellular antigens that would
otherwise be processed and presented by MHC. A search for tumor-specific surface antigens
expressed on tissues that are not essential for survival remains in progress. Also, the antibodyantigen interaction is much stronger than the TCR-antigen interaction which negatively impacts
T cell function since T cells are more likely to undergo activation induced cell death (AICD) [67,
68]. Also, there were several reports of adverse events after CAR T cell immunotherapy due to
tumor lysis syndrome and cytokine storm which are deadly side effects resulting from massive T
cell activation, cytokine production, and tumor cell killing [69-71].
An important question concerning the use of genetically engineered cells for the
treatment of cancer involves selection of the ideal T cell population unto which the gene should
be introduced. T cells can be categorized into distinct memory subsets based on their
differentiation states. CD8+ T cells follow a progressive pathway of differentiation from naïve T
cells into central memory and effector memory T cell populations [72]. Preclinical studies
strongly suggest that improved anti-tumor responses are seen when T cells in early stages of
differentiation (such as naïve or central memory cells) are transduced, a result supported by
studies in monkeys showing improved in vivo persistence of infused central memory compared
with effector memory cells [73, 74]. Also, the differentiation state of CD8+ T cells is inversely
correlated with their ability to undergo homeostatic proliferation. Homeostatic proliferation of
adoptively transferred cells and the presence of homeostatic cytokines such as IL-7 and IL-15

13

were shown to increase ACT efficacy [75, 76]. Adoptively transferred younger CD8+ T cells
need to get activated upon antigen stimulation, lyse the tumor target cells by secreting factors
like Granzyme, and secrete cytokines such as IFN and TNF [77]. CD4+ T cells are also critical
for tumor rejection and success of immunotherapy. Adoptively transferred CD4 + T cells were
shown to be required for supporting the CD8+ cytotoxic anti-tumor response [78-80]. CD4+ T
cells do not merely enhance CD8+ T cell function, but they also play a more direct role in tumor
elimination during immunotherapy [81]. The roles that CD4+ T cells play in the antitumor
immune response depend on their polarization, which is determined by their expression of key
transcription factors. Adoptively transferred Th1, Th2 and Th17 CD4 + T cells can directly clear
the tumor and promote long-lived antitumor immunity [82-85]. On the other hand, Tregs are
immunosuppressive and were shown to inhibit T cell anti-tumor responses and promote immune
escape [86, 87]. Overall, in order to achieve ACT immunotherapy success, not fully
differentiated cytotoxic CD8+ and CD4+ T cells need to be genetically modified to recognize a
suitable tumor antigen that is not expressed in an essential organ.
Immune Escape
Once adoptively transferred T cells reach the tumor, the major challenge they face is to
overcome the multiple mechanisms the tumor can elicit to avoid immune-mediated elimination.
The ability of T cells to recognize and destroy tumors relies on the antigenicity of tumor cells.
Tumors can express a variety of mutated and endogenous antigens that can be recognized by T
cells. However, to avoid anti-tumor responses the tumor cells can lose antigenicity [88]. Cancer
cells can lose antigenicity due to lack or mutation of tumor antigens, as well as through the
acquirement of defects and deficiencies in antigen presentation [89]. Downregulation of the cell
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surface expression of MHC class I molecules was found in approximately 20% to 60% of solid
tumors, including melanoma, lung, breast, renal, prostate, and bladder cancer [90, 91]. Tumors
can not only lose antigenicity but also immunogenicity in order to escape immune responses.
IFN produced by TILs can induce the upregulation of immunoinhibitory molecules on
malignant cells, surrounding stromal cells, and other immunosuppressive infiltrating immune
cells [36, 92]. Some of this immunoinhibitory molecules include but are not limited to ligands of
the PD-1, CTLA-4, LAG-3, TIM-3, and VISTA inhibitory receptors [93]. As described before,
these inhibitory pathways alter the balance between activation and inhibitory signals received by
T cells and lead to dampened antitumor T cell responses. In addition to these mechanisms, tumor
cells can also metabolically restrict T cell function via glucose and oxygen restriction. High
glucose intake by tumor cells creates a hypoglycemic TME and dampen TIL mTOR activity,
glycolytic capacity, and IFN production [94]. Solid tumors have large hypoxic areas which can
also interfere with immunity and cause T cell dysfunction [95, 96].
Non-neoplastic infiltrating cells can contribute to tumor progression and metastasis by
hindering the anti-tumor function of T cells and other immune cells. Tregs are immunosuppressive
CD4+ T cells that contribute to tumor immune evasion by secreting TGF and IL-10 which are
cytokines that help create an immunosuppressive environment that blunts the anti-tumor
functions of CD4+ and CD8+ effector T cells, and NK cells [97, 98]. Tregs also express an IL-2
receptor that has 100-fold higher affinity for IL-2 than the receptor form expressed in effector T
cells resulting in Tregs acting as competitive sinks for IL-2 in the TME [99]. In addition, Tregs can
secrete copious levels of the nucleoside adenosine [100]. Adenosine binds to its receptor (A2AR)
in effector T cells and downregulates the intracellular levels of 3’, 5’-cyclic AMP which result in
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T cells function inhibition and subsequent immunosuppression [101, 102]. In addition, the
adenosine pathways promotes further polarization, proliferation and expansion of T regs and
myeloid derived suppressor cells (MDSCs) [103]. MDSCs are myeloid cells found in the TME
that can also mediate immune escape through several mechanisms. MDSCs express high levels
of nitric oxide synthase arginase 1 which results in the metabolism of arginine and the
production of nitric oxide (NO) [104, 105]. The depletion of arginine from the TME impairs the
local proliferative capacity of T cells. NO has a direct suppressive role on effector T cells by the
induction of apoptosis, inhibition of STAT5 signaling, and formation of peroxynitrite, a potent
oxidant of amino acids that are essential for T cell function [104, 105]. Other mechanisms of
MDSC-mediated immune suppression include the sequestration of cysteine leading to the limited
availability of this essential amino acid for T cells [106], the secretion of suppressive cytokines
including IL-10 [107], and the overproduction of reactive oxygen species [108]. Other myeloid
cells with immunosuppressive abilities that play a role in immune escape are TAMS and tumor
associated dendritic cells (TADCs). TAMs produce lower levels of proinflammatory cytokines,
such as IL-1, TNF, and IL-12, and higher levels of immunosuppressive mediators IL-10,
TGF, and vascular endothelial growth factor (VEGF) indicating that TAMs not only suppress T
cell function but promote tumor angiogenesis [109]. TAMs are also stunted in their ability to
mediate direct lysis of malignant cells. TADCs express no or low levels of costimulatory
molecules CD40, CD80, and CD86, and express indoleamine 2, 3-dioxygenase, an enzyme that
degrades the essential amino acid tryptophan that leads to the suppression of T cell functions
[110, 111]. TADCs also possess defects in the machinery to effectively present antigen to T cells
and downregulate MHC class I and II molecules in addition to other proteins important for this
process like transporter associated with antigen processing (TAP) [112].
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Overall, tumors are complex structures composed of both malignant and nonmalignant
cells that support cancer growth and prevent immune destruction. The understanding of the
cellular constituents of the tumor microenvironment has helped guide the design of powerful T
cell therapies that can cause the regression of large tumor burdens. Finding appropriate tumor
antigens, overcoming the immunosuppressive and immunotolerant tumor microenvironment, and
reducing are major obstacles being investigated today in order to improve the efficacy of cancer
immunotherapy.
Sexual Dimorphism in Immune Responses: The role of Estrogen
Other examples of host specific factors that can affect the efficacy of immunotherapy are
the patient’s age, sex, and reproductive stage in life. While the lethal side-effects of
immunotherapy are markedly exacerbated with aging [113, 114], age was shown to not
significantly affect the outcome or clinical efficacy of checkpoint blockade immunotherapy
[115]. Elucidating the effect of patient’s sex on the outcome and efficacy of immunotherapy was
proven to be controversial and there are very few studies investigating this. Meta-analysis of
checkpoint blockade immunotherapy treated melanoma and NSCLC patients showed that men
had overall better survival rates than women indicating a sex-difference in immunotherapy
efficacy [116]. This conclusion cannot be generalized to all patient populations since other group
found no sex-effect on the efficacy of Nivolumab in melanoma patients [117]. On the other hand,
a preclinical model of melanoma treated with checkpoint blockade immunotherapy showed
increased tumor rejection and overall survival in females compared to males [118]. This was
found to be through mechanisms involving estrogen signaling in Tregs and Ag-specific CTLs
[118]. While all these studies investigated the role of sex in checkpoint blockade
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immunotherapy, there are no reports on the effect of sex and hormone signaling on ACT
immunotherapy due to the lack of adequate sample size and statistical power. It is well known,
though, that there are marked physiological differences in T cell immunological responses and
tumor incidence between males and females [119-122]. While some of these sex-specific tumor
and immunological differences are genetically and environmentally mediated, many of them
accentuate with puberty and reproductive senescence indicating an involvement of sex
hormones, androgen and estrogen. This indicates that sex and sex hormone signaling could be an
important factor to consider in order to improve efficacy of anticancer immunotherapies and
further research in this field is highly necessary. In this dissertation, the role of sex and estrogen
receptor signaling on Ag-specific T cells for ACT immunotherapy is studied utilizing novel
approaches to characterize the role of estrogen receptor signaling on T cell cytokine production
and anti-tumor function.
Circulating estrogen is present physiologically in females, and in lower concentrations in
males. Additionally, adult women are exposed to exogenous estrogen in therapeutic forms as oral
contraceptives and hormone replacement therapy (HRT). The next sections focus on describing
the signaling and downstream effects of physiological estrogen (17-estradiol or E2), which is
the most common form of active estrogen in the body, and the principal hormone employed in
the studies for this dissertation. Then, the effect of estrogen signaling on main immune cell types
which account for the observed sex-specific differences in immunity is described as well.
Sources of Estrogen
Physiologically available estrogens are predominantly produced in the ovaries, the corpus
luteum and the placenta [123]. There are three major forms of physiological estrogens in
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females, estrone (E1), estradiol (E2 or 17-estradiol), and estriol (E3), and they are all
synthesized from cholesterol by a series of reactions called estrogen biosynthesis [123]. E2 is the
major estrogen biosynthesis product and plays a major role during women’s pre-menopausal
period. In the ovaries, E2 is synthesized in theca and granulosa cells. The luteinizing hormone
(LH) stimulates cholesterol uptake by theca cells where it is converted into progesterone and
later into androstenedione [124, 125]. In response to LH, androstenedione is then diffused into
granulosa cells. Follicle-stimulating hormone (FSH) stimulates the enzyme aromatase in
granulosa cells to convert androstenedione into testosterone and testosterone into E2 by
aromatization of the A-rings of androgens [125]. Then, E2 is released into general circulation
and targets distal estrogen-responsive tissues including reproductive and non-reproductive
organs [123]. Circulating E2 reaches highest concentrations immediately before ovulation.
During the follicular phase, pre-ovulatory phase, and luteal phase serum E2 concentrations are
50-140 pg/mL, 110-410 pg/mL, and 50-160 pg/mL respectively (ranging from 0.5-1 nmol/L or
nM) [124]. During the menopausal transition, serum estrogen concentrations decrease by 8590% [123]. Circulating E2 concentrations in menopausal women and men are below 35 pg/mL
(under 0.1 nmol/L or nM) [124]. E1 can also be synthesized in the ovaries but plays a major role
after menopause when it is synthesized by adipose tissue [123]. E3 is the least potent form of
estrogen and it is synthesized in the placenta from E1 hydroxylation during pregnancy [123].
In addition to the ovary, extra gonadal estrogen biosynthesis takes place in astrocytes in
the hypothalamus and hippocampus regions of the brain, in stromal cells and adipocytes in the
breast, in osteoblasts and chondrocytes of the bone, in adrenocortical cells of the adrenal glands,
in skin fibroblasts and in hepatocytes [126]. These peripheral sites biosynthesize estrogen which
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tends to act locally at high concentrations, and which signaling is especially important in
menopausal women and men [127]. High concentrations of locally produced estrogen can also be
found in the TME of some cancers including breast cancer and hepatocellular carcinoma (HCC).
These high estrogen concentrations found in the TME are partially due to aromatase expression
dysregulation in tumor and stromal cells [128, 129]. Overexpression of aromatase in breast
cancer was found in tumor, stromal and parenchymal cells and it was upregulated by factors
including inflammatory cytokines and secreted factors like prostaglandins [130, 131]. Elevated
aromatase expression was detected in cirrhotic and malignant HCC tissue [128, 132-134]. This
elevated aromatase expression results on high local estrogen concentrations in the liver. In
addition, estrogen metabolism is abnormal in patients with cirrhosis and HCC which show
decreased conversion of E2 into E1 and E3 via hydroxylation, and subsequent accumulation of
E2 in the liver or tumor tissue [135, 136].
Estrogen Receptors (ERs)
Estrogen exerts its physiological functions on target tissues through ER-dependent and
ER-independent mechanisms [137]. Estrogen can bind three specific but distinct receptors
including the nuclear receptors estrogen receptor alpha and beta (ER and ER) and the Gprotein coupled estrogen receptor (GPER). ER and ER are ligand activated transcription
factors which are located intracellularly and to some degree on the cell membrane [138]. Apart
from the gonads, each ER is differentially expressed in various tissues. ER is expressed in high
concentrations in the mammary glands, the pituitary, the kidney, the epididymis, the liver, bone
and the adrenal gland but it has very low or undetectable expression in the prostate, the pineal
gland, the thyroid gland, the urinary tract, and erythroid tissue [126, 139]. ER is expressed

20

predominantly in the prostate, the lungs, the bladder, and the hypothalamus [139, 140]. GPER is
ubiquitously expressed in the membrane of cells throughout the body including the heart, brain,
pancreas, skeletal muscle, kidney, vessels, and reproductive organs [141].
Structure of Estrogen Receptors
ER and ER belong to the steroid nuclear receptor family, which is composed of
proteins with four independent but interacting protein domains [142]. The A/B domain in the
amino (NH2) terminal, the C or DNA-binding domain, the D domain which is a hinge region, and
the E/F or the ligand binding domain in the carboxyl (COOH) terminal [143, 144] (Figure 2).
The NH2 terminal domain encodes a ligand-independent activation function (AF-1) which is a
region of the receptor involved in protein-protein interactions with other transcription factors and
co-activators of target-gene expression [144]. In ER this region was shown to be very active in
stimulating target-gene expression, and AF-1 was shown to be active even in the absence of
estrogen ligand [145]. In ER the activity of AF-1 is negligible and most of the protein-protein
interactions happen through AF-2 found in the ligand binding domain (LBD) (Figure 2) [146].
The DNA binding domain (DBD) is 97% homologous between ER and ER and contains a
zinc finger structure necessary for receptor dimerization and binding of the receptors to specific
DNA sequences denominated estrogen response elements (EREs) [144, 147]. The hinge region
contains the nuclear localization signal and links the C domain to the multi-functional COOHterminus E/F domain [142] (Figure 2). The hormone dependent AF-2 region in the E/F LBD is
important in estrogen ligand binding dependent transcriptional activity and co-activator proteinprotein interactions [148]. Besides ligand binding, the E/F region is necessary for nuclear
translocation, heat shock proteins interactions, and transactivation of target gene expression
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[144]. Heat shock protein such as Hsp90 act as ER chaperones in the absence of ligands, binding
to unliganded ERs and maintaining the receptors in an inactive yet functional state [149]. The
LBD of ER and ER are highly homologous in both primary amino acid sequence and tertiary
structure which results in similar affinity of both receptors for E2 and other antagonistic and
agonistic compounds [139, 150] (Figure 2).

Figure 2. Structure of Estrogen Receptor  and  and Percent Homology between Them.
Estrogen receptor  and  (ER and ) are nuclear receptors that can act as transcription factors
upon ligand binding. ER and  are highly homologous and contain four different functional
domains: the A/B domain in the amino (NH2) terminus which contains the AF-1, the C or DNAbinding domain, the D domain or hinge region, and the E/F carboxyl (COOH) terminus domain
which contains the ligand binding domain and the AF-2 important for receptor dimerization.
AF: activating function.

GPER is a membrane bound G s-protein coupled receptor. GPER associates with a
Gs/G complex in its inactive state. Upon estrogen ligand binding and GPER activation, Gs
and G quickly dissociate from GPER. Gs and G can then activate several signaling
pathways some of them which result in gene expression regulation [151]. GPER was also found
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to be expressed intracellularly in some specific tissues including the mammary glands, the
ovarian epithelium, and breast and ovarian cancer cells [141]. This indicates that GPER
expression and signaling is not restricted to the plasma membrane but can also signal from the
intracellular membranes of the endoplasmic reticulum (ER) and the Golgi apparatus [151].
Estrogen Receptor Signaling
Ligand-bound ER and ER can regulate the transcription rates and overall expression of
target genes by binding to EREs on their promoters or by assembling transcription regulation
complexes with other transcription factors. It was also previously shown that ERs can regulate
target gene expression in a ligand-independent manner. Membrane bound GPER signals upon
estrogen ligand binding and can activate several signaling pathways that regulate many cell
processes and can ultimately result in gene expression modulation.
Ligand-Dependent Estrogen Signaling
The classical pathway: the ERE-dependent genomic pathway (Figure 3A).
Transcription activation by ligand-bound ER is a multistep process that occurs in a sequential
order and requires the interaction of the ER with several enzymatic activities in order to obtain a
productive interaction with the transcription complexes [152]. Ligand-operated transcription by
ERs is initiated when the estrogen ligand binds to the inactive ER-chaperone complex [152]. The
estrogen ligand binds to the ER C-terminal LBD causing a conformational change which
mediates the dissociation of the ER from its chaperones [152]. Shedding the chaperones exposes
the dimerization, nuclear localization, and DNA binding domains. Dimerization of the ER
strengthens the stability of the receptors and ensures binding to the EREs on target-gene
promoters [152]. EREs are direct or indirect palindromic sequences separated by three non-
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specific nucleotides (TCCAGTnnnACTGGA or AGGTCAnnnTGACCT) [153]. Once bound to
the DNA, ER transcriptional ability depends on the AF-1 and AF-2 activating functions.
Although AF-1 and AF-2 can function independently, maximal ER transcriptional activity is
achieved when there is synergy between them [154]. AF-1 and AF-2 serve as sites for interaction
with several co-activator or co-repressor proteins. Co-activator proteins enhance gene expression
by remodeling chromatin and allowing interactions with the transcription machinery. The AF-1
region of the ER interacts with co-activators from the p160 family which include the steroid
receptor co-activators 1, 2 and 3 (SRC-1, 2, 3) [155]. p160/SRC function predominantly by
recruiting chromatin modifying enzymes such as histone acetylases (HATs) to the ER-DNA
complex [156]. Histone deacetylation results in chromatin de-condensation and increased
transcription of target genes. p160/SRC can also recruit other co-activators such as CREB
binding protein (CBP) and p300 [157, 158]. The hydrophobic region of the AF-2 domain binds
co-activator proteins such as GRIP1 and TIF2 [159, 160].
AF-1 and AF-2 can also recruit negative co-repressors to the ER-DNA complex which
inhibit gene activation or turn off activated genes. Negative coregulatory factors RIP140 and
LCoR compete with the p160/SRC co-activators for AF-1 and AF-2 binding [161, 162].
Repression by RIP140 and LCoR occurs through the recruitment of histone deacetylases
(HDACs) which results in chromatin condensation and suppression of the estrogen target genes
expression [156]. Other molecules found in the ER-DNA transcription complex can also recruit
co-repressors. While p300 is considered a co-activator of the ER due to its activity enhancing
transcription initiation when recruited to ER and ER, it was shown that p300 can also recruit
the co-repressor C-terminal-binding protein 1 (CtBP1) to the ER transcription factor complex.
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CtBP1 can stop and inhibit the transcription of target genes by recruiting HDACs which
deacetylate histone 3 lysine 9 (H3K9) and H3K13 [163]. Overall, transcription of estrogen target
genes is predominantly enhanced by the binding of the ligand-bound ER homo or heterodimer to
EREs on gene promoters and the recruitment of co-activators but in some cases, co-repressors
compete with co-activators for ER complex binding which results in target gene expression
downregulation.
Both ER and ER can signal this way in order to regulate target gene expression.
Interestingly, ER and ER can form homo or heterodimers upon ligand binding (ERER,
ERER or ERER) [164]. These homo or heterodimers show differential transcriptional
activities and could explain the selective actions of estrogen in different cell types and target
genes. Although both ER and ER are expressed in tissues and form functional heterodimers;
when co-expressed, ER can inhibit the transcriptional ability of ER and vice versa [165, 166].
Therefore, overall estrogen responsiveness in specific tissues depends on the ER versus ER
ratio.
The ERE-independent genomic pathway (Figure 3B)
In addition to the classical mechanism of ER function, ERs can regulate gene expression
of genes that lack EREs. Estrogen-bound ER dimers can bind to Jun and Fos dimers located on
gene activating protein-1 (AP-1) binding sites [167]. The co-activators (p160/SRC) recruited by
the ERs to Jun/Fos subunits of the AP-1 transcription factor which can then activate transcription
of the AP-1 site containing genes [167, 168]. Another way that ERs can affect transcription of
genes is by physically interacting with the Sp1 transcription factor. Ligand-bound ERs enhance
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Sp1 DNA binding which upregulates target gene expression [169]. ERs can also repress the
transcription of genes in an ERE-independent manner. ER can interact with and sequester the cRel subunit of the NFB transcription factor complex [170]. This interaction prevents NFB
from binding and stimulating expression of NFB response element containing genes [171].
Ligand-independent estrogen signaling (Figure 3C)
Another mechanism of ER action involves the ligand-independent ER activation through
ER phosphorylation by protein kinases or growth factor receptors. The epithelial growth factor
receptor (EGFR) and the insulin-like growth factor receptor (IGFR) are able to bind the AF-1
domain but not the AF-2 domain and phosphorylate ER via the MAP kinase or the PI3 kinase
(PI3K)-Akt pathways [172, 173]. ERs can also be directly phosphorylated by protein kinase A
(PKA) or PKC [174, 175]. Phosphorylated non-ligand bound ERs can then homo or
heterodimerize and translocate into the nucleus where they regulate expression of EREcontaining and non-ERE containing genes even in the absence of estrogen ligand.
Non-genomic membrane bound estrogen signaling (Figure 3D)
In addition to the nuclear genomic actions, estrogen signaling can exert rapid effects nonaccounted for by the transcriptional mechanisms. These non-genomic changes by rapid signaling
are provoked by membrane-bound ER and GPER. Palmitoylation of ER anchors a pool of
ER to the plasma membrane where they can interact with other signaling proteins such as Src
and p85, the regulatory subunit of PI3K [176]. Estrogen signaling through GPER occurs through
transactivation of EGFR and involves activation of non-receptor tyrosine kinases of the Src
family [177]. Estrogen binding to GPER induces activation of metalloproteinases which induce
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the release of heparin-binding EGF, which binds and activates EGFR leading to rapid activation
of downstream signaling molecules such as the MAP kinase pathway including ERK1/2 [177].
Estradiol activation of GPER also stimulates production of intracellular cyclic adenosine
monophosphate (cAMP), induces intracellular Ca2+ mobilization, and PI3K activation. In
addition to these rapid signaling events, GPER was also shown to be internalized from the
plasma membrane and was demonstrated to regulate gene transcriptional activity of genes such
as c-Fos, one of the monomers of the AP-1 transcription factor complex [178]. Overall, signaling
though membrane-bound ERs is more rapid than genomic ER signaling and leads to rapid
activation of signaling pathways that result in cellular processes such as increase DNA synthesis
and cell proliferation, and further gene transcription regulation.
Estrogen Effect on Key Cells of the Immune System
Estrogen receptors are expressed ubiquitously on immune cells and estrogen is known to
modulate the survival, development, differentiation, and function of key cells of the immune
system such as T and B cells, macrophages, dendritic cells (DCs) and natural killer cells (NK)
[179]. In the following paragraphs, the effects of estrogen signaling on different cells of the
immune system are described.
T cells & T cell cytokines
In the peripheral blood of humans, around 30% of white blood cells are lymphocytes and
around 85-90% of these lymphocytes are T cells [180]. Although the total lymphocyte count in
males is equivalent to females, the percentage of T cells within the total lymphocyte population
is higher in females compared to males and post-menopausal females [181]. Females have
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higher CD4+ T cell counts and higher CD8+/CD4+ ratios than age-matched males and postmenopausal females; whereas males have higher CD8+ T cell frequencies [182-184].

Figure 3. The Different Types of Estrogen Signaling in the Cell. The ligand-dependent and ERE-dependent or ERE-independent
classical genomic estrogen receptor pathway consists on ERs binding to the estrogen ligand in the cytoplasm of the cell, dimerizing,
and translocating into the nucleus where they bind A) EREs in gene promoters, or B) form complexes with other transcription factors
such as AP-1 and regulate gene expression. C) The ligand-independent genomic estrogen receptor pathway happens when growth
factor tyrosine kinase receptors or protein kinases phosphorylate the ERs promoting dimerization and translocation into the nucleus
where they regulate gene expression in a ERE-dependent or independent manner. D) The non-genomic G-protein coupled estrogen
receptor signaling happens through GPER which activated the MAP kinase pathway upon estrogen ligand binding promoting
downstream signaling and gene expression regulation. E2: 17-estradiol, ERE: estrogen response element, AP-1: activator protein1, PKC/A: protein kinase C/A, MAPK: mitogen activated kinase, PI3K: phosphoinositide-3 kinase.
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Following in vitro T cell stimulation, females have higher numbers of proliferating T
cells and higher numbers of CD8+ and CD4+ activated T cells compared to males [181].
Transcriptional analysis of these activated T cells showed greater cytotoxic activity in T cells
from adult females, with stimulated female T cells upregulating more antiviral and proinflammatory genes compared to male activated T cells [185]. Notably, over half of these
activated genes have EREs in their promoters indicating direct involvement of estrogen signaling
on T cell function [185]. Both CD8+ and CD4+ T cell subsets express ER and ER and
estrogen signaling was shown to also affect T cell development and differentiation.
Estrogen stimulation was shown to cause structural changes in the thymus and to affect
immature T cell development. Ovariectomized mice that were treated with estrogen showed dose
dependent thymic atrophy with a decrease proportion of early T cell progenitors, and an
increased proportion of mature T cell populations [186]. Estrogen inhibits thymic development
by decreasing the number of triple negative immature T cells (CD3 -CD4-CD8-) and depleting the
rest of the maturation stages such as CD44+ CD25+, CD44-CD25+, and CD44- CD25- T cells
[186]. On the other hand, estrogen treatment increased the numbers of thymic CD8 + and CD4+
single positive mature T cells. All these effects were mediated by ER AF-1 and AF-2 functions
simultaneously since the deletion of the receptor or any of these functions abolished the
inhibitory effects of estrogen on the thymus [187]. Ovariectomized mice showed reduced levels
of CD8+ splenic T cells and the CD8+/CD4+ single positive cell ratio was increased after
physiological estrogen stimulation agreeing with the human observation on pre-menopausal
females [188]. Overall these data indicated that estrogen signaling though ER induces
differentiation of mature CD8+ and CD4+ T cells.
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Besides affecting the development of T cells, estrogen is capable of affecting T cell
activation and T cell function. T cells stimulated with post-menopausal estrogen levels showed
decreased activation-induced phosphorylation of the CD3/TCR complex and reduced expression
of the Janus kinases 2 and 3 (JAK2 and 3 kinases) compared to T cells treated with physiological
estrogen [189]. JAK2 and 3 are non-receptor tyrosine kinases that mediate cytokine-mediated
signals via the JAK-STAT pathway in response to IL-2 which secretion was also downregulated
in T cells treated with low estrogen [189]. In a model of colitis, it was observed that ERdeficient mice showed decreased T cell proliferation and activation state, and increased FoxP3
expression compared to WT mice indicating that T cells in ER-deficient mouse were skewed
towards a regulatory phenotype decreasing the severity of the autoimmune inflammation [190].
In addition to enhancing T cell activation, physiological estrogen stimulation was shown to
induce Th1 effector T cell responses. IFN is a major cytokine involved in cytotoxic and effector
Th1 T cells responses and it is sensitive to estrogen stimulation in mice and humans. Estrogen
can modulate IFN secretion by enhancing Ifn gene expression in CD4+ and CD8+ T cells [190].
This happens through direct interaction of ER with an ERE in the promoter of the Ifn gene
[191, 192]. Administration of physiological estrogen to ovariectomized mice resulted in an
increase of IFN producing cells as well as an increase of Th1 CD4+ antigen-specific T cell
responses [193]. Overall this indicates that physiological estrogen signaling through ER
promotes effector and Th1 responses which are reduced in the presence of low estrogen
concentrations like the ones found in post-menopausal females and males.
Most of the important aspects concerning the role of estrogen signaling on T cell function
were studied using T cells from autoimmune disease patients, and autoimmunity mouse models
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including multiple sclerosis (MS) and colitis. Using primary T cells from MS patients that were
treated with estrogen, it was shown that estrogen signaling mediated a dose dependent
enhancement on the secretion of IL-10 by CD4+ T cells [194]. The secretion of IFN by T cells
was also increased by estrogen in a dose dependent manner confirming the genomic regulation of
IFN through the ERE on its promoter [194]. The effects of estrogen on expression of TNF
expression were shown to be controversial. Physiological estrogen concentrations were shown to
enhance TNF expression, while pregnancy estrogen levels inhibited TNF expression [194].
On the other hand, in bone research studies, ovariectomy of mice enhanced the production of
TNF by CD8+ and CD4+ T cells, and the subsequent bone loss which was abolished by estradiol
replacement therapy [195].
Estrogen-induced changes in IL-4 mRNA or protein expression were not observed in
response to estrogen stimulation in MS patient’s primary T cells [194]. Interestingly, studies
characterizing the role of estrogen during pregnancy, a state where estrogen levels are higher
than physiological, demonstrated that the T cell immune response skewed toward the Th2 type
compared to Th1 type response [189]. Estrogen at pregnancy levels increased IL-4 secretion and
GATA3 expression in ER+CD4+ cells but not on ER- ones [190]. IL-4 is a common cytokine
secreted by Th2 cells and its expression is induced by GATA3 which is the transcription factor
that drives Th2 T cell differentiation. Peripheral mononuclear blood cells (PBMCs) stimulated
with different estrogen levels showed that those cells treated with physiological estrogen
enhanced production of IFN, IL-12, and IL-10 which is a Th1 skewed immune response [191].
On the other hand, cells treated with pregnancy estrogen levels had decreased IL-12 and IFN
ratio while IL-10 production was enhanced [191]. Overall, the estrogen mediated enhancement
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of cytokines such as IL-10 and IL-4 by T cells switches the T cell immune response from Th1 to
Th2.
Estrogen signaling has also been shown to affect immunosuppressive Tregs. Pregnancy
estrogen levels were reported to increase the expression of FoxP3 expression on CD4 +CD25+
cells [196-199]. Pregnancy estrogen levels were able to enhance FoxP3 expression in vivo and in
vitro and increase CD25+ cell number, which are reduced in ER-CD4+ cells [198]. Mouse
studies also showed that physiological estrogen concentration could induce expression of FoxP3
and enhance the number of CD25+ regulatory CD4+ T cells [188]. The role of estrogen
modulating Treg differentiation proves to also be controversial since post-menopausal women
were shown to have enhanced numbers of circulating Tregs compared to pre-menopausal women
[189].
While many studies have reported the effect of estrogen signaling on T cell function and
cytokine production, many of the reported results are contradicting and indicate opposite roles of
estrogen signaling on T cell function especially in cytokine expression and production. Overall
the studies summarized in this section indicate that the effect of estrogen on T cell function and
cytokine production is highly concentration dependent. Different effects were observed when T
cells were exposed to physiological, post-menopausal and pregnancy estrogen concentrations.
The effects of estrogen on T cell function and cytokine production were also affected by the
species in which they were tested with contradicting results obtained when testing the role of
estrogen signaling on human compared to mouse T cells. This indicates differences in T cell
biology and estrogen signaling between these species. Regarding T cell differentiation, estrogen
was reported to promote Th1, Th2, or Treg CD4+ T cell differentiation depending on the
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concentration of the hormone, again indicating concentration dependent effects. While these
studies demonstrated the effect of estrogen in signaling in T cell function and differentiation, not
many of them reported through which receptor estrogen is signaling through on each case. Most
of the time, estrogen signaling through ER was investigated while ER and GPER were not
mentioned. This indicates there is a high need for research characterizing the effects of estrogen
signaling at different concentrations through each of its receptors and signaling pathways on T
cell function, including the expression of several cytokines, as well as T cell differentiation.
B cells and Antibody Production
Regardless of age, females show greater B cell numbers, higher antibody responses, and
higher basal immunoglobulin levels than males [181]. Estrogen affects the development and
activity of B cells at different stages of differentiation and function, which can also vary among
lymphoid organs. For example, in the bone marrow, estrogen was shown to decrease the number
of B cells by negatively affecting the viability, proliferation and differentiation of early B cell
precursors [200]. On the other hand, estrogen treated ovariectomized mice showed increase
splenic weight and enlarged volumes of white and red pulp [201]. Even if estrogen treatment
promoted a decrease in B220+ splenic lymphocytes, there was a 10-fold increase in plasma cell
numbers and this effect required signaling though both ER and ER [202, 203]. Estrogen was
also shown to increase splenic B cell activation and plasma cell antibody secretion [204, 205]. It
was also shown that estrogen increases the expression of the anti-apoptotic gene bcl-2, and other
genes such as cd22, shp-1, and vcam-1 in B cells that result in increased survival and activation
[206, 207]. Estrogen signaling also modulates B cell function by increasing immunoglobulin
secretion such as IgG and IgM through ER signaling but not ER [208]. This overall indicates
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that while estrogen signaling inhibits B cell lymphopoiesis in the bone marrow, it enhances
mature B cell survival and differentiation into plasma cells as well as antibody production upon
activation.
Macrophages and Dendritic Cells
Antigen presenting cells, such as macrophages and dendritic cells, which are crucial for
induction of immune responses are another target of estrogen. Macrophages express ER, ER,
and GPER and estrogen signaling was shown to modulate macrophage polarization, activation,
and cytokine production [209]. Macrophages can be classified into classically (inflammatory) or
alternatively (anti-inflammatory) activated macrophages depending on the activation stimuli.
Classically activated macrophages result from activation in the presence of Th1 cytokines
including IFN or NF, while alternatively activated macrophages are activated in presence of
Th2 cytokines including IL-4 or IL-13 [210]. Classically activated macrophages downregulate
ER expression while they maintain ER and GPER expression, while alternatively activated
macrophages retain ER and ER expression [210]. Many studies have described how
physiological estrogen can upregulate inducible nitric oxide synthase (iNOS) and NO
production, increased production of proinflammatory cytokines and increased cell surface
expression of Toll-like receptor 4 (TLR4) in human and mice classically activated macrophages
probably through mechanisms involving ER or GPER [211-215]. This leads to increased
macrophage activation and killing thus to increased resistance to extracellular bacteria and
infections in the presence of estrogen [216]. On the other hand, high dose estrogen stimulation
reduced the production of inflammatory cytokines such as IL-1, IL-6, and TNF in activated
macrophages indicating a dose dependent effect of estrogen [217].
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Dendritic cells express ER and ER and estrogen signaling was shown to affect
functional DC differentiation from bone marrow progenitors. Differentiation of DC bone marrow
progenitors stimulated with granulocyte macrophage-colony-stimulating factors (GM-CSF) was
inhibited when cells were cultured in estrogen-deficient media or in vivo in ovariectomized mice
[218-220]. DC differentiation was restored when physiological estrogen concentrations were
introduced back. The estrogen-mediated DC bone marrow progenitor differentiation was found
to be mediated by ER and not ER signaling. ER signaling increases the expression of IRF4,
a key transcription factor induced by GM-CSF and critical for DC development [218, 219].
These estrogen-treated mature DCs were CD11c+CD11bintermediateLy6C- and expressed high
levels of MHC class II and co-stimulatory molecules B7.1, B7.2 and CD40 [220, 221]. These
DCs were able to stimulate the proliferation of CD4+ T cells and were able to produce higher
levels of the inflammatory cytokines IL-16 and IL-12 [221]. Short-term estrogen stimulation had
no effect on DC survival or surface marker expression. However, estrogen stimulation enhanced
activated DC IL-6, IL-8, and monocyte chemoattractant protein 1 (MCP-1) production and it
enhanced the migration of mature DCs towards chemokine C-C motif ligand 19 (CCL19) [222].
Overall, these data indicate that estrogen signaling enhances the differentiation and function of
DCs which can further result on more potent immune responses from DC-activated B cells and T
cells.
NK cells
NK cells are large granular lymphocytes from the innate immune compartment which
attributed with the ability to directly lyse virus-infected cells or tumor cells, and to produce and
release type I cytokines such as IL-2 or IFN. Surprisingly, the number and activity of NK cell
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changes during the menstrual cycle of human females [223]. NK cell activity increases during
the first trimester of pregnancy, but it significantly decreases during the second and third
trimesters indicating an important role of estrogen in regulating NK cell activity [224]. NK cells
express both ER and ER and estrogen signaling was shown to affect NK cell function.
Prolonged high concentration estrogen stimulation was shown to increase overall NK cell
numbers but to reduce NK cell activity in a dose dependent manner [224-226]. NK cell numbers
were increased by the estrogen mediated upregulation of minichromosome maintenance
component 7 and 10 (MCM7 and MCM10) expression which are proteins required for DNA
replication and NK cell proliferation [226]. On the other hand, the suppressed cytotoxicity of NK
cells was attributed to the estrogen down-regulation of activating receptors NKp46, NKG2D, and
CD244 which resulted in reduced secretion of Granzyme B and Fas ligand [226]. This
suppression of NK cell activity was observed in several mouse strains and human cells when the
duration of the estrogen treatment was prolonged over one month, and it was mediated by
ER signaling since no differences were observed when ER knockout (KO) mice were used
[224]. This overall indicates that while estrogen signaling enhances NK cell proliferation, it
decreases NK cell activation and cytotoxic function especially when NK cells are exposed to
high dose estrogen for long periods of time like in the case of pregnancy.
Estrogen and Disease
As described in the previous section, estrogen signaling has profound effects on the
development, differentiation, and function of key immune cells indicative that estrogen signaling
also affects those diseases that arise from immune cell function dysregulation, like
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autoimmunity, or those that are heavily controlled by immune responses, like infections and
cancer. In the next paragraphs the known effects of estrogen on these diseases are described.
Estrogen and autoimmunity
About 8% of the world’s population suffers from autoimmune diseases, of which 78% of
all autoimmunity cases are women [227]. The female to male autoimmune disease ratio ranges
from 2:1 in rheumatoid arthritis (RA) to 3:1 in MS, and to 9:1 in systemic lupus erythematosus
(SLE) [227, 228]. The effects of estrogen on autoimmune diseases cannot be generalized since
estrogen signaling differs depending on concentration, the estrogen receptor, and the target cell
type. Estrogen was shown to enhance the severity of some autoimmune diseases. Estrogen
signaling promotes systemic inflammation and induces B cell activation and anti-double stranded
DNA antibody production which increases reactivity to endogenous antigens that are expressed
in SLE [208, 229]. Altered expression of ER was shown in immune cells of SLE patients which
have upregulated expression of ER and decreased expression of ER compared to healthy
controls [230]. Increased ER expression in CD4+ and CD8+ T cells, macrophages, and DCs in
SLE enhances Th1 type autoimmune responses by the production of cytokines including IFN
and IL-12 [231]. T cells from SLE patients also have upregulated expression of the costimulatory ligand molecule CD40L which is shown to be important for activated Th1 T cells
priming and IFN production [232]. In a T cell dependent inflammatory bowel disease (IBD)
model, estrogen signaling through ER worsens prognosis by promoting the accumulation of
Th1 and Th17 T cells, and increasing T cell activation and proliferative state [233].
Contrary to other autoimmune disorders, estrogen has a protective role against MS, a
disease characterized by the presence of myelin reactive CD4+ T cells in the central nervous
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system which leads to demyelination of axons and neuronal death [234-236]. Estrogen signaling
through ER decreases autoantigen-specific proinflammatory molecules such as TNF, IL-17,
iNOS, and MCP-1 and inhibits autoimmune inflammation [236]. ER signaling was also shown
to be necessary for the estrogen-mediated protection against MS and for enhancing endogenous
myelination [237]. Pregnant mice showed reduced CNS pathology when compared to nonpregnant animals, and the rates of relapse increases post-partum at a phase where there is a
marked decrease in estrogen levels compared to pregnancy [238].
Estrogen was shown to have different effects in various autoimmune disorders. Given
that estrogen affects all cells of the immune system as well as non-lymphoid tissue that is in
proximity of target tissue, it is understandable that estrogen has different effects dependent on
the context of each autoimmune disorder. While estrogen plays a role in sex differences in
autoimmune diseases, clearly estrogen alone does not exclusively contribute to this sex
differential susceptibility.
Estrogen and infection
Females and males differ in the severity, prevalence, and pathogenesis of infections
caused by bacteria, virus, fungi and parasites, with males being generally more susceptible to
these infections than females [239]. Males exhibit higher incidence rates for leptospirosis (4-fold
increased incidence compared to females), schistosomiasis (1.5-fold), brucellosis, rabies,
leishmaniasis (3-fold), pulmonary tuberculosis (2.5-fold), and hepatitis A, B and C (1.5 to 3-fold)
[119, 240-243]. Similarly, premenopausal women are significantly less likely to develop
meningococcal or pneumococcal infections [119]. Estrogen is thought be protective against
infections due to the pro-inflammatory effects of estrogen signaling on immune cells.
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Physiological estrogen concentrations were used to treat different kinds of infections in murine
models and humans. Physiological estrogen administration was shown to reduce infection in
males and females that suffered viral infections with encephalomyocarditis or Friend virus [244,
245], bacterial infections with Salmonella typhimurium [246], fungal infections with Candida
albicans and Paracoccidioides brasiliensis [247, 248], and even infections with parasitic
protozoa like L. Mexicana [249]. Overall, these data indicate that estrogen signaling has a
protective role against some infectious diseases through the enhancement of immune cell
function against pathogens. Heightened immunity to pathogens among females contributes to
lower intensity, such as lower viral load found in the serum of hepatitis or HIV female patients
[250], and prevalence of infected individuals within a population compared to males, but it may
increase disease symptoms and severity among females compared with males as seen in
infections including malaria or HIV [251].
Estrogen and cancer
Sex is an important factor in the pathogenesis and prognosis of cancers that occur outside
of the reproductive tract [121]. For the majority of cancers throughout life, males have a higher
risk of malignancy compared to females [252, 253]. Males have two-fold greater rates of
mortality from malignant cancers compared to females, with sex-dependent outcomes being
greatest for larynx, esophagus, lung and bronchus, skin, and liver cancers [253]. This malebiased incidence and mortality is hypothesized to reflect a combination of factors including but
not limited to sex-differences in genomic predisposition, infection, immune function, gene
expression, and hormonal regulation. Estrogen is thought to have a protective role against cancer
which is supported by the observation that cancer incidence and mortality rates increase after
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menopause in women not undergoing hormone replacement therapy [254]. In some specific
cancers such as melanoma or liver cancer, estrogen signaling has an antitumor role by enhancing
antitumor immune responses [255-257]. Despite the normal and beneficial actions of
physiological estrogen in women, estrogen was classified as a carcinogen after the Women’s
Health Initiative research program discovered that postmenopausal women treated with HRT had
a significant increase in the incidence of breast cancer after at least 5 years of treatment [258].
The effects of estrogen are tissue-specific and depend on which ER is predominantly expressed
and further which downstream signaling pathways become activated.
Estrogen receptor signaling is well known to be cancer promoting in ER-positive (ER+)
breast tumors. In breast cancer cells, ERα regulates various genes that play key roles in cell
cycle progression and proliferation. ERα can transcriptionally upregulate c-Myc (as early as 15
minutes after estrogen stimulation) and cyclin D1 which are necessary for the G1-to-S phase
transition [259, 260]. On the other hand, ERβ signaling can induce G2 cell cycle arrest and
inhibit the estrogen-induced cancer cell proliferation [261-263]. Expression of ER and ER in
human NSCLC is correlated with worse prognosis and more aggressive disease [264, 265]. ER
and ER are found in the nucleus and cytoplasm of NSCLS cells and are phosphorylated in
residues commonly modulated by growth factors indicating ligand-independent ER signaling
[266, 267]. ER signaling promotes the early activation of the MAP kinase pathway which is
oncogenic in NSCLC [266]. In ovarian cancer, estrogen signaling was correlated with both
worse and better disease prognosis. Estrogen levels are often observed in ovarian cancer patients
and ER signaling promotes metastasis by inhibiting cell-cell adhesion and cell survival and
proliferation [268, 269]. On the other hand, ER expression in ovarian cancer predicts longer
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overall survival [270-272]. There is also contradicting evidence about the role of ER in ovarian
cancer. Some early studies correlate ER expression with worse ovarian cancer prognosis [273],
but ovarian cancer meta-analyses showed that ER expression is downregulated as disease
progresses and ER is predominantly expressed in advanced and metastatic disease [272, 274,
275].
In some cancers including endometrial, prostate, liver cancer and melanoma estrogen
signaling contributes to decreased tumor risk and better disease prognosis. Meta-analyses
revealed that ER expression of both ER and ER simultaneously correlate with better overall
survival of endometrial carcinoma [276]. Even if meta-analyses were not able to correlate
prostate cancer prognosis with ER expression, prostate cancer cells express ER, ER and
GPER and decreasing estrogen concentrations were observed to be associated with increased
prostate cancer risk [277, 278]. Melanoma tumors express both ERα and ERβ, and ER
expression decreases as the melanoma tumor develops. Although the mechanisms remain
unclear, it is thought that ER acts as a tumor suppressor but it is downregulated as the tumor
progresses [257, 279]. Estrogen can suppress the growth of human melanoma by inhibiting IL-8
production and subsequent chronic inflammation through ER signaling [280]. Estrogen is a key
molecule in cellular development and cell cycle regulation and therefore impacts many varieties
of cancer cells directly. In summary, R expression is correlated with better prognosis and
survival, and it can be concluded that ERβ acts as a tumor suppressor in most cancers. ERα acts
as an oncogene in breast, lung and ovarian cancers, even if ER expression is correlated with
better prognosis on melanoma, prostate, and endometrial cancer.
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Another cancer that is heavily affected by sex and estrogen receptor signaling is HCC.
HCC is the main disease model used in the studies of this dissertation. The next paragraphs
describe current knowledge on the causes and treatments of HCC, as well as the role of estrogen
on tumorigenesis.
Hepatocellular Carcinoma
Primary liver cancer consists of a heterogeneous group of malignant tumors not
including liver metastases from other cancer sites [281]. Primary liver cancer is the second
leading cause of cancer-related deaths worldwide, and it accounts for approximately 800,000
deaths each year [282, 283]. Hepatocellular carcinoma (HCC) is the most common primary liver
cancer and it accounts for 80-90% of all cases [284]. The incidence of HCC is highest in East
and Southeast Asia, and East and Western Africa but HCC incidence has risen in areas with
historically low rates in the last decades, such as Western Europe and North America making it a
major global health burden [285]. Life expectancy of HCC patients depends on the stage of the
cancer at the time of diagnosis. In advanced stage, survival of only few months is expected,
however, if diagnosis is early and effective treatment is performed, then five-year survival rate
can be achieved [286].
Causes
Around 90% of HCC tumors develop from the induction of liver fibrosis and/or cirrhosis
resultant from chronic inflammation of the liver caused by diseases such as chronic hepatitis B
virus (HBV) and HCV, autoimmune hepatitis, excessive alcohol consumption, non-alcoholic
fatty liver disease (NAFLD), diabetes mellitus, and excessive tobacco use [283, 287-289]. The
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liver has the unique ability to repair itself after acute damage. Differentiated hepatocytes have
the ability to re-enter the cell cycle and replace themselves [290]. However, under chronic
inflammatory conditions, the altered immune response and constant cell death of hepatocytes
promote liver fibrosis and tumorigenesis [284, 291]. Altered survival and proliferative signals
during chronic inflammation, cellular stress, epigenetic modifications, and senescence promote
tumorigenesis [283]. Chronic inflammation also promotes DNA damage, replication stress, and
genomic instability which are detectable before transformation fully occurs [292]. Cytokines
such as IL-6 and TNF, which activate the STAT3 and NF-B pathways respectively, were
reported to be responsible for chronic inflammatory conditions and development of HCC [293,
294]. Chronic inflammation of the liver can result on activation of oncogenic pathways and
suppression of tumor-suppressive mechanisms. The main oncogenic pathways involved in HCC
are PI3K-Akt and MAPK pathways, the Wnt/-Catenin pathway, c-myc, and the sonic hedgehog
(HH) pathway.
Activation by ligand binding and phosphorylation of growth factor tyrosine kinase
receptors such as c-MET and EGFR lead to activation of the MAPK and PI3K pathways [295].
MAPK pathway activates the oncogene cFos and transcription factor AP-1/c-Jun which induce
transcription of genes that drive cell proliferation of tumor cells [296]. Activation of the PI3KAkt pathway results on activation of the mammalian target of rapamycin (mTOR) pathway
promoting carcinogenesis [297]. This pathway can also be dysregulated by constitutive
activation of PI3K due to loss of function of the tumor suppressor PTEN by either mutations or
epigenetic silencing [298]. C-myc amplification is observed in around 33% of all HCCs and it
normally corresponds to large, less differentiated tumors in younger patients [299]. C-myc
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overexpression in HCC induces tumor cell stemness, cell proliferation, and increases glutamine
metabolism and cell growth [300-302]. Mutations on the Wnt/-Catenin pathway are observed in
around 50% of HCCs [303]. Activating mutations result in stabilization and hyperactivation of Catenin signaling [304]. Additionally, inactivation mutations in negative regulators of the Wnt
pathway and the tumor suppressor gene adenomatous polyposis coli (APC) further contribute to
Wnt pathway activation [304]. While mature hepatocytes show no HH signaling activity,
hyperactivation of HH and its pathway components were observed in 50% of HCCs [295, 305].
In HCC cells, reactivation of the HH pathway maintains tumor cell stemness and induces
epithelial-to-mesenchymal transition which increases risk of metastasis [305, 306].
Overall, several conditions including hepatitis infection, NAFLD, and excessive alcohol
consumption can result in chronic inflammation of the liver. Chronic inflammation of the liver
induces cell stress and cell death which can result in liver fibrosis and cirrhosis and subsequent
oncogenic transformation into HCC. Many signaling pathways can induce HCC including those
that enhance liver cell proliferation, stemness and metastatic capacity.
Estrogen and HCC
The age-adjusted incidence ratios of HCC in men and women are extremely consistent in
157 registries worldwide [253, 307]. Significantly higher incidence and mortality ratios of HCC
in men compared to women are well documented. Worldwide, male-to-female HCC incidence
rates range from 2 to 4, being greatest for age-matched males and females under 53 years of age
[308]. Women have significantly longer survival rates than age-matched men. While the overall
survival for women between 18-45 years old is 25 months, it is only 10 months for age-matched
men [309, 310]. The incidence and mortality of HCC significantly increase in post-menopausal
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women over 55 years old indicating that reproductive senescence increases the risk of HCC. The
HCC overall survival in women between 45-55 years old decreases to between 10 and 15 months
which almost matches the overall survival of age-matched men (8-9 months) [309, 310].
Interestingly, those menopausal women using estrogen hormone replacement therapy showed
decreased incidence of developing HCC compared to the non-estrogen users [311]. This
indicates that estrogen has a protective role against HCC and estrogen signaling inhibits tumor
formation and development making HCC significantly more prevalent in males compared to
females. Thus, male sex, menopause, and female therapeutic ovariectomies are considered risk
factors for HCC [312].
Estrogen signaling is protective against HCC in several ways. Estrogen signaling inhibits
chronic inflammation of the liver, the main cause of HCC. Estrogen signaling through ER
directly inhibits transcription and expression of IL-6 by binding to its promoter and impairing crel and RelA binding to the NF-B promoter site [170, 313]. This mechanism was observed upon
estrogen treatment in hepatocytes and Kupffer cells, the resident macrophages of the liver [293].
ER signaling also inhibits STAT3 activity, a critical factor regulating liver chronic
inflammation in hepatocytes [294]. ER transcriptionally activates protein tyrosine phosphatase
receptor type O (PTPRO) which dephosphorylates STAT3 and subsequently attenuates STAT3
signaling [314].
HCV infection, a cause for chronic inflammation of the liver that results in cirrhosis and
HCC, was shown to be inhibited by estrogen signaling through GPER in hepatocytes [315].
GPER signaling promotes the cellular export of matrix metallopeptidase 9 (MMP-9) which leads
to cleavage of occluding, which is a tight junction protein and HCV receptor, overall reducing

46

HCV hepatocyte infection and viral RNA production [315]. Estrogen signaling through ER in
hepatocytes was also shown to transcriptionally activate microRNA 34a (miR-34a) which
enhances activation of p53, a well-known apoptosis inducer and tumor suppressor [316]. These
data indicate that estrogen signaling not only reduces HCV infection of hepatocytes but also
reduces overall inflammation and induces apoptosis in a p53 dependent manner.
Estrogen signaling was also shown to affect HCC tumor infiltrating immune cells like
macrophages. During HCC progression, TAMS replace Kupffer cells as the main modulators of
chronic inflammation of the liver by secreting IL-6 and TNF. TAMs not only induce chronic
inflammation but also secrete immunosuppressive molecules such as TGF and IL-10 that
suppress the anti-tumor immune response and increase the fibrotic, hard to infiltrate, tumor
microenvironment [317]. Estrogen signaling functions as suppressor for macrophage alternative
activation into TAMs by inhibiting the JAK1-STAT6 pathway though ER . Overall these
data indicate that estrogen signaling suppresses tumor growth partially via regulating the
polarization of macrophages. Although this is promising in order to develop new therapies based
on estrogen, the role of estrogen signaling on other HCC tumor infiltrating immune cells remains
unclear and needs further investigation.
Treatments for HCC
Treatments for early stage HCC
According to the Barcelona Clinic Liver Cancer (BCLC) staging classification, HCC
patients are categorized into four different stages according to the tumor burden, the number of
tumors, the presence of vascular invasion, and the spread of nodules or presence of extrahepatic
metastases. According to these parameters, HCC patients are considered stage 0 or very early
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stage, stage A or early stage, stage B or intermediate stage, stage C or advanced stage, or stage D
or terminal stage [319, 320]. Resection, ablation, and transplantation are considered for patients
in the early HCC stages (0 and A). Surgical resection or radiofrequency ablation are indicated to
treat patients with preserved liver function, single nodule occurrence, and absence of cirrhosis.
Even if the five-year survival rate is high after these therapies (50-75%), the tumor recurrence
rate can reach 50% making resection and ablation not appropriate for patients with vascular
invasion or metastasis [281, 321]. In early stage HCC patients with cirrhosis, liver
transplantation is performed. Liver transplantation ensures reduced tumor recurrence rates and
increased survival however, there is a great lack of organs available for transplantation [322,
323]. Surgical resection, tumor ablation, and liver transplantation are efficacious treatments for
HCC but due to problematic HCC diagnosis that reveals high levels of false negatives and high
percentage of asymptomatic patients, these treatments can only be performed in under 20% of all
HCC cases [324].
Sorafenib
Intermediated or advanced stage (B and C) HCC patients with preserved liver function
are treated with Sorafenib. Sorafenib is an oral multi-kinase inhibitor with anti-angiogenic and
anti-proliferative properties [325]. In vascular endothelial cells, Sorafenib inhibits the receptor
tyrosine kinases VEGFR1, 2 and 3 and platelet-derived growth factor receptor-β (PDGFR-β)
which are involved in promoting tumor angiogenesis [325-327]. In tumor cells, Sorafenib targets
the MAP kinase pathway and induces apoptosis by inhibiting RAF isoform signaling [326, 327].
Sorafenib can also induce apoptosis in a MAP-kinase independent way by inhibiting the
phosphorylation of the translation initiation factor eIF4E which promotes the translation of anti-
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apoptotic protein myeloid cell leukemia-1 (Mcl-1) [327, 328]. Sorafenib increases overall
survival by 2.3-2.8 months and it is the current standard of care for patients with advanced HCC
[329]. Overall however, the median survival for Sorafenib treated patients with advanced stage,
unresectable HCC is less than one year (11 months) [330]. Sorafenib treatment in advanced HCC
patients also results in major side effects such as diarrhea, fatigue, and hand-foot syndrome, a
troublesome condition characterized by painful, erythematous, blistering patches on palms and
soles of the feet [330]. Overall, even if treatment with the multi-kinase inhibitor Sorafenib
provides some therapeutic benefit for advanced HCC cases, a great unmet need remains for
patients indicating that the development of new therapies to increase the overall survival of
advanced HCC patients is highly necessary.
Immunotherapy for HCC
Immunotherapy is an emerging treatment modality that could become a promising
treatment option for HCC as, first, it is an inflammation-associated cancer which makes
immunotherapy more likely to be effective [331]. Second, it was observed that HCC patients
whose tumors contain increased lymphocytic infiltration including CD8 + and CD4+ T cells show
longer overall survival and lower risk of recurrence than those patients with no immune tumor
infiltrates [332-334]. Third, the liver is an ‘immune privileged’ organ and it is tolerogenic to
immune responses to antigens by various immune-suppressive mechanisms, including immune
checkpoint expression, Treg recruitment, cytokine secretion dysregulation, and changes in the
local TME that suppress APCs and T cells [335-338]. Considering all these facts, the blockade of
immune checkpoints and the enhancement of the T cell anti-tumor immune response are
treatment possibilities that can be highly effective against HCC.
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Treatment of HCV-induced HCC patients with CTLA-4 inhibitor Tremelimumab showed
20% partial response rates and increased overall survival by around 7 months [339]. Moreover,
viral loads of HCV were significantly decreased indicating anti-viral immune responses, and no
patients experienced immune-related adverse events or hepatotoxicity [339]. High PD-L1 and 2
expression was observed in HCC tissue [340]. Several clinical trials were conducted treating
advanced HCC patients with PD-1 inhibitors Nivolumab and Pembrolizumab. Nivolumab treated
patients showed manageable adverse events and 5% of them showed complete response rate
while 20% showed partial response rate [341, 342]. The overall survival rate at 6 months was
72% indicating that Nivolumab did activate sustained tumor-specific immune responses [341,
342]. Furthermore, Sorafenib resistance in HCC was shown to be mediated by enhanced DNA
(cytosine-5)-methyltransferase 1 (DNMT1) expression induced by PD-L1 [343]. These data
indicate that PD-L1 blockade and Sorafenib combinatorial treatment could not only enhance the
anti-tumor immune response but also target the tumor cells themselves.
ACT immunotherapy for HCC consists on the use of genetically modified autologous T
cells that express a TCR specific for a HCC tumor antigen (Figure 4). ACT immunotherapy was
shown to be partially successful in treating HCC in preclinical models and clinical trials. ACT
shows unique advantages over Sorafenib and checkpoint blockade immunotherapy in treating
HCC since it improves the quality and quantity of cells destroying the tumor in order to
overcome immune tolerance [330]. ACT immunotherapy using the patient’s autologous TILs
expanded with IL-2 in vitro after liver surgical resection showed 68% overall survival rates [344,
345]. However, due to small tumor burden collected during biopsies and low T cell survival after
extraction, it is hard to isolate TILs from HCC patients [346]. Genetically modified T cells
including CAR T cell and TCR transduced T cells are being tested for ACT immunotherapy for
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HCC in phase I and II clinical trials targeting tumor antigens such as glypican-3 (GPC3)
expressed in the majority of HCCs [347-350] (Clinical trial IDs: NCT02715362, NCT03130712,
NCT03198546, NCT03146234), -fetoprotein (AFP) expressed in 60-80% of HCCs [351, 352]
(NCT03349255), mucin-1 (MUC-1) expressed in 60% of HCCs [353, 354] (NCT02587689), and
epithelial cell adhesion molecule (EpCAM) (NCT03013712). ACT immunotherapy for virallyinduced HCC was also clinically tested using HBV or HCV viral proteins as tumor antigens.
During chronic hepatitis infection, HBV and HCV can integrate its genetic material into the
hepatocyte’s genome, and HBV and HCV antigens are found in HCC tumors even after viral
infection clearance [355, 356]. Patients treated with HBV Ag-specific T cells showed positive
ORRs including volumetric reduction of lung metastases with no new lesions observed in the
liver or lungs [357]. In addition, no therapy-related adverse events were observed [357]. HCV
Ag-specific T cells for ACT immunotherapy were generated and tested in preclinical models
where they showed success, but they have not been tested in humans yet [51, 52, 358].
Overall, checkpoint blockade and ACT immunotherapy for HCC were proven to be a
partially successful and safe antitumor and antiviral method for advanced HCC, but the efficacy
of this therapies needs to be optimized to obtain higher response rates. Even if ACT
immunotherapy brings hope for the treatment of HCC, there are several aspects of it that need to
be further improved. These include the facilitation of greater T cell tumor infiltration, avoiding T
cell exhaustion and tumor immune scape, and reducing adverse side effects such as cytokine
storm.
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Figure 4. Adoptive T Cell Transfer Immunotherapy Using TCR Gene-Modified T Cells.
A) Viral or cancer antigen specific T cell clones are isolated from hepatocellular carcinoma
tumor infiltrating lymphocytes or peripheral blood and expanded in vitro to identify a
therapeutic Ag-specific TCR candidate. B) TCR  and  genes are identified and cloned into
retroviral vectors. C) Packing and producer cell lines are engineered to produce high titers of
retrovirus containing the Ag-specific TCR. D) Retrovirus are used to transduce activated
peripheral mononuclear blood cells from hepatocellular patients which are then expanded in
vitro, and E) re-infused back into the patient. These autologous Ag-specific T cells have
redirected specificity to provide anti-tumor immunity.
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Summary
The field of immunotherapy has shown great advances for the treatment of solid tumors
and hematopoietic malignancies in the last fest years. The use of genetically modified T cells that
express TCRs specific for tumor antigens for ACT immunotherapy represents a promising
approach to treating cancer patients [359]. Despite of the recent clinical success, there are many
issues that remain in optimizing the efficacy of this type of immunotherapy. Many studies have
focused on understanding the mechanisms of immune escape posed by the tumor including the
role of the immunosuppressive TME. Malignant and non-malignant immune cells in the TME
were characterized as well as their mechanisms to inhibit T cell anti-tumor function. On the other
hand, other host factors that can affect T cell function and ACT immunotherapy efficacy remain
well understudied. An example of this is the effect of sex and sex hormone signaling on the T
cell anti-tumor function during immunotherapy. The sex hormone estrogen is present at
physiological concentrations in females, and lower concentrations in males and post-menopausal
females. Interestingly, some tumor and tumor-adjacent cells were shown to upregulate the
expression of aromatase, the enzyme that synthesizes estrogen, which results in significantly
increased estrogen concentrations in the TME. This indicates that adoptively transferred T cells
will be exposed to different concentrations of estrogen throughout the body including the
peripheral circulation depending on the sex of the patient, and then the TME.
Estrogen signaling can affect the differentiation, maturation and function of immune cells
depending on various factors such as the concentration of hormone present, and the different
estrogen receptor signaling pathways. Given that, one important mechanism of estrogen
modulation of the immune system is by altering the differentiation, function, and cytokine
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production of T cells. Estrogen signaling at physiological concentrations is generally proinflammatory and enhances the function of T cells. However, the effect of estrogen on T cell
function at non-physiological concentrations like the ones found the TME remains unclear.
The effects of estrogen signaling on T cells and other immune cells results on differences
on pathogenesis of diseases that arise from immune cell function dysregulation, like
autoimmunity, or diseases that are heavily controlled by immune responses, like infections and
cancer. Estrogen generally enhances the pathogenesis of autoimmunity while is protective
against some infections and non-reproductive cancers. One malignancy that is heavily affected
by estrogen is HCC. HCC is significantly more prevalent in males compared to pre-menopausal
females [360, 361]. Post-menopausal females that are not undergoing estrogen HRT are also
more prone to develop HCC than pre-menopausal females and estrogen users. The protective
role of estrogen against HCC was shown to be mediated by estrogen receptor signaling inhibition
of IL-6-mediated chronic inflammation and tumor infiltrating macrophage polarization. The role
of estrogen signaling on other HCC tumor infiltrating immune cells remains unclear and needs
further investigation.
The goal of this dissertation is to better understand the effect of estrogen signaling on
genetically modified T cells used in ACT immunotherapy. The effect of estrogen signaling on T
cell function, cytokine production and polyfunctionality will be investigated at physiological and
non-physiological high estrogen concentrations. In addition, due to the many possibilities in
estrogen receptors and different downstream signaling, the receptors through which estrogen
predominantly signals in T cells from males and females, and the signaling happening
downstream from the estrogen receptors will be investigated in the context of immunotherapy.
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Lastly, using a novel HCC preclinical model, the effect of estrogen presence during ACT
immunotherapy will be measured. Taken together, these studies will help to understand how
estrogen can be beneficial or disadvantageous for T cell function in anti-tumor immune
responses and will aid to design better and stronger T cells for adoptive cell transfer ACT
immunotherapy.

CHAPTER II
MATERIALS AND METHODS
T Cells
All human female and male PBMCs samples used for T cell transductions were obtained
from HLA-A2+ buffy coats purchased from Zenbio Inc. (Research triangle Park, NC). T cells
were derived from the PBMCs of healthy donors isolated from buffy coats using Ficoll-Hypaque
(Sigma-Aldrich, St. Louis, MO) density gradient centrifugation. T cells were then maintained on
AIM-V serum-free media (Gibco) containing 10% pooled human male AB serum (SigmaAldrich), 300 IU/mL recombinant human IL-2, and 100 ng/mL recombinant human IL-15 (rhIL2 and rhIL-15, National Institute of Health, Biological Resources Branch Bethesda, MD) at 37ºC
in a humidified 5% CO2 incubator.
HCV1406 TCR Retroviral Vector
The retroviral vector containing the TCR specific for the HCV antigen was generated by
introducing the TCR chain genes and a truncated CD34 (CD34t) molecule lacking its
intracellular signaling domain into an original SAMEN vector described by Treisman et al. [362364]. The modified SAMEN vector, denominated HCV1406, contains the sequence for the  and
 chains of the TCR specific for the HCV non-structural protein 3 (NS3) antigen (amino acids
1406-1415) separated by a P2A-self-cleaving linker, and then it contains the CD34t sequence
separated by a T2A self-cleaving linker (Figure 5) [51, 358, 365]. The HCV1406 TCR retroviral
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vector was used to generate a high viral titer producer PG13 cell line which retroviral supernatant
was used to transduce human male and female primary T cells.

Figure 5. Structure of the HCV1406 TCR Retroviral Vector Used to Transduce Human Male
and Female T Cells. TCR retroviral vector containing the HCV1406 TCR  and  chain genes
fused by a P2A self-cleaving peptide linker. A truncated version of the CD34 molecule (CD34t)
missing the intracellular signaling domain serves as a marker for transduction and it is fused to
the 3’ end of the TCR b chain via a T2A self-cleaving peptide. LTR: long terminal repeat, SD:
splicing donor, SA: splicing acceptor, ’: packaging signal. This retroviral vector was previously
described by Rosen et al. J. Immunol. 2004.

Generation of High Viral Titer Producer PG13 Cells
To generate stable virus producer cells, 3×106 HEK-293gp cells were plated in a 10 cm
tissue culture plate in DMEM medium (Gibco) containing 10% FBS. The next day, the HEK293gp cells were transfected with 20 g of the HCV1406 TCR retroviral vector and 5g of a
plasmid encoding the vesicular stomatitis virus envelope gene in 50 L of Lipofectamine 2000
(LifeTechnologies). After six hours, the supernatant was carefully removed and replaced with 10
mL of fresh DMEM containing 10% FBS. After 48-hour incubation at 37ºC in a humidified 5%
CO2 incubator the viral supernatant was collected and filtered through a 0.45 m cellulose
acetate syringe filter (VWR). 2×106 PG13 cells were plated in a 10 cm tissue culture plate and
the viral supernatant from the HEK-293gp cells was used to transduce them over three days
while incubated at 37ºC in a humidified 5% CO2 incubator. Transduction efficiency was
quantified by measuring CD34 expression via flow cytometry with an anti-human CD34-PE
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antibody (BioLegend), and transduced cells were sorted for high and uniform CD34 expression
using a FACS Aria Illu cell sorter (BD BioSciences).
In order to generate HCV1406 TCR retrovirus for transductions, 10x106 sorted stable
producer PG13 cells were plated in a T-175 flask and treated with IMDM media supplemented
with 10% FBS, 1 M sodium butyrate (Sigma-Aldrich), and 10 mM HEPES (Gibco) for 8 to 10
hours. After treatment, sodium butyrate containing media was replaced with IMDM
supplemented with 10% FBS and cells were incubated overnight. Then, fresh retroviral
supernatant was collected and filtered through a 0.45 m cellulose acetate syringe filter and used
for T cell transduction.
HCV1406 Retroviral T cell Transduction
Primary human male and female T cells obtained from HLA-A2+ buffy coats were transduced
via inoculation [366, 367]. Prior to retroviral transduction, primary human male and female T
cells were activated with 50 ng/mL of anti-CD3 mAb OKT3 (BioLegend, San Diego, CA) for
four to five days. 24-well flat-bottom non-tissue culture plates (VWR) were coated with 30
mg/mL Retronectin (Takara, Otsu, Japan) in 0.5 mL of DPBS (Dulbecco’s modified phosphate
buffered saline) (Gibco) overnight at 4ºC. Before transduction, Retronectin coated plates were
blocked with 2% PBSA (bovine serum albumin in PBS) for 30 minutes at room temperature
(RT) and washed with DPBS. Then, 2 mL of fresh retroviral supernatant was added to each well
and plates were spun for 2 hours at 32ºC at 2,000×g. Then, viral supernatants were aspirated and
2×106 activated T cells were placed on each well in 1 mL of AIM-V media containing 10%
human serum, 600 IU/mL rhIL-2, and 200 ng/mL rhIL-15 in combination with 1 mL of retroviral
supernatant. Plates were spun for 2 hours at 32ºC at 2,000×g. Plates were then incubated
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overnight at 37ºC in a 5% CO2 humidified incubator and then cells were transferred to tissueculture treated plates in supplemented AIM-V medium. Three or four days after, transduction
efficiency was measured via flow cytometry using human anti-human CD3-APC-Cy7 and antiCD34-AlexaFluor700 antibodies (BioLegend).
Transduced cells were sorted by adding anti-CD34 magnetic microbeads (Miltenyi) to the
T cells and passing them through a magnetic column (positive selection sorting). T cells that
remained magnetically attached to the column were eluted and purity of selection was confirmed
via flow cytometric analysis. All experiments described in this dissertation were performed using
>90% pure CD34+ transduced T cell populations.
Cell Lines and Media
The PG13 cell line (stable viral producer cell line) and the T2 cell line (CD3 negative,
TAP-deficient HLA-A2-expressing APC) were gifts from Dr. Nishimura, Loyola University
Chicago, Maywood. PG13 cells were maintained in IMEM medium (Gibco) supplemented with
10% fetal bovine serum (FBS) (VWR, Radnor, PA). T2 cells were maintained in RPMI 1640
medium (Gibco) supplemented with 10% FBS, 5% penicillin and streptomycin (Gibco), and 5%
L-glutamine (Gibco).
Sorting of CD4+ and CD8+ Ag-specific T cells
Human male and female HCV1406 TCR transduced T cells were sorted into CD4+ or
CD8+ populations using CD4 or CD8 negative selection magnetic microbead kits (Miltenyi
Biotec). Non-CD4+ or non-CD8+ cells were labeled with a cocktail of biotin-conjugated
antibodies as indicated by the manufacturer. Subsequently, non-CD4+ cells or non-CD8+ target

59

cells were magnetically labeled with beads and passed through a magnetic column that captured
them. The column flow-through was collected and contained >90% pure unlabeled CD4 + or
CD8+ T cells. Flow cytometry was used to ensure purification with antibodies anti-human CD3APCyCy7, CD4-PECy7, and CD8-FITC (BioLegend).
Estrogen and Estrogen Receptor Antagonists and Agonists
17-estradiol (≥98% purity) powder suitable for cell culture was obtained from SigmaAldrich and reconstituted in DMSO at a 10 M concentration. Human female and male Agspecific T cells were treated with 0.5 nM (physiological) or 50 nM (super-physiological) 17estradiol for 2 hours and control cells were treated with DMSO alone for 2 hours prior to coculture with target T2 cells. The ER antagonist 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP-dihydrochloride) (≥98% purity),
and the ER antagonist 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3yl]phenol (PHTPP) (≥99% purity) were obtained from Tocris Biotechne and were reconstituted
in in DMSO at a 10 M concentration [368, 369]. Human female and male Ag-specific T cells
were treated with 100 nM of either antagonist or both simultaneously for 2 hours in combination
with 0.5 or 50 nM 17-estradiol for 2 hours prior to co-culture with target T2 cells.
Isolation of Cytoplasmic and Nuclear Extracts
As previously described in Navarro & Watkins (Gender and the Genome, 2017), 3×106
Ag-specific T cells from male and female donors were treated with none, 0.5, or 50 nM E2 for 2,
10, 30, 60, or 120 minutes and nuclear and cytoplasmic protein extracts were obtained using the
NE-PER Nuclear Cytoplasmic Extraction Reagent Kit (Pierce, Rockford, IL) according to the
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manufacturer's instructions. Treated cells were washed twice with ice-cold phosphate buffered
saline (PBS) and centrifuged at 500×g for 5 minutes. Cell pellets were resuspended in 100 L of
cytoplasmic extraction reagent I (CER I) by vortexing and incubated on ice for 10 minutes
followed by the addition of 5.5 L of CER II. They were then vortexed for 5 seconds, incubated
on ice for 1 minute, and centrifuged for 5 minutes at 16000×g. The supernatant fraction
(cytoplasmic) was transferred to a pre-chilled tube and stored at -80°C. The insoluble fraction
was resuspended in 50 L of nuclear extraction reagent and vortexed every 10 minutes for a total
of 40 minutes. Tubes were centrifuged at 16000×g for 10 minutes, and the resulting supernatant
was collected (nuclear fraction) and stored at -80°C until further Western Blot analysis.
Western Blot Analysis
As previously described in Navarro & Watkins (Gender and the Genome, 2017), equal
amounts of nuclear and cytoplasmic protein isolated from estrogen treated male and female Agspecific T cells were loaded onto a sodium dodecyl sulfate (SDS)/polyacrylamide gel. After
electrophoresis, proteins were transferred into a polyvinylidene fluoride membrane (Bio-Rad)
and blocked for 1 hour with 5% BSA in Tris-buffered saline containing Tween-20. After
blocking, membranes were incubated overnight with the anti-human ER primary antibody
clone D8H8 (1:1000) (Cell Signaling Technologies) at 4°C while shaking. After washing,
membranes were incubated for 1 hour at RT with the horseradish peroxidase-conjugated antirabbit IgG secondary antibody (1:5000) (Cell Signaling Technologies). Proteins were detected
using an enhanced chemiluminescence substrate kit (Thermo Fisher). All blots were stripped and
re-probed with anti-human β-actin antibody (1:2000) or anti-human Lamin A/C (1:1000) (Cell
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signaling Technologies). Western blots were imaged using a ChemiDoc MP imaging system
(Bio-Rad) and quantified using the software ImageJ.
Peptides
HCV-NS3 (1406–1415): KLVALGINAV and tyrosinase (368–376): YMDGTMSQV
peptides were obtained from Synthetic Biomolecules (San Diego, CA). Peptides were
reconstituted in dimethyl sulfoxide (DMSO) and stored at -20ºC. For all the experiments
described, T2 cells were pulsed with 5µg/mL of either peptide for 2 to 4 hours at 37ºC in a 5%
CO2 humidified incubator.
Cytokine Release Assays
T cell cytokine secretion was measured in cytokine release assays such as enzyme-linked
immune absorbent spot (ELISPOT) and enzyme-linked immunosorbent assay (ELISA). 2.5×104
T2 cells loaded with peptides or HCV-expressing tumor cells were used as target cells. T2 cells
were pulsed with 5 g/mL of HCV1406 or tyrosinase peptides for 2-4 hours, and 2.5×104 human
male and female HCV Ag-specific T cells were treated with 0, 0.5, or 50 nM estrogen for two
hours. IFN and Granzyme B secretion was measured via ELISPOT by coating ethanol activated
ELISPOT plates with anti-human IFN (BD Biosciences) or anti-human Granzyme B (R&D
Systems) capture antibodies overnight at 4°C. Plates were blocked with RPMI containing 10%
FBS for 2 hours at RT. Treated T cells were co-cultured with pulsed T2 target cells at a 1:1 ratio
on coated ELISPOT plates for 18 hours at 37ºC in a 5% CO2 humidified incubator. Co-cultures
were then aspirated and the relevant biotinylated secondary and streptavidin–horseradish
peroxidase antibodies (Streptavidin-HRP, BD Biosciences) were added and plates were
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incubated for 2 hours or 1 hour respectively at RT. Plates were developed using 3-Amino-9ethylcarbazole (AEC) substrate (BD Biosciences) and spots were quantified using a CTL
ImmunoSpot S6 reader. After each step of this process, the plate was thoroughly washed 5 times
with PBS containing 0.05% Tween-20.
TNF and IL-4 secretion was measured via ELISA by coating 96-wells ELISA plates
with anti-human TNF or IL-4 (MabTech) capture antibodies overnight at 4°C. Plates were
blocked using PBS with 10% FBS for 1 hour at RT. Then, 100 L of co-culture supernatant and
standards were added to the plate and incubated for 2 hours at RT. This was followed by
incubating the plate with the relevant biotinylated secondary and streptavidin-HRP antibodies for
1 hour at RT. Plates were developed using tetramethylbenzidine (TMB) substrate and stopped by
adding 1 M sulfuric acid. The absorbance was then read at 450 nm in iMark Microplate
absorbance reader (Bio-Rad). After each step of this process, the plate was thoroughly washed 5
times with PBS containing 0.05% Tween-20.
Flow Cytometry
Fluorochrome-conjugated antibodies were used to detect human transduced Ag-specific
T cell surface markers (CD3, CD34, CD4 and CD8) and activation markers (CD25, CD69). In
functional assays, Ag-specific T cells were also stained for the lytic marker CD107a and
intracellular cytokines (IFN, TNF, IL-2, IL-4, IL-17a, IL-22, and Granzyme B). Intra-nuclear
staining was used to detect T cell transcription factors (T-Bet, GATA3, RORt, and FoxP3). A
table summarizing all flow cytometry antibodies used can be found in Table 1.
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Flow cytometry staining standard protocols were followed for measuring extra and
intracellular protein expression. Cells were spun in 5 mL polystyrene tubes (VWR) and washed
with PBS containing 2% FBS and 0.01% sodium azide (FACS buffer) twice. Cell suspensions
were treated with anti-CD16/32 antibody (BD Pharmigen) for 10 minutes to block Fc receptors
and non-specific staining. Next, cell suspensions were incubated with extracellular marker
antibodies for 30 minutes at 4°C in the dark. Cells were washed to remove antibody excess and
incubated with intracellular fixation buffer (BioLegend) for 20 minutes at 4°C in the dark and
then washed twice with permeabilization buffer (BioLegend). Fixed and permeabilized cells
were then incubated with intracellular marker antibodies for 30 minutes at 4°C in the dark. Then,
cells were washed with permeabilization buffer and staining was measured in a BD Fortessa flow
cytometer. Data were analyzed using FlowJo software package.
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Table 1. Antibodies Used for Flow Cytometry Staining.

For transcription factor staining, cells that had been stained for extracellular markers
were incubated in 1 mL of Foxp3 Fixation/Permeabilization working solution (eBioscience) for
45 minutes at RT in the dark and then washed twice with permeabilization buffer (eBioscience).
Fixed and permeabilized cells were then incubated with transcription factor antibodies for 45
minutes at RT in the dark. Then, cells were washed with permeabilization buffer and staining
was measured in a BD Fortessa flow cytometer. Data were analyzed using FlowJo software
package.
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Multi-Intracellular Cytokine Assay
2.5×105 human male and female sorted HCV Ag-specific T cells were treated with 0, 0.5,
or 50 nM estrogen in combination with 100 nM MPP-dihydrochloride (ER inhibitor), or 100
nM PHTPP (ER inhibitor), or 100 nM of both MPP-dihydrochloride and PHTPP
simultaneously for 2 hours. Treated T cells were then co-cultured with 2.5×105 T2 cells that had
been pulsed with 5g/mL of HCV NS3 or tyrosinase peptides at 37ºC for 5 hours in the presence
of protein transport inhibitors GolgiPlug and GolgiStop (BD Biosceinces). Then extracellular
staining for markers CD3, CD34, CD4, CD8, and CD107a was performed as described before.
Subsequently, cells were fixed and permeabilized and staining for intracellular markers IFN,
TNF, IL-2, IL-4, IL-17a, IL-22 was performed as described before. Samples were ran in a BD
Fortessa flow cytometer and analyzed using FlowJoX.
Gating strategy to analyze these data consisted on selecting the singlet population (FSCA vs FSC-H), and then the T cell population was gated individually from T2 cells by FSC vs
SSC comparison. T cells were gated on CD3+CD34+ populations and then Ag-specific T cells
were gated on CD8+CD4- or CD8-CD4+ populations. These CD3+CD34+CD8+CD4- or
CD3+CD34+CD8-CD4+ populations were used as starting point for subsequent functional
analysis. Functional parameters included CD107a, IFN, TNF, IL-2, IL-4, IL-17a, and IL-22.
All these parameters were gated against SSC to obtain the percent frequency of
CD3+CD34+CD8+CD4- or CD3+CD34+CD8-CD4+expressing each of them
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Polyfunctional Flow Cytometry Data Analysis
In order to obtain the levels of expression of all the possible marker combinations,
Boolean combinatorial gating was applied to the seven markers expressed in both the
CD3+CD34+CD8+CD4- and CD3+CD34+CD8-CD4+ population. Boolean combinatorial gating
yielded a total of 128 marker combinations (2 n n=7 27=128). This seven-parameter functional
analysis yielded a dataset way too complex to graphically depict in FlowJoX. Comparisons of
expression of all these marker combination between sexes and estrogen and estrogen receptor
inhibitor treatments were also too complicated to perform using FlowJoX. Subsequent analysis
of these data was performed using the software Simplified Presentation of Incredibly Complex
Evaluation (SPICE). Pre-processing of the data was performed using the software Pestle. After
combinatorial Boolean gating, Pestle offers data formatting and background subtraction of
multivariate data sets. The polyfunctionality data obtained from Ag-specific T cells stimulated
with T2 cells pulsed with tyrosinase was used for background subtraction. Data sets were then
imported to SPICE for graphical analysis. While background subtraction can result in below zero
values, SPICE has a threshold approach which will minimize systematic bias and can maximize
the amount of information that can be gained from positive measurements [370]. Visualization of
data includes pie charts, bar graphs, and cool plots, a type of heat map. Heat maps were chosen
to represent the data. The mean of the percent frequency expression of each cytokine
combination for the 15 female and 15 male donors mean values were plotted in the heat maps.
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Animal Experiments
All NOD.Cg-Mcph1Tg(HLA-A2.1)1Enge Prkdcscid Il2rgtm1Wjl/SzJ (NSG-A2) mice aged 6-8
weeks were obtained from The Jackson Laboratory. Bilateral ovariectomies or sham surgeries
were performed on female and male mice. Briefly, any mouse having surgery was placed on
Carprofen gel diet (MediGel) 24 hours preceding surgery and kept on that diet for 72 hours postoperation. Each animal also received Enrofloxacin (Bayer Animal Health) injected
subcutaneously at 10 mg/kg as a broad-spectrum antibiotic. The animal was then anesthetized
using Isoflurane (Abbott Labs) and placed on its sternum and prepared for surgery using 70%
ethanol and iodine wipes. Two 1 cm skin incisions were made longitudinally over the animal’s
fat pads, then one at the time, the fat pads were pulled from the body cavity until the ovaries
were exposed. Ovaries were dissected away from the fat pad and the remaining uterine horns
were placed back into the cavity (this step was skipped during sham surgeries). Skin was closed
using 9 mm skin clips on each side. Then, the animal was placed in a clean cage with access to
Carprofen gel diet and Enrofloxacin treatments as indicated before. Skin clips were removed 14
days post-operation and tumor challenge was then performed.
To generate HCC tumors, human oncogenes c-MET and -catenin, and the HCV:NS3
antigen expressions vectors in combination with sleeping beauty (SB) transposons were used
[371, 372]. Plasmids maps containing the expression vectors for c-Met, catenin and sleeping
beauty transposase are described in Figure 6. The structure of the HCV NS3 expression vector is
described in Figure 7. 9 g of pT3hMET, 9 g of pT3CAT, and 9 g of pCDNAIII-NS3
(containing the sequence of the HCV:NS3 peptide) in combination with SB transposase at a 2:1
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ratio were diluted in 2 mL of normal saline (0.9% NaCl), filtered through a 0.2 m filter
(Corning), and injected into the lateral tail vein of female ovariectomized/sham mice or male
sham mice that were around 8-9 weeks old in <7 seconds. At day 20 or day 40 after tumor
challenge, mice were given ACT immunotherapy consisting of 10×106 sex-matched human HCV
Ag-specific T cells via tail vein injection. Mice that received ACT were given 2.5 g of rhIL-15
every 3 days to ensure human Ag-specific T cell survival. 20 days after T cell transfer, mice
were sacrificed, and livers and spleens were collected for analysis. All mice were housed under
specific pathogen-free conditions and were treated in accordance with NIH guidelines under
protocols approved by the animal care and use committee (IACUC) of Loyola University
Chicago (Maywood, IL).
Cell Isolations
Human Ag-specific T cells were isolated from single cell suspensions of tumors obtained
by digesting livers with 1 mg/mL collagenase D (Roche) for 30 minutes at 37°C while shaking
and dissociating them using a Stomacher bag (Sewer). Liver single cell suspensions were then
subjected to a Percoll (GE Healthcare) density gradient. Briefly, cell suspensions were prepared
in 10 mL cell culture media and underlayed with 40% and subsequently 80% Percoll to separate
out lymphocytes from tumor cells. Cells were collected at the 40/80 interface for further analysis.
Human Ag-specific T cells were also isolated from spleen single cell suspensions obtained by
pushing the tissue through a 70 m nylon filter. Then, red blood cells were lysed using
ammonium-chloride-potassium (ACK) lysis buffer (Lonza).
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Figure 6. Vector Maps of Human c-MET and Catenin-P3T, and Sleeping Beauty 100
Transposase-pCMV Used to Generate HCC in Mice. A) Human c-MET (9745 bp) and B)
human Catenin (7691 bp) are shown in the black arrows. C) Human SB100 (4752 bp) is shown
in the cyan after the T7 promoter. These vectors were previously described by Tward et al.
PNAS. 2007.

Figure 7. Structure of the pcDNAIII Vector Containing the HCV NS3 Sequence. The full
sequence of the HCV non-structural protein 3 (NS3) was linked to GFP with a T2A self-cleaving
peptide. LTR: long terminal repeat, SD: splicing donor, SA: splicing acceptor, ’: packaging
signal. This pdNAIII vector was described by Spear et al. Cancer Immunol Immunother. 2016.
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ELISPOT Using Tumor Cells as Targets
NSG-A2+ mice were injected with MET/CAT/HCV or MET/CAT hydrodynamically and
tumors were left to develop for 60 days. On day 60 tumors were extracted and digested using 1
mg/mL of collagenase D as previously described. Single cell suspensions of tumor cells were
washed using RPMI containing 10% FBS and counted. 2.5×105 tumor cells from mice injected
with MET/CAT/HCV or MET/CAT were then co-cultured with human female and male HCV
Ag-specific T cells from 3 different donors in triplicates in a 1:1 ratio for 18 hours on an antihuman IFN coated ELISPOT plate. After 18 hour co-culture plates were developed as
previously described and spots were quantified.
Statistical Analysis
All data are represented as the mean ± standard error of the mean (SEM). All the
statistical analyses were conducted using GraphPad Prism (version 7). For experiments that did
not require group wise comparisons, student’s t test was used with significance set at p<0.05. For
experiments that did require group wise comparisons, 1 or 2 way ANOVA were used with a
Tukey’s post-hoc test with significance set at p<0.05.
For experiments analyzing the effect of estrogen signaling on T cell polyfunctionality,
data were analyzed using MANOVA with a Tukey’s post-hoc test with significance set at
p<0.05. In order to test whether the effects of estrogen inhibitor treatments on the percent
expression for a given cytokine combination vary significantly based on estrogen treatment, and
vice versa, Michael Wesolowski, MPH (Clinical Research Office, Loyola University Chicago,
IL) performed linear regression model. Mixed-effects linear regression models were used to

72

estimate the expression of unique cytokine combinations for various estrogen and estrogen
inhibitor treatment combinations. Models including an estrogen main effect, an estrogen
inhibitor main effect, and an estrogen x estrogen inhibitor interaction term were run for each
unique cytokine combination. These models featured random intercepts to account for withindonor correlations existing between cells and treatments related to the same donor, and
unstructured variance-covariance structures. The estimated effects of estrogen and estrogen
inhibitor treatment combinations, as well as the average estimated cytokine expression for each
estrogen and estrogen inhibitor treatment combination, are reported. Post-hoc pairwise
comparisons between each index estrogen treatment (50 & 0.5) and the reference estrogen
treatment (0) were conducted within each estrogen inhibitor treatment stratum. Separate models
were run for each of 83 unique cytokine combinations, and as a result, an experiment-wise
Sidak-corrected significance level of α = 0.000618 was used to control the Type I error rate. An
additional Sidak adjustment was used to correct p values for the multiple, post-hoc pairwise
comparison tests.
Mixed-effects linear regression model was described as:
Within-Donor Model:
𝐶𝑦𝑡𝑜𝑘𝑖𝑛𝑒 𝐶𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛𝑖𝑗 = 𝑏0𝑖 + 𝑏1𝑖 *𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑖𝑗 + 𝑏2𝑖 *𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛𝑖𝑗
+ 𝑏3𝑖 *𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑖𝑗 *𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛𝑖𝑗 + 𝜀𝑖𝑗
Between-Donor Model:
𝑏0𝑖 = 𝛽0 + 𝜈0𝑖
𝑏1𝑖 = 𝛽1
𝑏2𝑖 = 𝛽2
𝑏3𝑖 = 𝛽3

CHAPTER III
ESTROGEN SIGNALING THROUGH ER AND ER DIFFRENTIALLY IMPACTS
HUMAN MALE AND FEMALE AG-SPECIFIC T CELL CYTOKINE PRODUCTION

Introduction and Rationale
Immunotherapy is a treatment modality that was proven to be effective in many types of
difficult to treat cancer, and it is a promising therapy option for HCC. Treatment of HCC patients
with checkpoint blockade immunotherapy showed some success with 20% partial response rates
[342]. Many tumor specific antigens that can be used as targets of T cells for ACT
immunotherapy were identified including but not limited to GPC3, -fetoprotein, MUC-1, and
the viral proteins of HCV and HBV [350, 351, 354, 357]. Even if ACT immunotherapy brings
hope for the treatment of HCC, critical aspects that need to be further improved upon during
immunotherapy include facilitating greater T cell tumor infiltration, avoiding T cell exhaustion,
and reducing adverse side effects such as cytokine storm. The role of host factors including sex
and estrogen signaling has never been investigated in ACT immunotherapy for HCC. Adoptively
transferred T cells are exposed to different estrogen concentrations in the body including
physiological estrogen or low estrogen depending on the sex and reproductive state of the
patient, and super-physiological estrogen in the TME. Considering that estrogen has a protective
role against HCC through mechanisms involving inflammation, it can be hypothesized that
estrogen signaling enhances T cell function and anti-tumor response which subsequently can
enhance the efficacy of ACT immunotherapy. Estrogen signaling in immune cells is highly
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dependent on concentration and estrogen receptor subtype hence it is necessary to investigate
these factors on immune cells mediating the anti-tumor immune response in order to optimize
immunotherapy treatment against HCC. This dissertation is based in studying the effects of
estrogen signaling on the function of TCR transduced T cells used for immunotherapy.
In order to characterize the effect of estrogen signaling on Ag-specific T cells used for
ACT immunotherapy against HCC, HCV was chosen as a model target antigen. HCV infects
approximately 140 million people worldwide and chronic HCV infection can result in associated
liver disease including cirrhosis and HCC [284]. Moreover, 50 to 80% of HCC cases derive from
chronic HCV infection [373]. Even if HCV protease inhibitor anti-viral drugs Telaprevir,
Boceprevir, and Simeprevir were developed and recently approved for clinical use [374, 375],
the rapidly mutating HCV genome generates drug resistance in hepatocyte [376, 377]. In
addition, many patients treated with anti-viral drugs have already developed associated liver
disease, such as cirrhosis, that cannot be treated with these drugs. Knowing all this, a TCR that
recognizes the HCV NS3 (amino acids 1406 to 1415) antigen was selected. This TCR,
denominated HCV1406, was isolated from a T cell clone found in an HLA-A2+ HCV+ HCC
patient that received an HLA-A2+ liver transplant [378]. T cells genetically modified with this
TCR were previously shown to recognize HCV+ target cells in vitro in an HLA-A2-dependent
manner, and to be able to reject patient-derived xenografts (PDX) tumors in vivo [51]. In the
following sections, the effect of estrogen signaling on human male and female HCV Ag-specific
T cell cytokine expression and production are described.
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Results
Ag-specific T cells from Male and Female Donors Express and Signal through ER in
Response to Estrogen Stimulation
To study the effect of estrogen signaling on human male and female Ag-specific T cells,
peripheral blood derived T cells from 15 healthy male and 15 healthy female donors were
transduced with the HCV1406 TCR (Figure 5). While 5 male and 5 female donors were of
unknown age, the remaining male and female donors were between 22 and 48 years old
corresponding to pre-menopausal age for female donors. The HCV1406 TCR retroviral vector
codes for a truncated version of CD34 (CD34t), which was used for transduction recognition and
purification of transduced T cells for further in vitro and in vivo studies. Transduction of either
male or female T cells with the HCV1406 TCR typically yielded around 30 to 60% transduction
efficiency (Figure 8 A). After purification by magnetic bead cell sorting using the CD34
expression as a target, studies described in this dissertation are based on the effect of estrogen on
a population of Ag-specific T cells at > 90% purity (Figure 8 A). HCV 1406 transduced sorted T
cells from male and female donors had very similar CD3+CD34+ mean fluoresce intensity (MFI)
which is important to achieve to ensure that differences on HCV1406 TCR expression between
donors did not give rise to differences on T cell activation and function (Figure 8 A). Transduced
T cell populations from male and females showed significantly higher frequencies of CD8 +
compared to CD4+ T cells but there were no significant differences on T cell subset distribution
between sexes (Figure 8 B, C).
After transduction and CD34+ purification, male and female HCV Ag-specific T cells
were sorted into CD4+ and CD8+ populations and ER expression was tested via western blot.
There were no sex-differences on the expression level of ER in the bulk population or in the
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CD4+ and CD8+ populations of Ag-specific T cells (Figure 9 A, B). CD4+ Ag-specific T cells
from both sexes showed significantly higher expression of ER compared to CD8+ T cells and
bulk T cell populations (Figure 9 A, B). In order to test if ER translocates into the nucleus after
estrogen ligand stimulation, male and female Ag-specific T cells were treated with no estrogen
(0), physiological (0.5 nM), or super-physiological (50 nM) concentrations of E2 for 0, 2, 10, 30,
60, and 120 minutes before lysis of the cells and separation of cytoplasmic and nuclear fractions
to tests for ER expression. ER was expressed in the cytoplasm of the cell of male and female
Ag-specific T cells but its expression was significantly decreased after 2-minute estrogen
treatment on female T cells (Figure 9 C, E) and after 10-minute estrogen treatment on male cells
as demonstrated by normalizing expression to -actin as a loading control (Figure 9 C, F). On the
other hand, ER expression in the nucleus was quickly increased in male T cells after 2-minute
estrogen treatment (Figure 9 D, F), and increased overtime after estrogen stimulation in female T
cells as demonstrated by normalizing expression to Lamin A/C loading control (Figure 9 D, E).
The time course of E2 treatment revealed that nuclear translocation of ER upon E2 ligation is
very rapid, within 2 to 10 minutes, in male and female Ag-specific T cells. This rapid
translocation was found to be transient since cytoplasmic ER expression re-accumulated, and
nuclear ER expression diminished over time. Cytoplasmic and nuclear ER was not
significantly different during this time course between T cells treated with 0.5 nM or 50 nM
estrogen concentrations indicating that ER can quickly translocate into the nucleus of male and
female Ag-specific T cells upon ligand binding in physiological and super-physiological
conditions.
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Figure 8. T Cells from Male and Female Donors Were Transduced to Express the
HCV1406 TCR to Study Ag-specific T Cell Function. A) Representative flow cytometry dot
plots for one female and one male donor T cells before transduction showing T cell populations
with very low CD34 expression, after transduction showing T cell populations with variable
expression of CD34, and after CD34 magnetic bead sorting showing T cell populations over
+

+

+

+

95% CD3 CD34 . B) Representative dot plots for CD4 and CD8 T cell subsets of TCR
+

+

transduced and sorted T cells. C) CD4 and CD8 frequencies of TCR transduced and sorted T
cells from 15 female and 15 male human healthy donors. Each donor plotted and SEM
indicated. Analyzed using 2-way ANOVA with Tukey’s post-hoc. p<0.0001=****,
p<0.001=***.
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Figure 9. Female and Male HCV1406 TCR-transduced T Cells Express ER which
Rapidly Translocates into the Nucleus upon 17-estradiol (E2) Stimulation. A)
Representative western blot showing ER expression in the bulk Ag-specific T cell population
+

+

or sorted CD4 or CD8 T cells from one female and one male donor, and B) quantification of
+

+

the relative expression of ER compared to Actin in bulk T cells, CD4 , and CD8 sorted Agspecific T cells. TCR-transduced T cells were then treated with 0.5, or 50 nM E2 for 0, 2, 10,
30, 60, or 120 minutes and ER expression was measured via western blot from protein extracts
of C) the cytoplasm or D) the nucleus. ER expression compared to Actin cytoplasmic loading
control or Lamin A/C nuclear loading control was quantified for Ag-specific T cells from E)
female and F) male donors treated with 0.5 or 50 nM E2 and normalized to T cells treated with
no estrogen (0 nM). Data represents n=4 donors, each donor plotted and the SEM indicated.
Analyzed using 2-way ANOVA with Tukey’s post-hoc. p<0.001=***, p<0.01=**, p<0.05=*.
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This western blot analysis was not able to be performed to test for ER nuclear
translocation due to lack of reliable antibodies [379, 380]. ER was previously shown to be
expressed in human CD4+ and CD8+ T cells even if it was expressed at significantly lower levels
than ER  Knowing than ER and ER are highly homologous and have similar affinity
for the estrogen ligand [382], it can be hypothesized that ER also translocates into the nucleus
of Ag-specific T cells upon estrogen ligand binding. The roles of estrogen signaling through both
ER and ER on male and female Ag-specific T cell function were studied throughout this
dissertation.
Estrogen Signaling through ER and ER Differentially Modulates T cell Cytokine
Expression and Secretion
In order to determine the effect of physiological and super-physiological estrogen
signaling through ER and ER on T cell function, Ag-specific T cells were activated with their
HCV cognate antigen in the presence of estrogen and ER and ER selective inhibitors, and
cytokine production was measured. The best system to assess HCV1406 TCR-transduced T cell
activation and cytokine production would be to use HCV-expressing human liver cells or liver
tumor cells, but these cells were not available for the experiments described. As an alternative,
HLA-A2+ T2 cells were pulsed with the HCV NS3 antigen and used as Ag-specific T cell
targets. T2 cells pulsed with a tyrosinase irrelevant peptide were used as controls. Male and
female Ag-specific T cells were treated with no estrogen, physiological (0.5 nM), or superphysiological (50 nM) estrogen in combination with 100 nM of an ER, or ER selective
antagonists, or both inhibitors simultaneously for two hours. The ER and ER inhibitors used
were MPP-dihydrochloride and PHTPP respectively. MPP-dihydrochloride is a selective, high
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affinity silent antagonist of ER that displays greater than 200-fold selectivity of ER over
ER (Ki values are 2.7 and 1800 nM at ER and ER respectively) [383, 384]. PHTPP is a
selective ER antagonist that exhibits 36-fold selectivity for ER over ER (Ki values 139 nM
and 2.22 M at ER and ER respectively) [384].
Treated T cells were then co-cultured with pulsed T2 cells. Co-cultures were maintained
for 5 hours in the presence of protein transport inhibitors to avoid secretion of markers, and then
cells were stained and analyzed for expression of several T cell cytokines. The cytokines
assessed included IFN, TNF, IL-2, IL-4, IL-17a, IL-22 and the lytic marker CD107a was
assessed on the surface. These markers were chosen to represent the signature cytokines of the
different effector and helper T cell subsets (effector CD8+, and CD4+ Th1, Th2, Th17, and Th22)
excluding Tregs which do not mediate tumor cell killing or beneficial T helper responses for
immunotherapy. CD8+ effector T cells commonly secrete high amounts of cytotoxic granules
(Perforin and Granzymes), as well as IFN and TNF upon Ag stimulation and activation [385].
Effector CD4 Th1 cells can secrete IFN and TNF as well, while Th2 cells also secrete IL-4.
IL-17 and IL-22 were chosen to represent the Th17 and Th22 subsets respectively. Upon
activation, Ag-specific CD4+ and CD8+ T cells also produce IL-2 which promotes survival of
both CD4+ and CD8+ T cells, and induces subset differentiation of CD4+ T cells 5 [385]. CD107a
was chosen as an indicator of Granzyme B release [386]. Granzyme B is released by effector T
cells upon antigen stimulation and activation; it is a serine protease which activates apoptosis
once in the cytoplasm of the target cell [385, 386]. Gating strategy of these cytokines and
CD107a for CD4+ and CD8+ HCV Ag-specific T cells is represented in Figure 10. Gates were
selected for the CD3+CD34+ transduced T cell population and CD8+ and CD4+ T cell subsets
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were analyzed separately. For each T cell subset each cytokine and the lytic marker CD107a
were plotted against side scatter (SSC) and gated based on unstained controls. The dot plots in
Figure 10 represent the data obtained for CD8+ Ag-specific T cells of one donor out of the 30
analyzed. The majority of the donors showed highly increased frequency of CD8 + and CD4+ T
cells expressing IFN, CD107a and TNF upon activation which correspond to a cytotoxic CD8+
or an effector Th1 CD4+ T cell response. Some donors also showed increased frequency of CD4+
T cells expressing IL-4 upon activation corresponding to Th2 responses. Surprisingly, CD8 + Agspecific T cells also expressed IL-4 upon antigen stimulation. IL-2 was expressed by low
frequencies of activated T cells. Recombinant human IL-2 was added to Ag-specific T cell
cultures during their expansion after transduction and this IL-2 supplementation could be the
reason why activated Ag-specific T cells do not express high IL-2 upon antigen stimulation.
Also, IL-4 is another gamma cytokine that was shown to enhance the survival of T cells and
promote memory formation [387-389] indicating that T cells in these experiments could be
partially surviving by IL-4 downstream signaling instead of IL-2. IL-22 and IL-17 were
expressed in very low frequencies of T cells upon activation indicating low Th17 and Th22
responses (Figure 10). ELISPOT or ELISA were used to measure effector and helper T cell
cytokine secretion including TNF, IL-4, IFN, and Granzyme B from the co-cultures of
estrogen treated Ag-specific T cells from male and female donors and T2 cells pulsed with the
HCV antigen or the tyrosinase irrelevant peptide. While the expression or secretion of several of
the cytokines tested were not directly affected by estrogen receptor signaling, the expression and
secretion of three of the cytokines (TNF, IL-4, and IFN) and the lytic molecule Granzyme B
were significantly changed upon estrogen stimulation and estrogen receptor signaling as
described in the following sections.
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Figure 10. Representative Gating Strategy to Measure Cytokine and CD107a Expression
on HCV 1406 TCR-transduced T Cells. T cells were activated with T2 target cells pulsed with
the HCV NS3 relevant antigen, T2(HCV), or an tyrosinase irrelevant peptide, T2(TYRO).
+
+
Singlet cells were gated in the lymphocyte population, and then CD4 CD34 transduced T cells
+
+
were gated into CD4 and CD8 populations. Cytokines and CD107a were gated against side
+
+
scatter (SSC) for both CD4 and CD8 transduced T cell populations.
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Estrogen Signaling Through ER Enhances TNF Expression and Secretion in a Dose
Dependent Manner
The percent frequency of male and female transduced CD8+ T cells stimulated with the
HCV cognate antigen expressing TNF was significantly increased upon super-physiological
estrogen stimulation (Figure 11 B). The estrogen-mediated increase of TNF expression was
abrogated when male and female CD8+ T cells were treated with estrogen in combination with an
ER inhibitor, or when T cells were treated with estrogen in combination with ER and ER
inhibitors simultaneously (Figure 11 B). On the other hand, the estrogen-mediated increase of
TNF expression was not affected by blocking ER signaling with an R-specific inhibitor
(Figure 11 B). A representative example of these flow cytometry results is depicted in Figure 11
A. These data indicate that super-physiological estrogen enhances the expression of TNF in
male and female CD8+ Ag-specific T cells through ER and not ER mediated signaling. The
expression of TNF in CD4+ male and female Ag-specific T cells showed similar trends like the
ones observed in CD8+ T cells but due to variability among donors resulting in larger error bars,
significance was not achieved (Figure 11 C). There were no sex differences observed in the
expression of TNF since similar frequencies of CD8+ and CD4+ male and female T cells
expressed TNF upon activation (Figure 11 B, C).
TNF secretion by male and female Ag-specific T cells stimulated with cognate or
irrelevant antigen was measured via ELISA. Estrogen stimulation of male and female Agspecific T cells significantly increased TNF secretion at physiological (0.5 nM), and superphysiological (50 nM) concentration (Figure 11 D, E).
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Figure 11. Estrogen Signaling through ER Enhances TNF Expression and Secretion in Female and Male Ag-specific T
Cells upon Ag Stimulation. Male and female HCV Ag-specific T cells were treated with no estrogen, physiological (0.5 nM), or
super-physiological (50 nM) estrogen in combination with 100 nM of an ER inhibitor (MPP-dihydrochloride), an ER inhibitor
(PHTPP), or both inhibitors simultaneously for 2 hours prior to activation with T2 cells pulsed with HCV cognate antigen or a
tyrosinase irrelevant peptide. After 5 hour activation in the presence of protein transport inhibitors, T cells were analyzed for TNF
expression via flow cytometry intracellular staining. A) Representative dot plots for the expression of TNF in treated T cells from
+
+
one donor. B) & C) The percent frequency of female and male activated B) CD8 and C) CD4 Ag-specific T cells expressing TNF
after being treated with 0, 0.5, or 50 nM estrogen in combination with ER inhibitors. D) & E) In order to measure TNF secretion,
the supernatant of 18 hour co-cultures containing equal number of estrogen treated T cells and pulsed T2 target cells were tested via
anti-human TNF ELISA. Data represents n=15 or n=4 donors, each donor plotted and the SEM indicated. Analyzed using 2-way
ANOVA with Tukey’s post-hoc. p<0.01=**, p<0.05=* comparing the different estrogen receptor treatment groups. p<0.0001=####,
p<0.001=###, p<0.01=##, p<0.05=# comparing estrogen treatments (0, 0.5, 50 nM) within each group.
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Overall these data indicate that estrogen stimulation can enhance the secretion of TNF,
and estrogen signaling through ER can enhance the expression of TNF on CD8+ male and
female Ag-specific T cells.
Estrogen Signaling Through ER Modulates the Overall Expression of IL-4, and Further
Enhances its Expression and Secretion in a Dose Dependent Manner
The percent frequency of male and female transduced CD8+ T cells stimulated with their
HCV cognate antigen expressing IL-4 was significantly increased upon estrogen stimulation at
physiological and super-physiological concentrations (Figure 12 B). The estrogen-mediated
increase in IL-4 expression was completely abrogated when male and female CD8 + T cells were
treated with estrogen in combination with an ER inhibitor or with ER and ER inhibitors
simultaneously (Figure 12 B). Not only the estrogen-mediated increase on IL-4 expression was
abrogated but IL-4 expression was decreased to the levels observed in CD8+ T cells stimulated
with the tyrosinase irrelevant antigen (Figure 12 B). On the other hand, blocking ER during
estrogen stimulation showed no effect on the estrogen-mediated increase, or the overall IL-4
expression of male and female CD8+ Ag-specific T cells (Figure 12 B). Similar results were
obtained regarding the expression of IL-4 on estrogen stimulated CD4+ male and female Agspecific T cells. Estrogen stimulation significantly increased the frequency of CD4 + T cells
expressing IL-4 upon cognate antigen activation, and the blockade of ER signaling during
estrogen stimulation decreased IL-4 to the levels of Ag-specific T cells activated with tyrosinase
(irrelevant peptide) (Figure 12 C). Blockade of ER signaling during estrogen stimulation had no
effect on the estrogen-mediated increase of IL-4 expression (Figure 12 C). There were no sex
differences observed in the expression of IL-4 since similar frequencies of CD8+ and CD4+ male
and female T cells expressed IL-4 upon activation (Figure 12 B, C). These data indicate that
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estrogen signaling through ER and not ER modulates the overall expression, and the estrogenmediated enhancement of expression of IL-4 in male and female Ag-specific T cells.
IL-4 secretion by male and female Ag-specific T cells stimulated with cognate or
irrelevant antigen was measured via ELISA. Estrogen stimulation at physiological (0.5 nM), and
super-physiological (50 nM) concentrations significantly increased IL-4 secretion of male and
female Ag-specific T cells (Figure 12 D, E). Interestingly, estrogen stimulation increased the
secretion of IL-4 on male T cells activated with tyrosinase irrelevant antigen (Figure 12 E). This
indicates that estrogen stimulation can directly upregulate IL-4 secretion independently from
TCR stimulation and T cell activation. These results demonstrate that estrogen signaling through
ER and not ER modulates the overall expression of IL-4, and estrogen stimulation at
physiological and super-physiological concentrations enhances IL-4 expression and secretion on
male and female activated Ag-specific T cells.
Ideally, in order to conclude that Estrogen signaling through ER directly enhances
expression and secretion of TNF and IL-4, a different set of experiments need to be performed
in which human Ag-specific T cells are treated with an ER agonist instead of estrogen. The
ER selective agonist 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) which shows
a 410-fold selectivity for ER over ER can be used [368, 369]. If expression and/or secretion of
TNF and IL-4 are enhanced in male and female Ag-specific T cells treated with PPT after Ag
stimulation to levels similar to those treated with estrogen, then ER alone may enhance the
expression/secretion of these cytokines. This can be fully concluded if the PPT-mediated
enhancement on the cytokine expression/production is abrogated in T cells treated with PPT and
MPP-dihydrochloride (ER antagonist) simultaneously.
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Figure 12. Estrogen Signaling through ER Modulates Overall IL-4 Expression and Enhances IL-4 Secretion on Male and
Female Ag-specific T Cells upon Ag Stimulation. Male and female HCV Ag-specific T cells were treated with no estrogen,
physiological (0.5 nM), or super-physiological (50 nM) estrogen in combination with 100 nM of an ER inhibitor (MPPdihydrochloride), an ER inhibitor (PHTPP), or both inhibitors simultaneously for 2 hours prior to activation with T2 cells pulsed
with HCV cognate antigen or a tyrosinase irrelevant peptide. After 5 hour activation in the presence of protein transport inhibitors, T
cells were analyzed for IL-4 expression via flow cytometry intracellular staining. A) Representative flow cytometry dot plots for the
expression of IL-4 in treated T cells from one donor out of the 30 tested. B) & C) The percent frequency of female and male activated
+
+
B) CD8 and C) CD4 Ag-specific T cells expressing IL-4 after being treated with 0, 0.5, or 50 nM estrogen in combination with ER
inhibitors. D) & E) In order to measure IL-4 secretion, the supernatant of 18 hour co-cultures containing equal number of estrogen
treated T cells and pulsed T2 target cells were tested via anti-human IL-4 ELISA. Data represents n=15 or n=4 donors, each donor
plotted and the SEM indicated. Analyzed using 2-way ANOVA with Tukey’s post-hoc. P<0.001=***, p<0.01=**, p<0.05=*
Comparing the different estrogen receptor treatment groups. p<0.0001=####, p<0.001=###, p<0.01=##, p<0.05=# comparing
estrogen treatments (0, 0.5, 50 nM) within each group.
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On the other hand, if treating Ag-specific T cells with PPT does not enhance cytokine
expression upon Ag-stimulation, then estrogen signaling through other receptor is mediating this
effect. Inhibition of ER showed no effect on the estrogen-mediated enhancement of these
cytokines’ expression indicating that ER signaling is not required for their expression. Estrogen
signaling through GPER could be enhancing T cell cytokine expression in response to Ag. To
investigate that possibility, male and female Ag-specific T cells need to be treated with estrogen
in combination of a GPER antagonist. If the expression of TNF and IL-4 is decreased in T cells
treated with estrogen in combination of a GPER antagonist compared to estrogen treated cells
then, estrogen is enhancing TNF and IL-4 expression through GPER. GPER signaling was
shown to upregulate expression of some cytokines such as IL-10 and IL-1 [390, 391] so there is
a possibility that GPER signaling controls expression of other cytokines such as TNF and IL-4.
Unfortunately, these experiments could not be performed, but these results in combination with
the ones reported in this chapter, would indicate that estrogen signaling through ER and GPER
enhance Ag-specific T cell cytokine expression and secretion.
Estrogen Stimulation Enhances Ag-specific T cell IFN and Granzyme B Secretion
Even if some trends were observed, the frequency of male and female CD4+ and CD8+
Ag-specific T cells expressing IFN was not significantly changed by estrogen stimulation and
estrogen receptor signaling during activation as measured by flow cytometry (Figure 13 A, B).
The trends observed indicated that estrogen stimulation increased IFN expression possibly
through ER and not ER. Although IFN expression was not significantly affected by estrogen
stimulation, there was a significant increase on IFN secretion upon super-physiological estrogen
treatment in female and male CD8+ and CD4+ Ag-specific T cells activated with the HCV
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cognate antigen as measured by ELISPOT (Figure 13 C, D, E). Physiological estrogen
significantly increased the secretion of IFN in activated male CD4+ Ag-specific T cells (Figure
13 D). Interestingly, the secretion of IFN was overall higher in CD8+ and CD4+ Ag-specific T
cells from female donors compared to male donors (Figure 13 C, D, E). While female Agspecific T cells showed an average of 600 to 800 IFN spots at baseline estrogen, male T cells
showed an average of 300 IFN spots at baseline estrogen (Figure 13 C, D). Overall these data
demonstrate that estrogen significantly enhances the secretion of IFN on male and female CD4+
and CD8+ T cells upon antigen stimulation even if female T cells secrete more IFN than male T
cells in an estrogen-independent manner.
The secretion of Granzyme B was also measured via ELISPOT on estrogen treated male
and female activated Ag-specific T cells. There was a significant increase on Granzyme B
secretion on male and female CD8+ Ag-specific T cells treated with super-physiological estrogen
(Figure 14 A, B, C). The secretion of Granzyme B was also significantly increased by superphysiological estrogen treatment on female CD4+ Ag-specific T cells, and a trend was observed
for male CD4+ T cells even if significance was not achieved (Figure 14 A). The secretion of
Granzyme B by female CD4+ T cells was higher than by male CD4+ T cells at baseline estrogen
(around 100 average Granzyme B spots compared to 50) and it was increased significantly upon
estrogen treatment to around 300 Granzyme B spots compared to only around 100 spots in male
CD4+ T cells. Overall these results indicate that estrogen signaling enhances the secretion of
Granzyme B in female and male CD8+ T cells, and female CD4+ T cells which secrete more
Granzyme B than male T cells in an estrogen-independent manner
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Figure 13. Estrogen Signaling Enhances Male and Female Ag-specific T Cell IFN Secretion upon Ag Stimulation. Male and
female HCV Ag-specific T cells were treated with no estrogen, physiological (0.5 nM), or super-physiological (50 nM) estrogen in
combination with 100 nM of an ER inhibitor (MPP-dihydrochloride), an ER inhibitor (PHTPP), or both inhibitors simultaneously
for 2 hours prior to activation with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide. After 5 hour activation
in the presence of protein transport inhibitors, T cells were analyzed for IFN expression via flow cytometry intracellular staining.
+
+
A) & B) The percent frequency of female and male activated A) CD8 and B) CD4 Ag-specific T cells expressing IFN after being
treated with 0, 0.5, or 50 nM estrogen in combination with ER inhibitors. In order to measure IFN secretion, 18 hour co-cultures
+
+
containing equal number of estrogen treated C) female or D) male sorted CD8 or CD4 T cells and pulsed T2 target cells were tested
+
+
via ELISPOT. E) Representative ELISPOT plate image from co-cultures of CD8 or CD4 T cells from one female and male donor
out of the 4 donors tested. Data represents n=15 or n=4 donors, each donor plotted and the SEM indicated. Analyzed using 2-way
ANOVA with Tukey’s post-hoc. P<0.0001=****, p<0.01=**, p<0.05=*.
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Figure 14. Estrogen Signaling Enhances Granzyme B Secretion in Female and Male
+
+
CD8 Ag-specific T Cells, and Female CD4 Ag-specific T Cells upon Ag Stimulation.
In order to measure Granzyme B secretion, 18 hour co-cultures containing equal number
+
+
of estrogen treated A) female or B) male CD8 or CD4 T cells and pulsed T2 target cells
were tested via anti-human Granzyme B ELISPOT. C) Representative ELISPOT plate
+
+
from co-cultures of CD8 or CD4 T cells from one female and male donor out of the 4
donors tested. Data represents n=4 donors, each donor plotted and the SEM. Analyzed
using 2-way ANOVA with Tukey’s post-hoc. P<0.0001=****, p<0.01=**, p<0.05=*.
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Chapter Discussion
This chapter of the dissertation was aimed to determine the impact of sex and estrogen
signaling in regulating Ag-specific T cell function and cytokine production. For the first time, it
was demonstrated that estrogen signaling and sex of the donor regulate the expression and
secretion of effector, helper, and lytic T cell cytokines such as TNF, IL-4, IFN, and Granzyme
B in human Ag-specific T cells.
Herein it was shown that male and female Ag-specific T cells express equivalent levels of
the canonical estrogen receptor, ER. ER is well known to bind the estrogen ligand in the
cytoplasm of the cell and then to translocate into the nucleus where it can regulate target gene
expression by binding to EREs on gene promoters or by binding other transcription factor
complexes. ER rapid nucleus translocation upon ligand binding was observed when both male
and female Ag-specific T cells were stimulated with physiological (0.5 nM) or superphysiological (50 nM) estrogen concentrations. This rapid translocation was transient since
reduced nuclear ER expression, and increased cytoplasmic ER expression was observed
overtime after estrogen treatment. This indicates that both male and female Ag-specific T cells
can signal through ER in response to two different estrogen ligand concentrations. It is notable
that estrogen can also bind to ER with same affinity as ER  which elicits different
downstream effects and modulates different gene expression than ER. Due to insufficient
antibody validation [379, 380], the nuclear translocation of ER upon estrogen binding in Agspecific T cells could not be tested at this time. Knowing that human T cells express ER ,
ER signaling effects on T cell function cannot be dismissed and are further studied in the
chapters of this dissertation. Estrogen can also bind to the membrane bound GPER which
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mediates rapid non-genomic responses such as the activation of the MAPK pathway [177]. The
changes in cytokine secretion and expression observed in Ag-specific T cells could be the work
of not only the canonical ERs but also be influenced by GPER. This needs to be further studied
to better understand how to improve the beneficial signaling cascades in these T cells that will
promote stronger antitumor responses.
To determine the functional consequences of ER expression in T cells, cytokine
expression and secretion was measured from antigen stimulated CD8 + and CD4+ T cells.
Estrogen signaling through ER was shown to enhance the expression of TNF in male and
female CD8+ Ag-specific T cells, and estrogen treatment also enhanced the secretion of TNF in
male and female Ag-specific T cells in a concentration dependent manner. The promoter of
TNF contains an ERE at position -1044 bp [392] indicating that the enhancement of TNF
expression and secretion in male and female Ag-specific T cells could be mediated by canonical
ligand-dependent genomic ER signaling (Table 2).
Estrogen signaling through ER was shown to regulate the overall expression of IL-4 in
male and female CD8+ and CD4+ Ag-specific T cells. The estrogen-mediated enhancement of IL4 expression and the overall IL-4 expression were abrogated when T cells were treated with
estrogen in combination with an ER inhibitor, suggesting that estrogen regulates IL-4
expression in a classical ligand-dependent genomic manner. Surprisingly, an ERE was not found
on the promoter of IL-4 which could indicate ERE-independent ER genomic signaling. It was
demonstrated that a significant correlation exists between the expression of ER and GATA3 in
breast cancer cell lines and mouse T cells, and an ERE was found at position -1502 bp on the
promoter of GATA3 (Table 2) [393-395]. GATA3 is an essential Th2 transcription factor that
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not only drives differentiation of TCR stimulated CD4+ T cells into the Th2 subset but also
directly induces IL-4 gene expression [396, 397]. In fact, T cells from GATA3 KO mice fail to
develop appropriate Th2 cytokine expression including IL-4 [398, 399]. Overall this indicates
that ER signaling regulates IL-4 expression and secretion in Ag-specific T cells through
mechanisms that are ERE-independent possibly including the upregulation of expression of
GATA3.
Estrogen signaling was shown to enhance the secretion of IFN in female and male Agspecific T cells. IFN contains an ERE at position -8342 bp of its promoter which indicates that
estrogen signaling through ER can enhance IFN secretion through the ligand-bound EREdependent canonical pathway. In addition, an ERE was also found on the promoter of T-BET at
position -1676 bp (Table 2). T-BET is a transcription factor known to mediate Th1 T cell
differentiation and induce IFN expression [400, 401]. Estrogen signaling enhancement of TBET expression could result in subsequent IFN expression and secretion enhancement in
activated T cells. Estrogen was also shown to enhance the secretion of Granzyme B in female
and male Ag-specific T cells. While Granzyme B does not contain an ERE in its promoter,
proteinase inhibitor 9 (PI-9), which is a Granzyme B inhibitor, contains one ERE at position -200
bp of its promoter [402, 403]. This indicates that estrogen could be upregulating Granzyme B
secretion by negatively regulating transcription of PI-9 through ER ligand-bound EREdependent genomic pathway.
Estrogen treatment increases the expression and/or secretion of TNF, IL-4, IFN, and
Granzyme B in human Ag-specific T cells. TNF, IFN, and Granzyme B are cytokines
commonly secreted by Type I cytotoxic CD8+ T cells and effector Th1 CD4+ T cells in response
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to antigen stimulation. On the other hand, IL-4 is secreted by Type II CD8+ T cells and it is the
prototypic Th2 CD4+ T cell cytokine required for Th2 T cell differentiation. The Th1 and Th2
CD4+ T cell subset differentiation pathways can downregulate each other and are believed to be
mutually exclusive [404, 405]. Estrogen signaling through ER can upregulate the expression
and secretion of both Type I/Th1 and Type II/Th2 cytokines in male and female Ag-specific T
cells. This could indicate that estrogen modulates the balance of the CD8+ Type I and Type II,
and the CD4+ Th1 and Th2 T cell responses. Most of the effects on these cytokines were
observed when T cells were stimulated with super-physiological estrogen (50 nM) indicating that
the estrogen-mediated Th1/Th2 T cell response balance could happen in locally elevated
estrogen environments including the HCC TME. In order to test if ER signaling can modulate
the balance between Th1 and Th2 T cell subset differentiation, first, estrogen receptor binding to
the EREs present on the GATA3 and T-BET gene promoters needs to be confirmed via
chromatin immunoprecipitation (ChIP); and, second, enhancement of T-BET and GATA3
expression by ER signaling needs to be confirmed by real time polymerase chain reaction (RTPCR) or by transducing T cells with expression vectors containing the promoters of T-BET and
GATA3.
Apart from their roles in Th1 and Th2 T cell differentiation, the cytokines enhanced by
estrogen in Ag-specific T cells have important anti-tumor roles. IFN is cytotoxic to certain
malignant cells, and it enhances MHC class I expression [406]. Granzyme B directly lyses
malignant cells, and TNF promotes T cell activation, co-stimulation, and promotes certain
cancer cell death [406]. IL-4 promotes T cell and B cell survival, induces Ig class switch to IgE
and IgG in B cells, drives long-term development of CD8+ T cell memory, and in combination
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with TGF it drives Th9 T cell differentiation which are T cells that augment anti-tumor
responses in ACT models [387-389, 407, 408]. Overall these data indicate for the first time, that
estrogen signaling through ER enhances expression and secretion of cytokines that enhance the
T cell anti-tumor immune response and estrogen signaling is an important factor to consider
when designing ACT immunotherapies for estrogen-sensitive and estrogen-producing
malignancies like HCC.

Table 2. Estrogen Response Elements Found in the Promoters of TNF, GATA3, IFN, TBX21(T-BET), and IP-9 Genes. Table
shows the human (Hs) gene name, the chromosome location, the ERE sequence and its position in respect to the gene starting site.
EREs were found in the EREfinder database described by Bourdeade et al. Mol Endocrinol. 2004.
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CHAPTER IV
ESTROGEN SIGNALING THROUGH ER AND ER DIFFRENTIALLY IMPACTS
HUMAN MALE AND FEMALE AG-SPECIFIC T CELL POLYFUNCTIONALITY

Introduction and Rationale
The results presented in the previous chapter demonstrated that estrogen signaling
enhances the expression and secretion of T cell cytokines typically classified into the CD4+ Th1
or Th2 subsets, or into the CD8+ Type I or Type II subsets. Despite their differences, both Type
I/Th1 and Type II/Th2 T cell responses were shown to enhance anti-tumor immunity by
enhancing CTL expansion and survival, and by killing tumor cells directly [409, 410]. Most
importantly, ACT immunotherapy was shown to be most successful when CD8 + T cells were
delivered in combination with a mixture of CD4+ Th1 cells and Th2 cells [82, 411]. More
recently, other T cell subsets were correlated with enhanced T cell anti-tumor immune responses
such as the IL-9 producing Th9 CD4+ T cells [412, 413], and the IL-17a producing Th17 CD4+ T
cells [83]. Even if the anti-tumor or tumor-promoting role of IL-22 producing Th22 CD4+ T cells
remains controversial, Th22 infiltration was correlated with tumor rejection in colorectal cancer
[414]. The presence of multiple T cell subsets secreting varying combinations of cytokines
indicates that the evaluation of a single cytokine at one time does not accurately characterize the
role of estrogen signaling on the overall T cell anti-tumor function. In fact, a previous study
demonstrated that analysis of expression of only one effector T cell cytokine, such as IFN in
advanced stage cancer patients was not correlated with survival advantage, but once other
98
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cytokines, such as IL-2, were analyzed simultaneously via flow cytometry with IFN there was
an association with clinical outcome [415]. In addition to the heterogeneity of their subset
phenotype, T cells show differences in their functional profile or the mixture of cytokines that
they secrete upon TCR ligation. It was found that T cells can not only be subdivided based on
prototypic cytokine and transcription factor expression, but also based on the distinctive patterns
of cytokines secreted after stimulation [416]. Activated T cells can be monofunctional if they
only express one cytokine, or polyfunctional if they expressed over two different cytokines upon
TCR stimulation.
T cell polyfunctionality is described as the ability of one T cell to deploy a broad
spectrum of immune programs upon antigen stimulation. These immune programs can be
cytokines or lytic markers with polyfunctional T cells being able to, for example, secrete IFN,
IL-2 and degranulate producing Granzyme B simultaneously. Polyfunctional CD8 + and CD4+ T
cells were shown to be able to generate superior anti-tumor immune responses [417-420], and to
clear viral infections better than monofunctional T cells [421, 422]. In the setting of
immunotherapy, several studies have found enhanced numbers of tumor Ag-specific
polyfunctional T cells in patients responding favorably to ACT, and checkpoint blockade using
anti-CTLA-4 [423-427]. A study by Rossi et al. using CD19-targeted CAR T cells to treat acute
lymphoblastic leukemia demonstrated that CAR-T cell polyfunctionality was correlated with
patient clinical outcome [428]. Even if only approximately 20% of adoptively transferred CAR T
cells were polyfunctional (able to produce >2 out of 32 different cytokines and chemokines
simultaneously), this low frequency of polyfunctional cells was still able to produce superior
anti-tumor immune responses compared to monofunctional T cells. Polyfunctional CD8+ CAR-T
cells in this study produced combinations of IFN, macrophage inflammatory protein-1 (MIP-
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1) (or CCL3), IL-8, and Granzyme B simultaneously while CD4+ CAR-T cells expressed
combinations of IFN, MIP-1, IL-8, IL-2, IL-17a, and IL-5 simultaneously [428]. T cell
polyfunctionality was also correlated with CD8+ T cell memory formation. Memory CD8+ T
cells were shown to be highly polyfunctional expressing cytokine combinations such as IFN+IL2+TNF+MIP-1+ (or CCL4), IFN+TNF+IL-2+, and IFN+IL-2+CD107a+ during antigen
stimulation [429-432]. This indicates that the use of polyfunctional T cells could increase the
efficacy of ACT immunotherapy by generating superior anti-tumor responses and subsequent T
cell memory development against tumor antigens.
Since estrogen signaling was able to enhance the secretion of several effector Th1 and
helper Th2 cytokines in female and male Ag-specific T cells, it was hypothesized that estrogen
signaling enhances the polyfunctionality or the ability of Ag-specific T cells to express several
cytokines simultaneously upon antigen stimulation. In order to study the effect of estrogen
receptor signaling on Ag-specific T cell polyfunctionality, male and female Ag-specific T cells
were treated with physiological (0.5 nM) or super-physiological (50 nM) estrogen alone or in
combination with an ER inhibitor (100 nM), an ER inhibitor (100 nM), or both inhibitors
simultaneously prior to activation with T2 cells pulsed with the HCV cognate antigen or a
tyrosinase irrelevant peptide. After 5 hour activation in the presence of protein transport
inhibitors, multi-dimensional flow cytometry was used to measure expression of IFN, TNF,
IL-2, IL-4, IL-17a, IL-22 and the lytic marker CD107a. This multi-functional evaluation was
designed to reflect the changes in mono or polyfunctional phenotypes of T cell populations. The
analysis of these seven functional markers after gating on CD3+CD34+ transduced T cells
generated 128 possible combinations (2n, n=7, 27=128) of markers expressed by CD8+ or CD4+ T
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cells; from monofunctional cells that only express one marker, to highly polyfunctional cells that
expressed all 7 markers simultaneously. Since they were a total number of 12 treatments,
including 3 estrogen conditions (0, 0.5, and 50 nM) and 4 ER inhibitor conditions (no inhibitor,
ER inhibitor, ER inhibitor, and both inhibitors), an exceptionally complex dataset was
generated that was difficult to analyze with basic flow cytometry software (FlowJoX).
Analysis of polyfunctionality data using FlowJo is very limited since it restricts the
visualization of data to one or two parameters at a time. In this case, visualization and analysis of
7 markers requires 21 pairwise dot plots for a single Ag-stimulation condition per estrogen
treatment. Figure 15 shows a representative example of pairwise dot plots in untreated female
CD8+ HCV Ag-specific T cells stimulated with HCV (Figure 15 A) or tyrosinase (Figure 15 B)
pulsed T2 target cells. Even if these comparisons are very limited, some simple observations can
be deduced by observing the percent frequency of T cells that express two markers
simultaneously. The highest frequency of bifunctional CD8 + cells expressed the IFN+TNF+
combination but IFN+ cells also expressed CD107a, or IL-4 simultaneously. Similarly, TNF+
cells also expressed IL-4, and some CD107a or IL-2 simultaneously. This was surprising since
CD8+ T cells could express cytokines like IFN and TNF which are believed to be restricted to
the type I (Th1) phenotype, simultaneously with the type II (Th2) cytokine IL-4. These data
contradicts what is normally accepted in the field of T cell immunology concerning type I and II
T cell populations and function. This indicates that evaluation of several functional markers and
generation of polyfunctional T cell profiles can shine light on the study of new patterns of T cell
function benefigureFficial for generating superior anti-tumor immune responses.

+

Figure 15. Pairwise Comparisons of Each Functional Marker Expressed by Activated CD8 HCV Ag-specific T Cells. HCV
Ag-specific T cells from one female donor were co-cultured with T2 cells pulsed with the A) HCV cognate antigen or B) a tyrosinase
irrelevant peptide for 5 hours in the presence of protein transport inhibitors. Cells were then stained for flow cytometric analysis of
CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, Il-17a, and IL-22. Gating and analysis was
performed using FlowJoX. Uni-dimensional histograms represent the expression of each functional marker, and each dot plot
+
represents pairwise comparisons between each of the 7 functional markers expressed by CD8 Ag-specific T cells
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In order to generate the frequency of T cells expressing each of the 128 different cytokine
combinations, higher resolution multi-dimensional analysis was performed within FlowJo using
Boolean combinatorial gates for all 7 markers. The frequencies of populations were added into
categories comprising cells expressing 1 through 7 markers simultaneously. Percent frequencies
of T cells expressing >2 makers simultaneously were considered polyfunctional. By grouping
polyfunctional phenotypes into categories according to the number of markers expressed, clear
comparisons between female and male T cells and different estrogen and inhibitor treatments can
be made. Statistical analysis of these data can be performed using a Multivariate Analysis of
Variance (MANOVA) which is a multivariate ANOVA with two or more continuous response
variables. MANOVA allows analyzing CD8+ and CD4+ T cells within one sex under one
treatment condition (either estrogen or estrogen + ER inhibitor) and compares two or more
continuous response variables, in this case 7 different categories, or groups of T cells expressing
1 through 7 markers simultaneously. Post-hoc pairwise comparisons between each index
estrogen treatment (50 & 0.5) and the reference estrogen treatment (0) were conducted within
each estrogen inhibitor treatment.
Despite these meaningful interpretations, analysis in FlowJo lacks the ability to
graphically represent individual polyfunctional phenotypes or display how estrogen signaling
impacts their relative abundance. In order to compare the levels of expression of all 128 marker
combinations, Boolean gating with FlowJo was followed by analysis in Pestle and SPICE data
processing software packages which allow to adequately visualize individual and polyfunctional
populations. Using the data generated from Pestle and SPICE, heat maps were created containing
the percent frequency of cells expressing each combination of markers. Results from these

104

analyses are discussed in the following sections. Statistical analysis of the percent expression of
each cytokine combination can be performed using MANOVA. MANOVA is used on CD8 + and
CD4+ T cells within one sex under one treatment condition (either estrogen or estrogen + ER
inhibitor) and compares two or more continuous response variables, in this case all the different
(up to 83) combinations of cytokines expressed by Ag stimulated T cells. Post-hoc pairwise
comparisons between each index estrogen treatment (50 & 0.5) and the reference estrogen
treatment (0) were conducted within each estrogen inhibitor treatment stratum.
Results
CD8+ Ag-specific female T cells are inherently more polyfunctional than male T cells
It was observed that non-estrogen treated CD8+ and CD4+ Ag-specific T cells contained
similar percentages of monofunctional and polyfunctional cells when stimulated with their HCV
cognate antigen. Both populations exhibited around 30 to 40% of monofunctional and
bifunctional cells, and around 15 to 20% of trifunctional cells. Less than 10% of CD8+ and CD4+
Ag-specific T cells expressed more than 4 markers simultaneously and percentages for those
cells expressing 6 or 7 markers were so low that are not represented on the results (Figure 16).
While there were no sex-differences on the polyfunctionality of CD4+ Ag-specific T cells when
marker combinations were analyzed as added groups (Figure 16 B), significantly higher
percentage of male CD8+ Ag-specific T cells were monofunctional (only expressed 1 marker)
compared to female CD8+ T cells (Figure 16 A). A trend was observed for higher percentages of
female CD8+ T cells expressing 3 markers simultaneously compared to male CD8 + T cells. This
indicates that independently from estrogen signaling, female CD8 + Ag-specific T cells are
inherently more polyfunctional than male CD8+ T cells. While these results were shown to be
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statistically significant, there was a high variability between male donors in the percentage of
CD8+ T cells expressing only one marker. Most of the male donors had frequencies of
monofunctional cells similar to those of female donors, but some of the male donors showed
very high percentage of monofunctional cells. This variability is not surprising due to genetic
and environmental differences between humans, and it indicates that there are differences in
polyfunctionality between same sex donors. This could be caused by differences on age (some of
the donors used for the experiment were of unknown age), disease background, circulating
hormone levels, and differences on T cell activation.
The female and male CD8+ and CD4+ Ag-specific polyfunctional responses were very
diverse expressing a great amount of marker combinations that were polyfunctional,
bifunctional, and monofunctional. CD8+ T cells from females and males expressed 71 different
functional marker combinations in response to antigen stimulation (Figure 17 A). While a lot of
these marker combinations were expressed by a very low frequency of cells, some combinations
including TNF+ (~10-15%), IFN+TNF+ (~25-30%), IFN+ (~25%), CD107a+IFN+TNF+
(~7%), IFN+ IL-2+TNF+ (~5%), and IFN+IL-4+TNF+ (~4%) were expressed at higher levels.
The only combination that shows significant differences in expression between female and male
T cells was TNF alone which was expressed by a significantly higher frequency of male T cells
compared to female T cells (Figure 17 A). Other combinations that showed trending differences
in expression included CD107a+IFN+TNF+, CD107a+IFN+, IFN+IL-2+TNF+, IFN+IL4+TNF+, and IFN+TNF+ which were all expressed by higher frequencies on female T cells
compared to male T cells. Taking these data together with the ones obtained in Figure 16 A, it
can be concluded that female CD8+ Ag-specific T cells are inherently more polyfunctional upon
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antigen stimulation than male CD8+ Ag-specific T cells. In addition, higher percentages of
female CD8+ polyfunctional cells expressed marker combinations that are detrimental to tumors,
such as the ones containing cytotoxic cytokines IFN TNF, and the marker CD107a, as well as
marker combinations that include cytokines known to enhance T cell survival like IL-2 and IL-4.
Male and female CD4+ Ag-specific T cells expressed up to 83 different functional marker
combinations upon antigen stimulation (Figure 17 B). As observed in the CD8 + T cell subset,
most of the combinations were expressed by very low frequency of cells with the exception of
the highest expressed functional combinations being IFN+TNF+ (~30%), IFN+ (~22%),
TNF+ (~15%), IFN+ IL-4+TNF+ (~), and IFN+IL-2+TNF+ (~) (Figure 17 B). The
only combination that showed a significant difference in expression between female and male
CD4+ T cells was IFN alone which was expressed by a significantly higher frequency of female
T cells compared to male T cells (Figure 17 B). Other trending differences in expression were
observed including higher frequencies of female CD4+ T cells expressing
IFN+TNF+ and IFN+IL-4+TNF+ compared to male CD4+ T cells. While there may be
differences in expression on some polyfunctional phenotypes between female and male CD4 + T
cells, significance was not achieved and taken these results with the ones observed in Figure 16
B it can be concluded that there are no sex-differences in male and female CD4+ T cell
polyfunctionality.
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Figure 16. Female CD8 Ag-specific T Cells are More Polyfunctional than Male
Counterparts upon Ag Stimulation. Male and female HCV Ag-specific T cells from 15
female and 15 male donors were co-cultured for 5 hours with T2 cells pulsed with HCV cognate
antigen or a tyrosinase irrelevant peptide in the presence of protein transport inhibitors. Cells
were then stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional
markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX,
+
+
the frequency of CD8 and CD4 T cells expressing each combination of these 7 markers was
+
+
generated and added into 7 functional categories. The frequencies of A) CD8 , and B) CD4
female and male Ag-specific T cells expressing one through seven markers simultaneously was
+
+
plotted. The frequencies of CD8 and CD4 T cells stimulated with the tyrosinase irrelevant
peptide were used for background subtraction. Data for T cells expressing 6 or 7 markers
simultaneously is not shown since the percent frequency was very low (<1%). Data represents
n=15 donors, each donor plotted and SEM indicated. Data was analyzed using MANOVA and
Tukey’s post-hoc. p<0.05=*.

+
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Figure 17. Significantly Higher Percentage of Male CD8 Ag-specific T Cells Express TNF in Combination with no Other
+
+
Marker Compared to Female CD8 T Cells. Significantly Higher Percentage of Female CD4 Ag-specific T Cells Express
+
IFN in Combination with no Other Marker Compared to Male CD4 T Cells. Male and female HCV Ag-specific T cells from
15 female and 15 male donors were co-cultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant
peptide in the presence of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34, CD8, and
CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX, and the software
+
+
SPICE the frequency of CD8 and CD4 T cells expressing each combination of these 7 markers was generated. The frequencies of
+
+
A) CD8 and B) CD4 female and male Ag-specific T cells expressing each of the 128 possible markers combinations was plotted.
Data represents the mean of n=15 donors. Data was analyzed using MANOVA and Tukey’s post-hoc. p<0.001=***, p<0.05=*.
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Estrogen signaling through ER enhances female and male CD8+ Ag-specific T cell
polyfunctionality
A significant decrease on the percent frequency of monofunctional male and female
CD8+ Ag-specific T cells was observed upon estrogen treatment, especially at superphysiological concentrations. While the percent frequency of bifunctional cells was not
significantly changed, the percent frequency of CD8+ T cells expressing 3 markers
simultaneously was significantly increased upon estrogen treatment (Figure 18 & 19 A). This
indicated that estrogen signaling enhances the percentage of polyfunctional cells while
decreasing the percentage of monofunctional cells. The estrogen-mediated enhancement of CD8+
male and female T cell polyfunctionality was not affected by blocking ER with a specific
antagonist (MPP-dihydrochloride) during estrogen treatment (Figure 18 & 19 B). In fact, upon
ER blockade, the estrogen-mediated decrease on monofunctional T cell percentage and
increase on trifunctional percentages was even more significant at physiological estrogen
concentrations. Thus demonstrating that ER signaling does not enhance CD8+ Ag-specific
polyfunctionality but rather it partially inhibits it when T cells are exposed to physiological
estrogen. Surprisingly, the estrogen-mediated enhancement of CD8+ T cell polyfunctionality was
completely abrogated when ER signaling was blocked with a specific antagonist (PHTPP)
(Figure 18 & 19 C). No changes in polyfunctionality were observed when male and female CD8 +
T cells were treated with estrogen in combination with both ER and ER antagonists (Figure 18
& 19 D). Overall these data reveal that estrogen signaling through ER enhances CD8+ male and
female Ag-specific T cell polyfunctionality.
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Figure 18. Estrogen Signaling through ER Enhances the Percentage of Polyfunctional
+
Female CD8 Ag-specific T Cells and Decreases the Percentage of Monofunctional T Cells after
Ag Stimulation. Female HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50
nM estrogen in combination with an ER inhibitor, and ER inhibitor, or both inhibitors
simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours with
T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of
protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34,
CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using
+
Boolean gates in FlowJoX, the frequency of CD8 T cells expressing each combination of these 7
+
markers was generated and added into 7 functional categories. The frequencies of CD8 female Agspecific T cells expressing one through seven markers simultaneously after treatment with A)
estrogen, B) estrogen in combination with an ER inhibitor, C) estrogen in combination with an
ER inhibitor, D) estrogen in combination of both ER and ER inhibitors were plotted. Data for
T cells expressing 6 or 7 markers simultaneously is not shown since the percent frequency was very
low. Data represents n=15 donors, each donor plotted and SEM represented. Data was analyzed
using MANOVA and Tukey’s post-hoc. p< 0.001=***, p<0.05=*.
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Figure 19. Estrogen Signaling through ER Enhances the Percentage of Polyfunctional
+
Male CD8 Ag-specific T Cells and Decreases the Percentage of Monofunctional T Cells
after Ag Stimulation. Male HCV Ag-specific T cells from 15 donors were treated with 0, 0.5,
or 50 nM estrogen in combination with an ER inhibitor, and ER inhibitor, or both inhibitors
simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours
with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence
of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3,
CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and
+
IL-22. Using Boolean gates in FlowJoX, the frequency of CD8 T cells expressing each
combination of these 7 markers was generated and added into 7 functional categories. The
+
frequencies of CD8 male Ag-specific T cells expressing one through seven markers
simultaneously after treatment with A) estrogen, B) estrogen in combination with an ER
inhibitor, C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both
ER and ER inhibitors were plotted. Data for T cells expressing 6 or 7 markers simultaneously
is not shown since the percent frequency was very low. Data represents n=15 donors, each donor
plotted and SEM indicated. Data was analyzed using MANOVA and Tukey’s post-hoc. p<
0.01=**, p<0.05=*.
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The percent frequencies of female and male CD8+ Ag-specific T cells expressing
CD107a+ IFN+TNF+ was significantly increased by super-physiological estrogen treatment
(Figure 20 & 21 A). The percent frequency of female CD8+ T cells expressing IFN+IL-4+TNF+
was also significantly increased by super-physiological estrogen treatment (Figure 20 A). On the
other hand, the frequencies of male and female CD8+ T cells expressing TNF+IFN+, IFN+,
and TNF+ were significantly decreased upon physiological and super-physiological estrogen
treatments (Figure 20 & 21 A). The estrogen-induced significant changes on expression of
polyfunctional (CD107a+IFN+TNF+), bifunctional (TNF+IFN+), and monofunctional (TNF
or IFN alone) phenotypes were maintained when CD8+ Ag-specific T cells were treated with
estrogen in combination with an ER inhibitor (Figure 20 & 21 B). In female CD8+ T cells,
blockade of ER during physiological estrogen treatment significantly enhanced the expression
of CD107a+IFN+TNF+ indicating that ER signaling could be partially inhibiting the
expression of these three markers simultaneously (Figure 20 B). When male and female Agspecific T cells were treated with estrogen in combination with an ER inhibitor or with ER
and ER inhibitors simultaneously, all significant changes on expression of monofunctional or
polyfunctional phenotypes were abrogated (Figure 20 & 21 C, D). Overall, taking these data
together with the results obtained in Figures 18 & 19, it can be concluded that estrogen signaling
through ER enhances CD8+ Ag-specific T cell polyfunctionality by increasing expression of
polyfunctional phenotypes CD107a+IFN+TNF+ and IFN+IL-4+TNF+ and decreasing
expression of monofunctional and bifunctional phenotypes including TNF+IFN+ TNF+, and
IFN+
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Figure 20. Estrogen Signaling through ER Increases the Percent Frequency of CD8 Female Ag-specific T Cells Expressing
+
+
+
+
+
+
+
+
CD107a IFN TNF and IFN IL-4 TNF and Decreases the Percent Frequency of T Cells Expressing IFN TNF ,
+
+
IFN , and TNF . Female HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in combination
with an ER inhibitor, and ER inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells were cocultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of protein
transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers
CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX, and the software SPICE the frequency of
+
+
CD8 T cells expressing each combination of these 7 markers was generated. The frequencies of CD8 female Ag-specific T cells
expressing each of these marker combinations after treatment with A) estrogen, B) estrogen in combination with an ER inhibitor,
C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both ER and ER inhibitors were plotted. Data
represents the mean of n=15 donors. Data was analyzed using MANOVA and Tukey’s post-hoc. p<0.0001=****, p< 0.01=**.
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Figure 21. Estrogen Signaling Through ER Increases the Percent Frequency of CD8 Male Ag-Specific T Cells Expressing
+
+
+
+
+
+
+
CD107a IFN TNF and Decreases the Percent Frequency of T Cells Expressing IFN TNF , IFN , and TNF . Male
HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in combination with an ER inhibitor, and ER
inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours with T2 cells
pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of protein transport inhibitors. Cells were then
stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL+
17a, and IL-22. Using Boolean gates in FlowJoX, and the software SPICE the frequency of CD8 T cells expressing each combination
+
of these 7 markers was generated. The frequencies of CD8 male Ag-specific T cells expressing each of these markers combinations
after treatment with A) estrogen, B) estrogen in combination with an ER inhibitor, C) estrogen in combination with an ER inhibitor,
D) estrogen in combination of both ER and ER inhibitors were plotted. Data represents the mean of n=15 donors. Data was
analyzed using MANOVA and Tukey’s post-hoc. P<0.0001=****, p< 0.001=***, p<0.01=**, p<0.05=*.
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Estrogen Signaling through ER Enhances Female and Male CD4+ Ag-specific T cell
Polyfunctionality
Estrogen signaling had similar effects on CD4+ T cell polyfunctionality to those observed
in CD8+ Ag-specific T cells. Estrogen stimulation at super-physiological concentrations
significantly decreased the percent frequency of monofunctional CD4 + T cells, and significantly
increased the percent frequency of polyfunctional cells expressing three markers simultaneously
(Figure 22 & 23 A). Super-physiological estrogen also significantly decreased the percentage of
bifunctional female CD4+ T cells (Figure 22 A). ER signaling blockade had no effect of the
estrogen-dependent enhancement of polyfunctionality of male CD4+ T cells, but it increased
CD4+ T cell polyfunctionality at physiological estrogen concentration in female CD4 + T cells
(Figure 22 & 23 B). Indicating that ER signaling inhibits female CD4+ T cell polyfunctionality.
Blockade of ER or ER and ER simultaneously completely abrogated the estrogen-mediated
increase in polyfunctionality of CD4+ male and female Ag-specific T cells (Figure 22 & 23 C,
D). Overall these data indicate that estrogen signaling through ER increases polyfunctionality
of male and female CD4+ T cells, and estrogen signaling through ER inhibits female CD4+ T
cell polyfunctionality at physiological estrogen concentration.
The percent frequencies of male and female CD4+ Ag-specific T cells expressing
IFN+TNF+, and IFN+ or TNF+ were significantly decreased by physiological and superphysiological estrogen treatment (Figure 24 & 25 A). The percent frequency of male CD4+ T
cells expressing IFN+IL-4+TNF+ was also significantly increased by super-physiological
estrogen treatment (Figure 25 A). A trending increase on the frequencies of CD4 + T cells
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expressing IFN+ IL2+IL4+TNF+, and IFN+IL-2+TNF+ were observed upon estrogen
treatment even if significance was not achieved. Female CD4+ Ag-specific T cells also showed a
trending increase on expression of IFN+IFN+TNF+ upon estrogen treatment (Figure 24 A).
Blockade of ER showed no effect on the estrogen-mediated changes on expression of
functional phenotypes indicating that ER signaling does not affect CD4+ T cell
polyfunctionality (Figure 24 & 25 B). On the other hand, ER blockade or ER and ER
simultaneous blockade during estrogen treatment abrogated the estrogen-mediated decrease of
monofunctional (IFN or TNF alone) and bifunctional (IFN+TNF+) T cell phenotypes, and
increase in polyfunctional phenotypes such as IFN+IL-4+TNF+ (Figure 24 & 25 C, D). Overall,
taking these data together with the results obtained in Figures 22 & 23, it can be concluded that
estrogen signaling through ER enhances CD4+ Ag-specific T cell polyfunctionality by
increasing expression of polyfunctional phenotypes such as IFN+IL-4+TNF+ and decreasing
expression of monofunctional and bifunctional phenotypes including TNF+IFN+ TNF+, and
IFN+
Ideally, in order to conclude that the effects of estrogen signaling on polyfunctionality are
fully mediated by ER signaling another set of experiments need to be performed using ER
agonists to stimulate human Ag-specific T cells instead of estrogen. The ER-specific agonist
diarylpropionitrile (DPN) which has a 70-fold selectivity over ER (EC50 values are 0.85 nM
and 66 nM for ER and ER respectively) [150] can be used to determine if estrogen signaling
through ER is directly upregulating T cell polyfunctionality upon Ag stimulation. In order to
test this, male and female Ag-specific T cells need to be treated with DPN alone, DPN in
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combination with PHTPP (ER antagonist), and DPN in combination with PHTPP and estrogen.
If after DPN treatment alone the polyfunctionality of T cells is enhanced to levels similar to
those observed in estrogen treated T cells, then estrogen signaling through ER alone enhances T
cell polyfunctionality. These data can be confirmed if T cells treated with DNP and PHTPP
simultaneously show no increase in polyfunctionality. If treating T cells with DPN shows no
increase on T cell polyfunctionality but treating T cells with estrogen, DNP and PHTPP do show
an increase, then estrogen signaling through other receptor is causing the estrogen-mediated
enhancement of polyfunctionality. Inhibition of ER during estrogen stimulation was shown to
enhance polyfunctionality, even to higher extent than estrogen alone in some cases, indicating
that ER has an inhibiting effect. Estrogen signaling through its other receptor, GPER, may be
enhancing T cell polyfunctionality. In order to rule out that polyfunctionality is enhanced
through GPER signaling, male and female Ag-specific T cells need to be treated with estrogen in
combination of a GPER antagonist. If T cell polyfunctionality is decreased in T cells treated with
estrogen in combination with a GPER antagonist compared to estrogen treated T cells, then
estrogen signaling through GPER enhances T cell polyfunctionality. GPER signaling was shown
to rapidly activate the PI3K and the MAPK pathways which are known to contribute to T cell
cytokine secretion downstream from the TCR [177] indicating that GPER signaling could have
an enhancing effect on TCR signaling leading to polyfunctionality. Unfortunately, these
experiments could not be performed due to lack of time and support but these results would
indicate that estrogen signaling through ER and GPER enhance T cell polyfunctionality
downstream from the TCR.

120

Figure 22. Estrogen Signaling Through ER Enhances the Percentage of Polyfunctional
+
Female CD4 Ag-specific T Cells and Decreases the Percentage of Monofunctional and
Bifunctional T Cells after Ag Stimulation. Female HCV Ag-specific T cells from 15 donors
were treated with 0, 0.5, or 50 nM estrogen in combination with an ER inhibitor, and ER
inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells
were co-cultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase
irrelevant peptide in the presence of protein transport inhibitors. Cells were then stained for
flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN,
+
TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX, the frequency of CD4
T cells expressing each combination of these 7 markers was generated and added into 7
+
functional categories. The frequencies of CD4 female Ag-specific T cells expressing one
through seven markers simultaneously after treatment with A) estrogen, B) estrogen in
combination with an ER inhibitor, C) estrogen in combination with an ER inhibitor, D)
estrogen in combination of both ER and ER inhibitors were plotted. Data for T cells
expressing 6 or 7 markers simultaneously is not shown since the percent frequency was very
low. Data represents n=15 donors, each donor plotted and SEM represented. Data was analyzed
using MANOVA and Tukey’s post-hoc. p<0.0001=****, p< 0.001=***, p<0.01=**, p<0.05=*.
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Figure 23. Estrogen Signaling Through ER Enhances the Percentage of Polyfunctional
+
Male CD4 Ag-specific T Cells and Decreases the Percentage of Monofunctional T Cells
after Ag Stimulation. Male HCV Ag-specific T cells from 15 donors were treated with 0, 0.5,
or 50 nM estrogen in combination with an ER inhibitor, and ER inhibitor, or both inhibitors
simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours
with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence
of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3,
CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and
+
IL-22. Using Boolean gates in FlowJoX, the frequency of CD4 T cells expressing each
combination of these 7 markers was generated and added into 7 functional categories. The
+
frequencies of CD4 male Ag-specific T cells expressing one through seven markers
simultaneously after treatment with A) estrogen, B) estrogen in combination with an ER
inhibitor, C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both
ER and ER inhibitors were plotted. Data for T cells expressing 6 or 7 markers simultaneously
is not shown since the percent frequency was very low. Data represents n=15 donors, each donor
plotted and SEM represented. Data was analyzed using MANOVA and Tukey’s post-hoc. p<
0.001=***, p<0.01=**, p<0.05=*.
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Figure 24. Estrogen Signaling Through ER Decreases the Percent Frequency of Female CD4 Ag-specific T Cells Expressing
+
+
+
+
IFN TNF , IFN , and TNF . Female HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in
combination with an ER inhibitor, and ER inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T
cells were co-cultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence
of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional
markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX and the software SPICE, the
+
+
frequency of CD4 T cells expressing each combination of these 7 markers was generated. The frequencies of CD4 female Agspecific T cells expressing one through seven markers simultaneously after treatment with A) estrogen, B) estrogen in combination
with an ER inhibitor, C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both ER and ER inhibitors
were plotted. Data for T cells expressing 6 or 7 markers simultaneously is not shown since the percent frequency was very low. Data
represents the mean of n=15 donors. Data was analyzed using MANOVA and Tukey’s post-hoc. p<0.0001=****, p< 0.001=***,
p<0.01=**, p<0.05=*.
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Figure 25. Estrogen Signaling Through ER Increases the Percent Frequency of CD4 Male Ag-specific T Cells Expressing
+
+
+
+
+
+
+
IFN IL-4 TNF and Decreases the Percent Frequency of T Cells Expressing IFN TNF , IFN , and TNF . Male HCV
Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in combination with an ER inhibitor, and ER
inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours with T2 cells
pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of protein transport inhibitors. Cells were then
stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL+
17a, and IL-22. Using Boolean gates in FlowJoX and the software SPICE, the frequency of CD4 T cells expressing each combination
+
of these 7 markers was generated. The frequencies of CD4 male Ag-specific T cells expressing each of the markers combinations
after treatment with A) estrogen, B) estrogen in combination with an ER inhibitor, C) estrogen in combination with an ER inhibitor,
D) estrogen in combination of both ER and ER inhibitors were plotted. Data represents the mean of n=15 donors. Data was
analyzed using MANOVA and Tukey’s post-hoc. p< 0.001=***, p<0.01=**, p<0.05=*.
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Estrogen Signaling through ER Enhances the Percent Frequency of Ag-specific T cells
Expressing Polyfunctional Marker Combinations
Up to this section of the results, polyfunctionality data were statistically analyzed for
CD4+ and CD8+ T cells within each sex separately for each of the estrogen or estrogen +
inhibitor treatments individually. This indicates that statistical significance was reported by
comparing the percent frequency of T cells expressing each marker combination when treated
with estrogen alone (0.5 nM or 50 nM) or in combination with each ER inhibitor or both
simultaneously to the percent frequency of T cells expressing each marker combination when
treated with 0 nM estrogen in combination with each inhibitor or both separately. In order to
statistically analyze the interaction of estrogen and estrogen receptor inhibitor treatment on the
expression of each of the combination of cytokines, a mixed-effect linear regression model was
used. The estrogen main effect, estrogen inhibitor main effect, and estrogen x estrogen inhibitor
interaction were run for every unique marker combination. An n=10 is needed for statistically
analyzing each main effect/interaction so an n=30 was achieved by analyzing Ag-specific T cells
from 15 female and 15 male donors together. Analyzing the data from male and female Agspecific T cells together has its limitations since the effect of sex in the expression of each
marker combination is not taken into account but, based on previous data, it was demonstrated
that estrogen signaling affects the polyfunctionality of male and female T cells similarly. Also,
the bulk Ag-specific T cell population was analyzed instead of analyzing CD8 + and CD4+ T cell
subset separately since during HCC immunotherapy T cells are infused into patients as a mixed
population and superior anti-tumor immune responses are achieved when both functional subsets
are found infiltrating the tumor, indicating a combined CD8+ and CD4+ T cell anti-tumor
function [352].
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IFN+IL-4+TNF+ was one of the cytokine combination that demonstrated a significant
interaction effect between estrogen and estrogen inhibitor treatments (p = 0.0002). This indicates
that the effect of estrogen treatment on IFN+IL-4+TNF+ expression varies significantly based
on each estrogen inhibitor treatment, and vice versa. Physiological and super-physiological
estrogen treatment significantly enhanced the percent frequency of cells expressing IFN+IL4+TNF+ (4.4731% and 5.1938% compared to 3.3751% in 0 nM treated T cells) (Table 3). The
percent frequency of T cells expressing IFN+IL-4+TNF+ was significantly decreased when T
cells were treated with 0.5 or 50 nM estrogen in combination of an ER inhibitor was added
(3.2479% and 2.9269%) or both ER and ER inhibitors are added (3.182% and 2.9945%)
(Table 3). On the other hand, the percent frequency of T cells expressing IFN+IL-4+TNF+
significantly increased when T cells were treated with 0.5 nM or 50 nM estrogen in combination
with an ER inhibitor (5.0915% and 5.5498%) (Table 3). This indicates that physiological and
super-physiological estrogen signaling through ER enhances the expression of IFN+IL4+TNF+, while signaling through ER significantly inhibits expression of IFN+IL-4+TNF+.
Other cytokine combinations that demonstrated a significant interaction effect between
super-physiological estrogen and estrogen inhibitor treatments (p<0.000618). This indicates that
the effect of super-physiological estrogen concentration on the expression of IFN+IL-2+IL-4+IL17a+TNF+, and IL-2+IL-4+TNF+varies significantly based on each estrogen inhibitor
treatment, and vice versa. The percent frequency of T cells expressing these marker
combinations were significantly increased when treated with physiological (0.5 nM) or superphysiological (50 nM) estrogen concentrations (Table 4). A significant decrease on the frequency
of cells expressing IFN+IL-2+IL-4+IL-17a+TNF+, and IL-2+IL-4+TNF+ was observed when T
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cells were treated with super-physiological estrogen in combination with an ER inhibitor, or
ER and ER inhibitors simultaneously when compared to those cells treated with estrogen only
(Table 4). A significant increase on the frequency of cells expressing IFN+IL-2+IL-4+IL17a+TNF+, and IL-2+IL-4+TNF+ was observed when T cells were treated with superphysiological estrogen in combination with an ER inhibitor (Table 4). Overall these result
indicate that estrogen signaling through ER enhances the expression of polyfunctional
combinations IFN+IL-2+IL-4+IL-17a+TNF+, and IL-2+IL-4+TNF+ in Ag-specific T cells
while estrogen signaling through ER inhibits the expression of these polyfunctional
combinations.
Significant interaction effect between super-physiological estrogen and estrogen inhibitor
treatments (p<0.000618) were also found for Ag-specific T cells expressing only IFN+ or
TNF+ in combination with no other marker. Percent frequency of T cells expressing only IFN+
or TNF+ were significantly decreased when treated with physiological (0.5 nM) or superphysiological (50 nM) estrogen concentrations (Table 4). A significant increase on the frequency
of cells expressing only IFN+ or TNF+ was observed when T cells were treated with superphysiological estrogen in combination with an ER inhibitor, or ER and ER inhibitors
simultaneously when compared to those cells treated with estrogen only. A significant decrease
on the frequency of cells expressing only IFN+ or TNF+ was observed when T cells were
treated with super-physiological estrogen in combination with an ER inhibitor (Table 4).
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Table 3. Estimated Effects of Estrogen and Estrogen Inhibitor Treatment on the Percent
+
+
+
Frequency of Ag-specific T Cells Expressing IFN IL-4 TNF . The 95% confidence interval
+
+
+
mean estimates for the percent frequency of Ag-specific T cells expressing IFN IL-4 TNF is
represented for each estrogen treatment (0.5, 50 nM) compared to 0 nM treatment, and for each
estrogen treatment (0.5 or 50 nM) in combination with either ER or ER inhibitors or both
simultaneously, compared to estrogen treatment in combination with no inhibitor (none).
Significant at p=0.000618.
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Table 4. Adjusted Effects of Estrogen and Estrogen Inhibitor Treatment on Unique
Cytokine Combination Expression. The 95% confidence interval mean estimates for the
+
+
+
+
+
+
percent frequency of Ag-specific T cells expressing IFN IL-2 IL-4 IL-17a TNF , IFN ,
+
+
+
+
IL-2 IL-4 TNF , and TNF is represented for each estrogen treatment (0.5, 50 nM)
compared to 0 nM treatment, and for each estrogen treatment (0.5 or 50 nM) in combination
with either ER or ER inhibitors or both simultaneously, compared to estrogen treatment in
combination with no inhibitor (none). Significant at p=0.000618.
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Overall these result indicate that estrogen signaling through ER enhances the expression of
monofunctional combinations IFN+ or TNF+ in Ag-specific T cells while estrogen signaling
through ER inhibits the expression of these monofunctional combinations.
Overall these statistical analysis indicates than in a human HCV Ag-specific population
comprised of a mixture of CD4+ and CD8+ T cells that are activated with the HCV cognate
antigen, estrogen signaling through ER significantly enhances the percentage of T cells
expressing polyfunctional phenotypes such as IFN+IL-4+TNF+, IFN+IL-2+IL-4+IL17a+TNF+, and IL-2+IL-4+TNF+ and inhibits the expression of mono-functional phenotypes
such as IFN+ or TNF+. On the other hand, estrogen signaling through ER significantly
inhibits the percentage of cells expressing polyfunctional phenotypes while enhancing the
percentage of cells expressing mono-functional phenotypes. This results demonstrate that
estrogen signaling through ER enhances the polyfunctionality of Ag-specific T cells for
immunotherapy.
Chapter Discussion
This chapter of the dissertation was aimed to determine the impact of sex and estrogen
signaling in regulating Ag-specific T cell polyfunctionality. Here it was found that female CD8 +
T cells are inherently more polyfunctional than male CD8+ T cells indicating that sex
intrinsically impacts CD8+ T cell function upon antigen stimulation. In addition, it was shown
that estrogen signaling through ER and not ER enhances male and female CD8+ and CD4+
Ag-specific T cell polyfunctionality. Overall these results report, for the first time, the impact of
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estrogen stimulation on T cell polyfunctionality, and recognize specific functional phenotypes
that are directly affected by estrogen receptor signaling in Ag-specific T cells.
T cell polyfunctionality was evaluated by measuring the expression of cytokines IFN,
TNF, IL-2, IL-4, IL-17a, and IL-22 and the lytic marker CD107a. Analysis of these factors
yielded highly complex multi-dimensional data sets that were analyzed using software packages
FlowJo, Pestle, and SPICE which allowed for graphical representation of the data and allowed to
make comparison between sexes and estrogen receptor inhibitor treatment groups. It was found
that male and female CD8+ and CD4+ Ag-specific T cells are highly diverse on their phenotypic
and functional complexity. Female CD8+ Ag-specific T cells were more polyfunctional than
male CD8+ T cells upon antigen stimulation expressing higher degrees of functional phenotypes
such as CD107a+IFN+TNF+, IFN+IL-2+TNF+, and IFN+TNF+ indicating strong type I T
cell responses. On the other hand, significantly higher percentages of male CD8 + Ag-specific T
cells expressed TNF+ compared to female T cells. This indicates that male CD8+ Ag-specific T
cells also produce strong type I effector responses but T cells are less likely to express several
markers simultaneously.
Despite the sex differences on CD8+ T cell polyfunctionality, estrogen signaling showed
equal effects modulating the polyfunctionality of male and female CD8 + and CD4+ Ag-specific T
cells. Estrogen signaling through ER significantly increased the frequency of T cells expressing
trifunctional phenotypes like CD107a+IFN+TNF+, and IFN+IL-4+TNF+ and significantly
decreased the frequency of T cells expressing bifunctional or monofunctional phenotypes
including IFN+TNF+, IFN+, and TNF+. ER signaling enhances the expression of
polyfunctional phenotypes that include effector type I cytokines that enhance the T cell anti-
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tumor immune response, the lytic marker CD107a indicating T cell degranulation, and the type II
cytokine IL-4 which promotes T cell survival and memory formation. Since polyfunctional CD8+
and CD4+ T cells were shown to generate superior anti-tumor immune responses [417, 423, 428,
433], it can be hypothesized that female CD8+ T cells can modulate stronger anti-tumor immune
responses compared to male CD8+ T cells. Based on the findings in this chapter it can also be
hypothesized that estrogen signaling through ER can modulate stronger CD8+ and CD4+ T cell
anti-tumor immune responses through enhancement of their polyfunctionality.
Estrogen signaling through ER was also shown to enhance the polyfunctionality of the
whole Ag-specific T cell population containing CD4+ and CD8+ T cells and independently of the
sex of the 30 donors tested. Physiological and super-physiological estrogen signaling through
ER enhanced the percent frequency of Ag-specific T cells expressing IFN, TNF, and IL-4
simultaneously upon activation. Surprisingly, estrogen signaling through ER significantly
inhibited the percent of Ag-specific T cells expressing this polyfunctional phenotype. Superphysiological concentrations of estrogen significantly increased the percentage of Ag-specific T
cells expressing INF+IL-2+IL-4+ and IL-17a+TNF+IL-2+IL-4+TNF+ and the superphysiological estrogen-mediated enhancement of expression was abrogated when ER was
blocked, but significantly enhanced when ER was blocked. Opposite results were obtained for
monofunctional phenotypes IFN+ and TNF+ which were significantly decreased upon estrogen
treatment, but significantly increased when physiological estrogen signaling through ER was
inhibited. On the other hand, the percent of Ag-specific T cells expressing monofunctional
phenotypes IFN+ and TNF+ was significantly decreased when ER was blocked indicating that
super-physiological estrogen signaling through ER enhances monofunctional phenotypes.
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Overall, these results indicate that estrogen signaling through ER enhances the
polyfunctionality of the bulk Ag-specific T cell population in a dose-dependent manner, while
estrogen signaling through ER inhibits the polyfunctionality of the bulk Ag-specific T cell
population. Previously, ER signaling was shown to enhance expression of specific cytokines,
IFN, TNF and IL4, through its genomic pathway. This could indicate that ER is enhancing
Ag-specific T cell polyfunctionality through modulating T cell pathways and genes that promote
polyfunctionality.
T cell polyfunctionality is induced by TCR ligation of the antigen-MHC complex
resulting in subsequent T cell activation, proliferation and cytokine production. Upon antigen
ligation the TCR gets phosphorylated by lck and the kinase ZAP70 is recruited to
phosphorylation sites. ZAP70 then activates several signaling pathways that modulate T cell
function and cytokine expression. The three major pathways activated downstream from the
TCR are the MAP kinase pathway, the NFB pathway, and the NFAT pathway [6]. NFAT and
NFB are transcription factors that translocate into the nucleus when activated by TCR
downstream signaling and modulate expression of immune genes and cytokines [6]. The MAP
kinase pathway induces the expression of the transcription factor c-Fos which together with Jun
form the dimeric transcription factor complex AP-1 [6]. AP-1 can also modulate expression of
immune genes and cytokines. While the effect of ER on TCR downstream signaling remains
unknown, there are studies confirming a relationship between estrogen signaling and activation
of the MAPK, NFAT, and NFB pathways. While the specific estrogen receptor was not
reported, estrogen signaling was shown to induce rapid activation of the MAP kinase pathway in
mammalian cells [434]. Estrogen activation of the MAPK pathway is preceded by a rapid
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increase in cytosolic Ca2+ concentration indicating that estrogen promotes Ca2+ release from the
intracellular storages [435, 436]. The estrogen-mediated increase of cytosolic Ca2+ can also
activate NFAT [437]. NFAT is activated via dephosphorylation by the Ca2+-dependent
phosphatase calcineurin [438]. This indicates that estrogen can enhance intracellular Ca2+ levels
which result on subsequent activation of the MAPK and NFAT pathways. Estrogen was also
shown to rapidly activate the NFB pathway in endothelial and breast cancer cells [439]. While
treating cells with estrogen ligand enhanced NFB signaling, ER and ER were shown to
inhibit NFB binding to DNA target sites in myocardial cells impeding NFB target gene
expression, and to enhance expression of the NFB inhibitory protein IK [440, 441]. The
controversial effect of estrogen signaling on NFB seems to be cell dependent and it cannot be
ruled out that estrogen signaling through ER enhances NFB signaling.
In addition to the evidence supporting that estrogen activates these TCR downstream
signaling pathways, EREs were found in the promoters of genes coding for important TCR
downstream signaling proteins like lck, ZAP70 and c-Fos. Lck contains an ERE at position 3451
bp of its promoter, and ZAP70 contains an ERE at position 4305 bp of its promoter, and c-Fos
contains an ERE at location -3411 of its promoter (Table 5) [442]. This indicates that
transcription of these genes could be regulated by ligand and ERE-independent ER canonical
genomic signaling. Overall, given that ER enhances T cell polyfunctionality which is induced
by TCR signaling, and knowing that estrogen signaling can enhance TCR signaling proteins
expression and activation of downstream pathways it can be hypothesized that ER enhances
human male and female Ag-specific T cell polyfunctionality by enhancing overall TCR
signaling.
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In order to exclude the possibility that ER mediated enhancement of CD8+ and CD4+
Ag-specific T cell polyfunctionality is caused by changes on monofunctional and polyfunctional
T cell survival and proliferation rather than enhancement of the TCR signaling, cell viability and
proliferation staining need to incorporated into these experiments. Survival of monofunctional
and polyfunctional Ag-specific T cells after antigen stimulation can be assessed by a viability
dye and compared between estrogen and ER inhibitor treatments. Ag-specific T cell proliferation
can be accessed via Ki67 staining and equally compared between estrogen and ER inhibitor
treatments.

Table 5. Estrogen Response Elements Found in the Promoters of LCK, ZAP70, and FOS. Table shows the human (Hs) gene
name, the chromosome location, the ERE sequence and its position in respect to the gene starting site. EREs were found in n the
EREfinder database. c-Fos ERE was previously reported by Weisz & Rosales, Nucleic Acids Res, 1990.
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CHAPTER VI
ESTROGEN ENHANCES T CELL SURVIVAL, TUMOR INFILTRATION AND ANTITUMOR FUNCTION DURING IMMUNOTHERAPY FOR HCC
Introduction and Rationale
The protective role of estrogen against HCC is widely accepted and supported by the
observation that the HCC female-biased survival is significantly reduced after menopause [311].
Post-menopausal females undergoing estrogen hormone-replacement therapy have a decreased
risk of HCC and increased survival rates compared to non-estrogen users [311]. Previous studies
demonstrated that the protective activity of estrogen against HCC is mediated through inhibition
of expression and signaling of IL-6 and inactivation of the STAT3 pathway in hepatocytes and
Kupffer cells, as well as inhibition of tumor-associated macrophages, which all result in
reduction of chronic inflammation of the liver and subsequent transformation [293, 318, 443].
The effect of estrogen on other immune cells present in the TME that impact anti-tumor immune
responses and may have critical bearings on the success of ACT immunotherapy, including T
cells, remains unclear and understudied. Since higher frequencies of infiltrating lymphocytes
including CD4+ and CD8+ T cells have been correlated with increased survival in HCC patients
[333, 334], it is important to study the role of estrogen signaling regulating the function of T
cells in the HCC TME. The previous chapters of this dissertation demonstrated that estrogen
signaling through ER enhances the expression of specific cytokines including IFN, TNF, and
IL-4, in Ag-specific T cells upon TCR ligation and estrogen signaling through ER significantly
138
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enhances the polyfunctionality, or the ability to express several functional markers
simultaneously, of human male and female Ag-specific T cells activated by their cognate
antigen. These results indicate that estrogen signaling through both ER and ER contribute to
enhancing Ag-specific T cell function in response to antigen stimulation.
ACT immunotherapy using genetically modified T cells including CAR-T cells and
TCR-transduced T cells showed some success for treating HCC in preclinical models, and in
early stage clinical trials. However, due to high fibrosis and cirrhosis, HCC tumors are hard to
penetrate physically by Ag-specific T cells [444] therefore, currently the clinical results in
treating HCC remain unsatisfactory. In addition, the HCC TME comprises immunosuppressive
stromal cells and molecules including checkpoint molecules that promote tumor growth by
exhausting T cells [444]. These data indicate that there is a high need for ways to improve the
anti-tumor function of Ag-specific T cells in order to generate more successful ACT
immunotherapy for HCC. Since estrogen has a protective role against HCC through mechanisms
involving inflammation, and can enhance cytokine production and polyfunctionality of T cells in
vitro, it was hypothesized that the protective role of estrogen against HCC is partially due to the
estrogen-mediated enhancement of the T cell anti-tumor immune response. Estrogen receptor
signaling was shown to enhance T cell activation, proliferation, and survival in models of
autoimmune disease [233], indicating that estrogen could further strengthen the efficacy of ACT
immunotherapy for HCC. In this chapter of the dissertation, the impact of estrogen signaling on
tumor growth and T cell function is assessed during ACT immunotherapy using human HCV
Ag-specific T cells to treat a HCV+HCC generated in mice.
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Results
The ideal target tumor tissue to be used for studying the role of estrogen during ACT
immunotherapy for HCC would be patient derived xenografts (PDX) from HCV +HCC HLA-A2+
patients. PDX are transplanted into immune-deficient mice which then receive ACT
immunotherapy with human HCV Ag-specific T cells, and tumor rejection can be measured as
well as T cell function. Unfortunately, HCV+HCC xenografts from HLA-A2+ patients were not
available to be used for the following experiments so a genetic HCC mouse model was used
instead. HCC can be generated in mice by forcing the expression of human oncogenes c-MET
(MET) and −catenin (CAT) in hepatocytes by sleeping beauty (SB) transposase-mediated
somatic integration [445]. SB100 is retrovirally transduced into the liver in combination with
transposon containing vectors for MET and CAT. SB recognizes and binds to inverted repeats
flanking the MET and CAT sequences, excises the sequences, and inserts them into a new
location containing a TA dinucleotide in the hepatocyte genome (Figure 26) [445]. This is a
previously described clinically relevant HCC model that relies on the co-activation of MET and
CAT which often occur in human HCC cases [371, 446, 447]. Co-delivery of both MET and
CAT simultaneously on mouse livers using the sleeping beauty transposase system induces HCC
within 40 to 60 days [372]. In order to include the HCV specific antigen in these HCC tumors
that could be recognized by human Ag-specific T cells, a pcDNAIII expression vector containing
the sequence of the full length HCV NS3 (Figure 7) [51, 358] was also delivered in combination
with MET and CAT. Using this model, HCC tumors expressing the HCV NS3 antigen were
generated. Ideally these tumors generated in mice would be treated syngeneically using mouse
HCV Ag-specific T cells. On the other hand, considering that the effects of estrogen cytokine
production and polyfunctionality were observed specifically in human T cells, it was decided to
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use human male and female HCV Ag-specific T cells to perform ACT immunotherapy for HCC
in these mice. In order to test human T cells in the mouse system, the strain of mice used were
the NSG-A2+ mice which are completely immune-deficient HLA-A2 expressing mice. NSG-A2+
mice lack functional mature B cells, T cells, NK cells and have defective DCs and macrophages,
which prevents them from targeting and depleting or “rejecting” adoptively transferred human T
cells. Furthermore, human T cells were shown to survive and be fully functional in NSG-A2+
mice [448-450], indicating this is a valid mouse model for the study of human T cell based
immunotherapy.

Figure 26. Mechanisms of Sleeping Beauty 100 (SB100)-mediated Transposition. Diagram
of SB100 transposase-mediated cut-and-paste transposition of the sequences of the oncogenes
MET and CAT into hepatocyte’s genome. A transposon, defined by the mirrored sets of red
double arrows (IR/DRs) is shown on each end of the plasmid containing the sequence of MET
and CAT oncogenes. The transposon harbors the expression cassette consisting of a promoter
(blue square) that can direct the transcription of MET and CAT. SB100 binds to the IR/DRs and
cuts the transposons out of the plasmid. A DNA molecule, in this case genomic DNA in mouse
hepatocytes, containing the TA sequence becomes the recipient of the transposed transposon. In
this process the TA sequence at the insertion site is duplicated.
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While the MET-CAT HCC tumor model was previously used to study HCC oncogenesis
and pharmacological drug design and delivery, it has never been used before to study ACT
immunotherapy. To ensure that human HCC Ag-specific T cells could recognize the HCV
antigen presented in the context of HLA-A2 in mouse HCC cells, HCV+HCC tumors generated
in NSG-A2+ mice were digested into a single cell suspension and incubated with male and
female human Ag-specific T cells. T cell activation in response to target tumor antigen was
measured via IFN release by ELISPOT. It was observed that female and male Ag-specific T
cells secreted IFN in response to HCV+HCC cells but not in response to HCV-HCC cells
generated in mice challenged with MET/CAT (Figure 27). These resulting data demonstrate that
human Ag-specific T cells can recognize HCV antigen expressing HCC tumors generated in
mice but do not respond to hepatocytes or tumor cells in the absence of the cognate Ag. The lack
of response to tumors missing HCV Ag expression rules out the possible off-antigen reactivity to
mouse tissue. Overall these results indicate that HCC Ag-specific T cells can be safely used to
treat HCC bearing mice with ACT immunotherapy.
In order to study the role of estrogen signaling in the T cell anti-tumor immune response
generated during ACT immunotherapy in vivo, physiological estrogen was removed via
ovariectomy (OVX) which consists of surgically ablating the ovaries of female mice. The ovaries
are the main source of estrogen in the body of female mice and removing them was shown to
significantly reduce the serum estrogen concentration to levels similar to those observed in male
mice [451]. Physiological estrogen serum concentration in female mice is around 30-60 pg/mL
and ovariectomy was shown to reduce this concentration to around 1.5-3 pg/mL [451, 452].
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+

Figure 27. Human HCV Ag-specific T Cells Secrete IFN in Response to HCV HCC Cells
+
+
Generated in NSG-A2 Mice. NSG-A2 mice were challenged with c-MET and -catenin
human oncogenes in combination with an expression vector for the HCV NS3 peptide to
generate HCV-expressing HCC. HCC were left to develop for 60 days and then were collected
and digested into a single cell suspension. Tumor cells were co-cultured with human male or
female HCV Ag-specific T cells at a 1:1 ratio for 18 hours, and IFN secretion was measured
via ELISPOT. A) Female and male Ag-specific T cells secreted IFN in response to HCV
expressing-HCV but not to HCV HCC. B) ELISPOT plate demonstrating IFN secretion from
three different female and three different male donors (D1, D2, D3). Data represents n=3
donors, each donor plotted and the standard error of the mean indicated. Data was analyzed
using 2-way ANOVA with Tukey’s post-hoc. No significance was observed.
These serum estrogen concentrations can be correlated to the ones found in human females
before (30-800 pg/mL) and after menopause (less than 20 pg/mL). Ovariectomy of female mice
was considered a clinically relevant model to study the effect of physiological estrogen presence
or absence during ACT for HCC. Sham surgeries omitting the ablation of the ovaries were
performed in control female and male mice to take into account possible effects of surgerymediated inflammation on all experimental groups. Before tumor challenge, mice were left to
stabilize for 3 weeks which is the minimum time reported for accumulated serum estrogen
concentration to significantly decrease after ovariectomy [453, 454].
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Estrogen Inhibits Tumor Growth during Adoptive T cell Transfer Immunotherapy
Using mice at 6-8 weeks old, treatment groups consisted of ovariectomized females,
sham females and sham males were challenged with MET and CAT oncogenes in combination
with the HCV NS3 expression vector. After tumor initiation, at day 20 or day 40 after
MET/CAT/HCV injection, sham/OVX females and sham males received ACT immunotherapy
of 107 sex-matched human HCV Ag-specific T cells via tail vein. 20 days after ACT
immunotherapy, livers were collected and analyzed for tumor presence, and T cells were isolated
from livers and spleens for analysis. All mice in these experiments received HCV Ag-specific T
cells generated from one male and one female healthy donor. Phenotypical analysis of the Agspecific T cells before adoptive transfer demonstrated similar percentage and MFI of
CD3+CD34+ in male and female T cells indicating equal anti-HCV TCR expression in both sexes
(Figure 28 A). While female Ag-specific T cells showed a 1:1 CD8+:CD4+ ratio, the male T cells
showed a 2:1 CD8+:CD4+ (Figure 28 B). The percentage of CD8+ T cells expressing intracellular
Granzyme B was approximately 70% in female T cells compared to 85% in male T cells
indicating a higher percentage of CTLs in transferred male Ag-specific T cells (Figure 28 C).
Both male and female CD4+ T cells expressed low percentages of T-BET and high percentages
of GATA3 indicating low Th1 and high Th2 CD4+ populations (Figure 28 D, E). Approximately
18% of female T cells expressed RORt compared to only 2% of male T cells indicating a higher
Th17 population in female CD4+ Ag-specific compared to male T cells (Figure 28 F).
Surprisingly a high percentage of both male and female CD4 + T cells expressed FoxP3 (50-55%)
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indicating a high Treg population (Figure 28 G). These data indicate that the Ag-specific T cells
transferred into female mice consisted of a more heavily CD4 + helper T cell population including

Figure 28. Phenotype of Human Female and Male Ag-specific T Cells Used for ACT
Immunotherapy. Flow cytometry dot plots representing the percent frequency of human
+
+
female and male T cells that were A) CD3 CD34 . B) Percent frequency of female and male
+
+
+
+
CD3 CD34 that were either in the CD8 or CD4 subset. C) Percent frequency of
+
+
+
CD3 CD34 CD8 female and male T cells expressing Granzyme B. Percent frequency of
+
+
+
CD3 CD34 CD4 T cells expressing D) T-BET, E) GATA3, F) RORt, and G) FoxP3.

high percentage of Th2 and Th17 cells, while Ag-specific T cells transferred into male mice
consisted of a more CD8+ CTL population.
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HCC tumors in mice are commonly quantified by measuring the ratio of tumor over body
weight [455]. Since mice used for these experiments were a range of ages, and male mice were
bigger than female mice, no significant differences in tumor over body weight ratios were found
between sexes or treatment groups. It is important to note that the transformed livers were three
times heavier than livers of non-challenged mice, healthy livers weighting approximately 1.5
grams and fully transformed livers weighting approximately 4 grams. Alternatively, to using the
ratio of liver tumor:body weight, the BCLC staging classification was used to compare tumor
burden between experimental groups. According to this staging method, HCC tumors are
classified into four different categories according to the number of tumors, the size of the tumors,
the presence of vascular invasion, and the spread of nodules or presence of extrahepatic
metastases [320]. According to these parameters, HCC tumors are considered stage 0 (very early
stage) when only one small nodule <2 mm is found, stage A (early stage) when between 1 and 3
small nodules are found, stage B (intermediate stage) when several nodules >3 mm are found,
stage C (advanced stage) when several large nodules are found and there is portal invasion, or
stage D (terminal stage) when several large nodules are present and there is extrahepatic spread
[319-321]. Extrahepatic spread in mice HCC models is described as presence of metastases in
the lungs, the spleen, the kidneys, and the heart [456]. HCC tumors that were left to develop for
20 days before ACT were on the very early stage (stage 0) since tumor nodes were not detected.
Only OVX females and sham males, which have minimal estrogen levels, that did not receive
ACT showed transformation of the liver and tumor node presence (Figure 29 B lower panel).
This indicates that ACT immunotherapy prevented tumor development since none of the mice
that received ACT had tumor nodules present compared to untreated mice (Figure 29 B upper
panel).
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Tumors that were left to develop for 40 days prior to ACT were in very advanced HCC
stage and resulted in an almost complete transformation of the liver (Figure 29 C). HCC tumors
were multinodular, nodules were very large, and some mice even presented tumor nodules on the
spleen which were characterized as metastases (represented on Figure 29 C), indicating that these
tumors were in the intermediate (stage B), advanced or very advanced stages (stage C and D). In
mice that did not receive ACT immunotherapy, tumor burden was greater in OVX females and
sham males compared to sham females (Figure 29 C lower panel). Tumor burden was overall
reduced in mice that received ACT indicating T cell tumor recognition and killing. Sham females
treated with ACT immunotherapy showed less tumor burden than OVX females and sham males
counterparts (Figure 29 C upper panel). These data overall support the hypothesis that estrogen
has a protective roll against HCC. The HCC tumor burden in ACT treated mice was quantified
and showed that even if tumor burden was improved with ACT immunotherapy, OVX females
had the overall worst diagnosis when compared to sham females or sham males. A significantly
greater percentage of ACT treated OVX female mice developed HCC tumors in the very advance
stage D (multinodular and spleen metastasis presence) compared to sham females (Figure 29 D).
HCC tumor burden on OVX females treated with ACT was also worse compared to sham males
showing higher percentage of mice in the very advanced stage even if significance was not
achieved. Overall, sham females that received immunotherapy showed significantly less
advanced tumor burden compared to OVX females, and trending less advanced tumor burden
compared to sham males (Figure 29 D). These results indicate that removal of endogenous
estrogen enhances HCC tumor burden and decreases ACT immunotherapy efficacy.
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Figure 29. Removal of Endogenous Estrogen via Ovariectomy Enhances HCC Tumor Burden and Reduces ACT
Immunotherapy Efficacy. A) Experimental set up. B) Representative pictures of livers of sham females, OVX females, and sham
males that were challenged with MET and CAT oncogenes in combination with an HCV antigen expression vector. Upper panels
show livers of mice that received ACT immunotherapy with sex-matched human HCV Ag-specific T cells 20 days after tumor
challenge and that were sacrificed 20 days after therapy administration. Lower panels show mice counterparts that did not receive
ACT immunotherapy. C) Representative pictures of mice that received ACT immunotherapy with sex-matched human HCV Agspecific T cells 40 days after tumor challenge and were sacrificed 20 days after therapy administration. Arrows point at tumor nodules.
Small panel shows a representative picture of a spleen metastasis (MET). D) HCC tumor burden was determined using the BCLC
staging based on the number of nodules, the percent transformation of the liver, and presence of spleen metastases in mice that
received ACT 40 days after tumor challenge compared to untreated mice. ACT day 20: n=6 sham females, n=7 OVX females, n=10
sham males. ACT day 40: n=5 sham females, n=5 OVX females, n=6 sham males. Data was analyzed with 2-way ANOVA with
Tukey’s post-hoc. p<0.05.

149

Estrogen Presence during Adoptive T cell Transfer Immunotherapy Enhances Human CD4+
Ag-specific T cell Tumor Infiltration
After assessing tumor burden, HCC tumors were digested and T cells were isolated from
whole tumors and analyzed via flow cytometry in order to determine Ag-specific T cell tumor
infiltration. T cells obtained from the tumors of each mouse were analyzed separately and no
tumors were pooled together. Even if the Ag-specific T cell numbers recovered were low they
were sufficient for analysis and for making meaningful comparisons. Significantly greater
numbers of human Ag-specific T cells were found infiltrating the livers of sham females, an
average of approximately 2000-4000 cells, compared to OVX females, an average of 1500-2000
cells, at both time points of ACT (Figure 30 B). A trend was observed indicating increased
numbers of infiltrating T cells in sham females compared to sham males but significance was not
achieved (Figure 30 B). The number of infiltrating CD8+ Ag-specific T cells was not
significantly different in early stage tumors treated with ACT immunotherapy at day 20 after
tumor challenge. On the other hand, significantly higher numbers of infiltrating CD8 + T cells
were found in advanced tumors of sham females, an average of approximately 1700 cells,
compared to OVX females and males that received ACT immunotherapy at day 40 after tumor
challenge, >500 cells (Figure 30 C). The numbers of infiltrating CD4+ Ag-specific T cells were
significantly higher in sham females compared to OVX females and males at both time points of
ACT (Figure 30 D). Overall, these data indicates that endogenous estrogen enhances tumor
infiltration of CD4+ Ag-specific T cells no matter on tumor burden, and enhances the infiltration
of CD8+ Ag-specific T cells in advanced tumors.
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Figure 30. Endogenous Estrogen Enhances Human Ag-specific T Cell Tumor Infiltration.
Human Ag-specific T cells were adoptively transferred into OVX/sham female or sham male
mice 20 or 40 days after HCC tumor challenge, and then isolated from tumors 20 days after
transfer for flow cytometric analysis. A) Representative flow cytometry dot plots containing
the gating strategy performed to analyze HCV Ag-specific T cells isolated from tumors of one
+
+
female sham, one female OVX, and one male sham mouse. Total number of B) CD3 CD34 ,
+
+
+
+
+
+
C) CD3 CD34 CD8 , or D) CD3 CD34 CD4 HCV Ag-specific T cells found infiltrating the
liver of sham females, OVX females, and sham males that were treated with ACT
immunotherapy either 20 or 40 days after tumor challenge. ACT day 20: n=6 sham females,
n=7 OVX females, n=10 sham males. ACT day 40: n=5 sham females, n=5 OVX females, n=6
sham males. Each mouse plotted and the standard error of the mean indicated. Data were
analyzed by 1way-ANOVA and Tukey’s post-hoc. p<0.001=***, p<0.01**, p<0.05=*.
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The subset distribution of CD4+ Ag-specific T cells infiltrating the tumors of OVX and
sham females was analyzed via flow cytometry staining. No significant differences were found
on expression of any of these transcription factors between sham and OVX females indicating
that endogenous estrogen does not affect CD4+ T cell subset differentiation during ACT
immunotherapy. High percent frequency of CD4+ T cells infiltrating the livers of female sham
and OVX mice expressed GATA3 and RORt compared to other transcription factors, which are
the prototypic transcription factors for the Th2 and Th17 CD4+ T cell subsets (Figure 31).

+

Figure 31. The CD4 Ag-specific T Cell Subset Distribution was not Affected by Removal
+
of Endogenous Estrogen. Human CD4 Ag-specific T cells isolated from livers of sham and
OVX female mice were intracellularly stained for the transcription factors T-BET, GATA3,
RORt, and FOXP3 which correspond to the Th1, Th2, Th17, and Treg subsets respectively. A)
Representative histograms showing the expression of T-BET, GATA3, RORt, and FOXP3 in
+
+
+
tumor infiltrating CD3 CD34 CD4 T cells from one sham female and one OVX female mouse.
+
+
+
Percent frequencies of tumor infiltrating CD3 CD34 CD4 T cells from sham females and
OVX females that received ACT immunotherapy B) 20 days or C) 40 days after HCC tumor
challenge. ACT day 20: n=6 sham females, n=7 OVX females. ACT day 40: n=5 sham females,
n=5 OV females. Each mouse plotted and the standard error of the mean indicated. Male group
+
is not included since not enough CD4 T cell numbers were present infiltrating the liver to
perform this analysis.
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Surprisingly, low frequency of CD4+ T cells, less than 10%, expressed the transcription
factor T-BET indicating low percentage of Th1 CD4 + Ag-specific T cells infiltrating the tumors
of sham and OVX mice. Low frequencies of CD4+ T cells, less than 10%, expressed FoxP3,
indicative of lack of immunosuppressive regulatory Tregs, infiltrating the tumors of sham and
OVX females (Figure 31). These results indicate that CD4+ T cells infiltrating the tumors of
female mice belonged mostly to the Th2 and Th17 subsets.
In order to demonstrate that the significant differences in CD4+ Ag-specific T cell
infiltration between sham females and sham males were not due to the differences in CD8+:CD4+
ratios observed in Ag-specific T cells populations before transfer (Figure 28), opposite sex ACT
immunotherapy was performed. Female mice received 107 male human Ag-specific T cells, and
male mice received 107 female human Ag-specific T cells on day 20 after tumor challenge. On
day 20 after ACT immunotherapy, livers were collected, and Ag-specific T cells were isolated. It
was observed that female and male mice that received opposite sex ACT had similar numbers of
CD3+CD34+ Ag-specific T cells infiltrating the tumor, approximately 2500 to 4000 TILs (Figure
32 B). The numbers of infiltrating CD8+ Ag-specific T cells were comparable in male and
females that received opposite sex ACT, m approximately 1200 TILs (Figure 32 C). On the other
hand, female mice that received male human Ag-specific T cells had significantly greater
number, around 500, of infiltrating CD4+ Ag-specific T cells compared to males, around 200,
that received human female T cells (Figure 32 C). These results indicate that females have
increased CD4+ Ag-specific T cell tumor infiltration independently of the sex of the T cell donor.
These results in combination with the ones presented in Figure 30 indicate that endogenous
estrogen enhances tumor infiltration of CD4+ T cells from male and female source.
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+

Figure 32. Endogenous Estrogen Enhances Tumor Infiltration of CD4 Ag-specific T Cells
+
Independently of the Donor’s Sex. Female and male NSG-A2 mice were challenged with
MET-CAT-HCV oncogenes and 20 days after they received ACT immunotherapy with T cells
of the opposite sex. 20 days after ACT immunotherapy, livers were collected and T cells were
analyzed via flow cytometry. A) Representative dot plots of infiltrating Ag-specific T cells from
one female (received male T cells) and one male (received female T cells) mouse. B) Total
+
+
number of CD3 CD34 Ag-specific T cells found in the liver of female and male mice. Total
+
+
+
+
+
+
number of C) CD3 CD34 CD8 or D) CD3 CD34 CD4 T cells found infiltrating the liver of
female or male mice. Data represents n=5 sham females, n=5 sham males. Each mouse plotted
and the standard error of the mean indicated. Data analyzed with Student’s t test. p<0.05=*.
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Estrogen Presence during Adoptive T cell Transfer Immunotherapy Enhances Human CD4+
Ag-specific T cell Survival
In order to determine if the overall survival of adoptively transferred cells outside of the
tumor was affected by estrogen removal, the number of circulating human T cells present in the
spleen was quantified. While no differences were observed in mice that received ACT 20 days
after tumor challenge and were bearing early stage tumors, there were significantly higher
numbers of CD3+CD34+ and CD3+CD34+CD8+ T cells in the spleens of sham female mice with
advanced stage tumors compared to OVX females and males which received ACT 40 days after
tumor challenge (Figure 33 B, C). CD3+CD34+CD4+ T cell numbers were significantly higher in
the spleens of sham female mice compared to OVX females and males at both time points of
ACT immunotherapy and independently of tumor stage (Figure 33 D). These data demonstrate
that estrogen enhances the persistence of adoptively transferred Ag-specific T cells. Estrogen
removal is deleterious for T cell survival with an even more significant impact on the survival of
the CD4+ T cell subset.
Ideally, conclusions of these experiments would be supported by data measuring the
effect of endogenous estrogen on the viability and proliferation state of tumor infiltrating and
circulating T cells in order to determine if decreased CD4+ numbers found in the tumors and
spleens of OVX females and sham males are due to increased T cell apoptosis or decreased
proliferation. To test this, HCC tumors and spleens from sham/OVX females and sham males
can be fixed and sectioned, and then stained for human CD4 + to detect the T cells in combination
with staining for fragmented DNA (a feature of apoptotic cells) by terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) [457].

Figure 33. Endogenous Estrogen Enhances Human Ag-specific T Cell Survival. Human Ag-specific T cells were adoptively
transferred into OVX/sham female or sham male mice 20 or 40 days after HCC tumor challenge, and then isolated from spleens 20 days
after transfer for flow cytometric analysis. A) Representative flow cytometry dot plots containing the gating strategy performed to
analyze HCV Ag-specific T cells isolated from spleens of one female sham, one female OVX, and one male sham mouse. Total number
+
+
+
+
+
+
+
+
of B) CD3 CD34 , C) CD3 CD34 CD8 , or D) CD3 CD34 CD4 HCV Ag-specific T cells found in the spleens of sham females, OVX
females, and sham males that were treated with ACT immunotherapy either 20 or 40 days after tumor challenge. ACT day 20: n=6 sham
females, n=7 OVX females, n=10 sham males. ACT day 40: n=5 sham females, n=5 OVX females, n=6 sham males. Each mouse plotted
and the standard error of the mean indicated. Data were analyzed by 1way-ANOVA and Tukey’s post-hoc. p<0.0001=****,
p<0.001=***, p<0.01**, p<0.05=*.
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If CD4+ T cells in OVX mice show increased TUNEL staining compared to sham females, then
estrogen inhibits CD4+ T cell apoptosis. This could happen through enhancing of expression of
anti-apoptotic genes such as Bcl-2. Lack of estrogen during ACT, removes the protective effect
of the hormone in enhancing expression of anti-apoptotic genes. If similar TUNEL staining is
found in CD4+ T cells from sham and OVX mice, then it would be concluded that removal of
endogenous estrogen would have no effect on the apoptosis of CD4+ T cells. This could be due
to CD4+ T cells dying through other mechanisms such as necrosis, or could simply be that
estrogen does not modulate CD4+ T cell survival. In this case, enhanced proliferation would be
the reason for increased CD4+ T cell numbers observed in the presence of estrogen which should
be confirmed in conjunction with proliferation staining using Ki67. If CD4+ T cells in female
sham mice show increased Ki67 staining compared to OVX mice, then it can be resolved that
estrogen enhances the proliferation of CD4+ T cells. T cell proliferation is induced through Ag
recognition and TCR activation and downstream signaling thus indicating the estrogen could be
regulating TCR downstream signaling. Based on data presented in previous chapters, estrogen
enhanced CD4+ T cell cytokine production and polyfunctionality which are downstream of the
TCR indicating that estrogen enhancing proliferation through TCR-mediated signaling is the
most likely scenario. In addition, estrogen could be enhancing signaling of pathways such as
MAP kinase which enhance T cell proliferation independently from the TCR. On the contrary, if
Ki67 staining is equally found in CD4+ T cells from both sham and OVX mice, then it would
have to be considered that estrogen may not modulate CD4+ T cell proliferation. In this case
reduced number of CD4+ T cells found in OVX mice could be due to reduced survival which
would rule out an effect of estrogen on proliferation/TCR signaling enhancement. However, it
should also remain a consideration that Ki67 staining is a single snap shot of time in the overall
156
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process and may need to be repeated at multiple time points after adoptive transfer in order to
truly determine whether proliferation occurs in the TME. If enhanced proliferation occurs in the
lymph nodes but T cells do not survive infiltration to the TME, the result of the stain may not be
able to be observed through the current measurement. If CD4+ T cells are positive for both Ki67
and TUNEL staining in the absence of estrogen, then this could be due to cells proliferating but
not surviving due to apoptosis-induced proliferation. This could indicate T cell exhaustion due to
constant Ag stimulation, and estrogen being protective against T cell exhaustion which would be
beneficial for immunotherapy.
Estrogen Enhances Tumor Infiltrating Lymphocyte Activation during Immunotherapy
Next, estrogen’s ability to modulate T cell activation of infiltrating adoptively transferred
T cells was tested. In order to measure T cell activation, Ag-specific T cells were stained for cell
surface expression of CD69 and CD25. CD69 and CD25 are activation markers which
expression is upregulated after antigen stimulation and TCR signaling activation [458]. A
significantly greater percentage of Ag-specific T cells expressing CD25 was found infiltrating
the livers of sham females compared to the estrogen depleted, OVX females at both time points
of ACT (Figure 34 B). Similarly, significantly greater frequency of Ag-specific T cells
infiltrating sham female tumors expressed CD69 than the ones infiltrating the tumors of OVX
female at both time points of ACT (Figure 34 C). Significantly greater percentage of TILs from
sham females expressed CD69 compared to TILs found in sham males (Figure 34 C). These data
demonstrate removing endogenous estrogen diminishes the activation state of TILs.
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Figure 34. Removal of Endogenous Estrogen Diminished Ag-specific T Cell Activation
State. Human Ag-specific T cells infiltrating the livers of sham females, OVX females, and
sham males were isolated and stained for CD25 and CD69 extracellular markers. A)
+
+
Representative flow cytometry dot plots of CD3 CD34 TILs expressing CD25 or CD69 from
one sham female, one OVX female, and one shame male mouse. B) Expression of CD25 in
tumor infiltrating Ag-specific T cells from sham/OVX females and sham males that received
ACT immunotherapy 20 or 40 days after tumor challenge. C) CD69 expression CD25 in tumor
infiltrating Ag-specific T cells from sham/OVX females and sham males that received ACT
immunotherapy 20 or 40 days after tumor challenge. ACT day 20: n=6 sham females, n=7 OVX
females. AdTx day 20: n=6 sham females, n=7 OVX females, n=10 sham males. ACT day 40:
n=5 sham females, n=5 OVX females, n=6 sham males. Each mouse plotted and the standard
error of the mean indicated. Data were analyzed by 1way-ANOVA and Tukey’s post-hoc.
p<0.01=**, p<0.05=*.
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Endogenous Estrogen Enhances TIL Cytotoxic and Helper Cytokine Production during
Immunotherapy
Ag-specific T cells found infiltrating the livers of HCC challenged sham/OVX females
and sham males expressed diverse levels of CD25 and CD69 indicating differential T cell
activation state and TCR signaling in response to antigen. Differences in T cell activation and
TCR signaling can result in altered T cell cytokine expression and T cell polyfunctionality in
response to antigen. It was previously demonstrated that estrogen signaling enhances the
secretion of certain cytokines including Granzyme B, IFN, TNF, and IL-4, upon T cell
activation. In order to investigate if estrogen presence during immunotherapy affects TIL
cytokine production, equal numbers of human Ag-specific TILs from sham/OVX females and
sham males were co-cultured in vitro with target T2 cells pulsed with HCV cognate Ag or
tyrosinase irrelevant peptide. Activated TILs were then stained extracellularly for CD107a (a
lytic marker indicative of Granzyme B degranulation), and intracellularly for IFN, TNF, IL-4.
As predicted, minimal numbers of Ag-specific TILs expressed any of these cytokines when cocultured with T2 cells pulsed with tyrosinase (Figure 35 A). No significant differences in the
percentage of HCV activated CD8+ Ag-specific TILs expressing IFN, TNF D107a were
found between sham females, OVX females, and sham males (Figure 35 B). Significantly greater
numbers of female sham CD8+ Ag-specific TILs expressed IL-4 in comparison to OVX female
TILs (Figure 35 B). This indicates that endogenous estrogen enhances the expression of IL-4 in
CD8+ Ag-specific TILs upon antigen stimulation. Significantly higher numbers of CD4 + TILs
from sham females expressed IFN, TNF IL-4 and CD107a compared to OVX female TILs
(Figure 35 C).

+
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Figure 35. Removal of Endogenous Estrogen Enhances Expression of Th1 and Th2 Cytokines in CD4 TILs. Isolated TILs
from livers of sham/OVX females and sham males were co-cultured with T2 cells expressing the HCV antigen for 5 hours in the
presence of protein-transport inhibitors, cytokine expression was then measured by flow cytometry staining. A) Representative
+
+
+
histograms of CD3 CD34 CD4 Ag-specific T cells from one sham and one OVX female expressing each of the cytokines after
+
+
+
stimulation with HCV cognate antigen or tyrosinase irrelevant peptide. B) Total number of CD3 CD34 CD8 human Ag-specific
TILs from sham/OVX females and sham males expressing IFN, TNF, IL-4 or CD107a that were transferred 40 days after tumor
+
+
+
challenge. C) Total number of CD3 CD34 CD4 human Ag-specific TILs from sham and OVX females expressing IFN, TNF, IL4 or Cd107a that were transferred either 40 days after tumor challenge. ACT day 40: n=5 sham females, n=5 OVX females, n=6 sham
males. Each mouse plotted and the standard error of the mean indicated. Data were analyzed by 1way-ANOVA and Tukey’s posthoc. p<0.05=*.
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This demonstrates that removing endogenous estrogen significantly reduces the expression of
cytotoxic and helper cytokines in CD4+ Ag-specific TILs activated with their cognate Ag.
Removal of Endogenous Estrogen Decreases CD4+ TIL Polyfunctionality during
Immunotherapy
To assess if polyfunctionality of adoptively transferred T cells is enhanced and/or
regulated by the presence and availability of endogenous estrogen, TILs from sham and OVX
females and sham males were activated using T2 cells as described before. Activated T cells
were then stained using fluorescent antibodies against six different intracellular cytokines
(TNF, IFN, IL-2, IL-4, IL-17a, and IL-22), and the cell surface lytic marker CD107a as
described in Chapter V. All the different 128 combinations of these markers that were expressed
simultaneously by activated TILs were calculated using tandem analysis with FlowJoX Boolean
gates, Pestle, and SPICE. Then, the percent frequencies of TILs expressing each marker
combination were added into 7 categories depending on the number of markers expressed
simultaneously, from one through seven markers. T cells were considered polyfunctional if they
expressed more than two markers simultaneously. The frequencies of cells expressing 6 and 7
markers simultaneously were under 1% so they were not depicted on the graphs in Figure 36.
Significantly higher frequency of CD8+ female TILs, regardless of the estrogen level, expressed
3 or 4 markers simultaneously compared to males (Figure 36 A). A significantly higher
frequency of male CD8+ TILs expressed two markers simultaneously compared to sham and
OVX female TILs (Figure 36 A). These data demonstrate that adoptively transferred CD8+
female T cells are inherently more polyfunctional than male T cells regardless of physiological
estrogen presence. A significantly higher frequency of CD4+ TILs from sham females expressed
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three markers simultaneously compared to OVX female TILs (Figure 36 B), demonstrating that
removal of endogenous estrogen reduces CD4+ T cell polyfunctionality.

+

+

Figure 36. Female CD8 Ag-specific TILs are More Polyfunctional than Male CD8 TILs
Independently of Estrogen, but Removal of Endogenous Estrogen Diminishes Female
+
+
+
CD4 TIL Polyfunctionality. Human CD8 and CD4 Ag-specific T cells were isolated from
HCC livers of sham females, OVX females, and sham male mice and co-cultured with T2 target
cells at a 1:1 ratio for 5 hours in the presence of protein transport inhibitors. Then, cells were
intracellularly stained for cytokines TNF, IFN, IL-2, IL-4, IL-17a, and IL-22 and the lytic
marker CD107a. Using FlowJoX Boolean combinatorial gates the % frequency of T cells
expressing every combination of these 7 markers simultaneously was generated and added into
+
+
+
7 categories. A) The percent frequency of CD3 CD34 CD8 TILs that expressed one through
five markers simultaneously when activated with their cognate antigen. B) The percent
+
+
+
frequency of CD3 CD34 CD4 TILs that expressed one through five markers simultaneously
when activated with their cognate antigen. ACT day 40: n=5 sham females, n=5 OVX females,
n=6 sham males. Each mouse plotted and the standard error of the mean indicated. Data were
analyzed by MANOVA and Tukey’s post-hoc. p<0.0001=****, p<0.001=***, p<0.01=**,
p<0.05=*.
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Analysis of all the possible marker combinations simultaneously expressed showed that
significantly higher frequencies of sham female CD4+ T cells expressed combinations including
CD107a+IFN+TNF+, IFN+IL-2+TNF+ and IFN+IL-17+TNF+ than OVX female T cells
(Figure 37). On the other hand, even if significance was not achieved, higher frequencies of
OVX female CD4+ TILs expressed combinations including IFN alone, TNF alone, or
IFN+TNF+ (Figure 37). Overall, these data demonstrate that endogenous estrogen enhances the
expression of polyfunctional phenotypes of three markers in CD4+ TILs used for
immunotherapy. In addition, removal of endogenous estrogen enhances the expression of monoand bifunctional phenotypes in CD4+ TILs found after ACT immunotherapy.
Overall, the data presented in this chapter demonstrate that estrogen removal during ACT
immunotherapy for HCC reduces Ag-specific T cell survival and tumor infiltration, impairs T
cell activation and decreases CD4+ T cell cytokine production and polyfunctionality. These
results were obtained by comparing sham female to OVX female mice. Surgically removing the
ovaries not only eliminates the main source of estrogen on the body but was also shown to
decrease progesterone and increase testosterone serum levels [459]. In order to conclude that
estrogen mediates T cell function during ACT immunotherapy, the effects of progesterone and
testosterone on T cell function need to be ruled out. In order to test this, a second set of
experiments in which estrogen is added back to OVX females during ACT immunotherapy needs
to be performed. Estrogen can be given back orally or subcutaneously via estradiol capsules to
obtain physiological estrogen concentrations in the serum of OVX females [460]. If adding back
estrogen to OVX mice via estradiol capsules enhances Ag-specific T cell tumor infiltration,
activation state, cytokine production and polyfunctionality to levels similar to those found in
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sham females, then estrogen signaling alone mediates all these aspects of T cell function. This
would indicate that estrogen can directly enhance the efficacy of ACT immunotherapy. Based on
the results obtained in the experiments testing the effects of estrogen signaling in vitro that
indicated estrogen enhances expression of T cell cytokines and polyfunctionality in response to
Ag-stimulation this is the most likely scenario. If rescuing estrogen in OVX mice does not
enhance Ag-specific T cell function to levels similar to those seen in sham female mice, then
estrogen alone does not mediate T cell function. This could indicate that the reduction in
progesterone or the increase in testosterone serum concentrations induced by ovariectomy are
detrimental for T cell tumor infiltration, activation, cytokine production, and polyfunctionality.
Progesterone was previously shown to exert immunosuppressive effects on human T cells during
pregnancy by inhibiting IFN expression [461], promoting naïve T cell differentiation into Tregs
[462], and by inhibiting Th1 differentiation [463] so it is not expected that the removal of ovaries
and subsequent decrease in serum progesterone impairs T cell function. Testosterone was also
shown to have immunosuppressive effects on T cells with humans with high testosterone levels
exhibiting lower activation-induced pro-inflammatory cytokine production [464], decreased Th1
differentiation [465], and increased IL-10 secretion by CD4+ T cells [466]. This indicates that the
increase of serum testosterone after ovariectomy could mediate the reduced T cell proliferation,
survival, cytokine production and polyfunctionality observed in OVX mice. Antagonistic effect
of testosterone and estrogen on T cell function is also a possibility that could be tested by giving
sham mice testosterone capsules with levels similar to those observed in males or OVX females,
or alternatively treating OVX mice with a testosterone blocker and comparing T cell function
during immunotherapy with sham females.
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+

Figure 37. Removal of Endogenous Estrogen Diminishes the Frequency of CD4 Ag+
+
+
+
+
+
+
specific TILs Expressing CD107a IFN TNF , IFN IL-2 TNF and IFN IL+
+
+
+
17a TNF . Human CD8 and CD4 Ag-specific T cells were isolated from HCC livers of
sham and OVX females and co-cultured with T2 target cells at a 1:1 ratio for 5 hours in the
presence of protein transport inhibitors. Then, cells were intracellularly stained for cytokines
TNF, IFN, IL-2, IL-4, IL-17a, and IL-22 and the lytic marker CD107a. Using FlowJoX
Boolean gating and the software SPICE all the possible combinations of these 7 markers
expressed simultaneously by T cells were generated. The heat map shows the mean % frequency
+
+
+
of CD3 CD34 CD4 Ag-specific TILs obtained from 5 mice that expressed each of the marker
combinations depicted on the left. ACT day 40: n=5 sham females, n=5 OVX females. Data
were analyzed by MANOVA and Tukey’s post-hoc. p<0.01=**, p<0.05=*.
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Chapter Discussion
This chapter of the dissertation was aimed to characterize the effects of sex and estrogen
on the T cell anti-tumor immune response generated during ACT immunotherapy. A forced
oncogene expression HCC model in combination with a HCV NS3 antigen expression vector
was used to generate HCV-expressing liver tumors in mice. Using this novel model, it was
demonstrated that estrogen enhances the anti-tumor function of HCV Ag-specific T cells by
increasing T cell tumor infiltration, survival, cytokine expression, and polyfunctionality. While
some of these effects were observed in both CD8+ and CD4+ T cell populations when advanced
stage tumors were present, enhanced T cell anti-tumor function was specially observed in the
CD4+ T cell subset. Removal of estrogen during ACT immunotherapy decreased CD4 + Agspecific T cells infiltration and survival, and decreased overall CD4+ T cell functions including
cytokine production and polyfunctionality. These results indicate that estrogen signaling during
ACT immunotherapy could improve the anti-tumor immune response of CD4+ male and female
Ag-specific T cells.
Using this HCV+HCC tumor model, it was first demonstrated that estrogen has a
protective role against HCC where sham female mice, which have circulating physiological
estrogen levels, showed reduced tumor burden compared to ovariectomized female and males,
which had minimal circulating estrogen. While these results do support the findings of previous
studies that estrogen has a protective effect on hepatocytes directly, more importantly, it was
found that ACT immunotherapy using HCV Ag-specific T cells reduced HCC tumor burden.
Furthermore, the differences were maintained based on the presence of physiological estrogen, in
sham females, or very low estrogen, in OVX females and males. Thus suggesting that ACT
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immunotherapy for HCC is enhanced by estrogen, and estrogen signaling should be considered
in the development and optimization of T cell based immunotherapies. ACT immunotherapy
using Ag-specific T cells was tested in mice 20 days after tumor challenge which developed
early stage tumors when not treated, and no visible tumors when treated with ACT. On the other
hand, mice that were treated with ACT immunotherapy 40 days after tumor challenge developed
very advanced HCC tumors. The effect of ACT immunotherapy on tumor burden was partial
with some of the ACT treated mice still presenting very advanced tumors. This could be due to
the highly the fibrotic and cirrhotic HCC TME which was previously shown to inhibit T cell
tumor infiltration and subsequent T cell anti-tumor responses [467]. Another possibility being
CD8+ T cells getting exhausted due to continuous antigen stimulation by HCV expression in
these large tumors.
Tumor burden in ovariectomized females was far greater than in control females and
surprisingly also greater than in males. This indicates that female adoptively transferred T cells
for immunotherapy require physiological estrogen stimulation to generate a superior anti-tumor
immune response. It was previously reported that HCC incidence and mortality significantly
increase in post-menopausal women compared to pre-menopausal women and post-menopausal
estrogen users. The results obtained in this study indicate that the increase in cancer incidence
after menopause may be partially mediated by the dampening of T cell anti-tumor immune
responses. Therefore, when designing of immunotherapies for post-menopausal women, their
lack of physiological estrogen, and consequent reduced T cell anti-tumor responses need to be
taken into account.
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Part of the mechanism of enhanced therapeutic outcome can be demonstrated by the
finding that estrogen enhanced T cell survival and T cell infiltration of HCC tumors.
Specifically, estrogen enhanced the persistence of CD4 + T cells which were found in greater
number in the spleen and infiltrating the tumors of sham females which have physiological
estrogen compared to OVX females and males. It was previously reported that CD4 + helper T
cells are critical for maintenance of CTL responses during cancer and infection [78-80]. CD4+ T
cells are not only necessary for supporting CD8+ T cell survival but it has been shown that CD4+
T cell subsets Th1 Th2 and th17 are required for successful anti-tumor immune responses [468470]. It was found that the majority of the CD4+ T cells that persisted in females were from the
Th2 and Th17 subsets ruling out immunosuppression by Tregs. The effect of estrogen signaling on
CD8+ T cells was found to be controversial since it mainly affected their survival and infiltration
when advanced tumors were present. This could indicate that estrogen signaling is especially
important for CD8+ T cells survival and function in environments where strong immune
tolerance and T cell exhaustion is being mediated by the tumor. Also, HCC tumors where shown
to produce high local estrogen concentrations indicating that super-physiological estrogen could
affect CD8+ T cells greater than physiological estrogen.
In addition to infiltration, significantly higher frequencies of TILs from estrogen
competent females expressed activation markers CD25 and CD69 than those of estrogen
depleted females or males. Expression of CD69 and CD25 is upregulated upon T cell activation
via TCR signaling, and is maintained during antigenic stimulation [471]. Estrogen signaling
through ER and ER was shown to enhance some important signaling molecules downstream
from the TCR like NFb, AP-1, and the NFAT pathways [211, 472, 473]. Up-regulation of these
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activation markers indicate that estrogen enhances TCR signaling in response to Ag stimulation
and subsequently increases the T cell activation state. Estrogen regulation of TCR signaling
components and T cell activation was previously shown in a colitis model for autoimmunity
[233], indicating that these findings not only apply to T cell function in cancer but also during
autoimmunity.
Functionally, expression of cytotoxic cytokines including IFN and TNF and the lytic
marker CD107a was increased in antigen stimulated CD4+ TILs from sham females compared to
OVX females. Expression of the Th2 cytokine IL-4 was also increased in antigen stimulated
CD4+ and CD8+ TILs from sham females compared to OVX females. While IFN, TNF are
cytokines expressed by cytotoxic and Th1 effector T cells, IL-4 is expressed mainly by T2 helper
T cells. Estrogen can enhance the expression of these cytokines which are in the two ends of the
inflammatory spectrum indicating that estrogen may be regulating the balance between
cytotoxic/effector and Th2 helper T cell responses agreeing with the results obtained in the
previous chapters in which estrogen signaling effect on Ag-specific function was investigated in
vitro.
In combination with the results from previous chapters indicating that estrogen enhances
CD4+ and CD8+ cytokine production directly as well as increases T cell polyfunctionality, results
of this chapter demonstrate similar effects directly on T cells in vivo. Specifically, estrogen
enhanced the polyfunctionality of CD4+ TILs. The frequency of CD4+ Ag-specific T cells
expressing three markers simultaneously in a polyfunctional manner was significantly higher in
estrogen intact females compared to OVX, estrogen depleted females. Three marker
combinations that were greatly expressed in CD4+ TILs in the presence of physiological estrogen
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included CD107a+IFN+TNF+, IFN+IL-17a+TNF+, and IFN+IL-2+TNF+. These
combinations include markers that are required for superior T cell anti-tumor immune responses,
indicating that estrogen enhances anti-tumor immunity during ACT immunotherapy.
Overall, the studies in this chapter demonstrate that physiological estrogen removal
during ACT immunotherapy for HCC has a detrimental effect on T cell survival and anti-tumor
function. These effects are especially observed on the CD4+ T cell subset indicating that estrogen
signaling enhances the survival, tumor infiltration and polyfunctionality of CD4 + T cells. CD4+ T
cells were previously shown to be critical for generating superior T cell anti-tumor responses,
and for enhancing the efficacy of ACT immunotherapy by supporting CTL survival, function and
by destroying tumor cells directly. The results presented demonstrate a previously unappreciated
role of estrogen signaling on CD4+ T cell function that is an avenue to enhancing infiltration,
effectiveness, and survival of adoptive transferred T cells for immunotherapy.

CHAPTER VII
OVERALL DISCUSSION AND FUTURE DIRECTIONS
Discussion
Adoptive cell transfer immunotherapy using TCR gene-modified or Ag-specific T cells is
rapidly evolving field. Several pre-clinical and clinical studies have had various levels of
efficacy using TCR transduced T cells to treat different solid tumors and hematopoietic
malignancies. Although evidence suggests the use of genetically modified Ag-specific T cells
can be effective, several challenges remain in order to improve these therapeutics. While many
studies have focused on optimizing Ag-specific T cells to overcome the immunosuppressive
TME and to enhance tumor infiltration and Ag recognition, other host factors that can affect Agspecific T cells during ACT immunotherapy remain understudied.
Evidence of this lack in research includes characterizing and an in depth understanding of
the effects of sex and sex hormone receptor signaling on Ag-specific T cell function. Sex
influences multiple aspects of adaptive immunity in humans. T cell populations and T cell subset
phenotypes vary significantly depending on sex. Females have greater CD4+ T cell counts and
higher CD4+:CD8+ ratios whereas age-matched males have higher CD8+ T cell frequencies [181184]. Females have higher numbers of activated and proliferating T cells in peripheral blood
compared to males, and transcriptional analyses demonstrates that activated female T cells
upregulate more antiviral and pro-inflammatory genes compared to T cells from males [185].
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While some of these sex-differences in T cell phenotype are genetically and
environmentally mediated, a lot of these differences heighten or decrease with puberty and
reproductive senescence indicating a sex hormone receptor involvement. Estrogen is considered
the female sex hormone and it is present at physiological concentration (0.5 nM) in females and
at low concentrations in males and post-menopausal females (<0.1 nM). Estrogen signaling was
shown to affect the differentiation, maturation, and function of T cells as described in the
introduction of this dissertation. For example, estrogen signaling was shown to enhance T cell
differentiation [203, 474], to increase the secretion of cytokines such as IL-10 and IFN ,
and to induce the expression of the Treg transcription factor FoxP3 [196]. Throughout available
scientific literature, most of the important aspects concerning the role of estrogen on T cells were
investigated in autoimmunity models and at hormone concentrations limited to physiological and
pregnancy estrogen levels. Other ranges of estrogen dosages were not investigated. Knowing that
sex and estrogen have direct effects on T cell differentiation and function, it is important to
carefully characterize their effects on Ag-specific T cells for immunotherapy in order to identify
possible mechanisms that can be targeted to enhance T cell anti-tumor immune responses and
immunotherapy efficacy.
The effects of sex and estrogen signaling on T cells and other immune cells result in
differences on pathogenesis of diseases that arise from immune cell function dysregulation, like
autoimmunity, or diseases that are heavily controlled by immune responses, like infections and
cancer. One malignancy that shows a pronounced sex-bias and is heavily affected by estrogen is
HCC. HCC is significantly more prevalent in males compared to pre-menopausal females [360,
361]. Post-menopausal females that are not undergoing estrogen HRT are also more prone to
develop HCC than pre-menopausal females and estrogen users [311]. The protective role of
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estrogen against HCC was shown to be partially mediated by estrogen receptor signaling
inhibition of IL-6-mediated chronic inflammation and tumor associated macrophage polarization
[293, 318]. While this research beautifully demonstrated the anti-HCC role of estrogen, the
impact of estrogen signaling on other HCC tumor infiltrating immune like T cells remains
unclear and needs further investigation. ACT immunotherapy using genetically modified T cells
showed some success on treating HCC in pre-clinical models and clinical trials but the efficacy
of ACT fighting HCC remains unsatisfactory. These data indicate that there is a high need for
ways to improve the anti-tumor function of Ag-specific T cells in order to generate more
successful ACT immunotherapy for HCC. The work performed in this dissertation was aimed to
characterize the role of estrogen signaling on T cell function in vitro, and during ACT
immunotherapy against HCC in vivo. In the following sections, the results obtained and their
implications for T cell biology and tumor immunology are discussed.
First, the effect of estrogen signaling was studied on the function of Ag-specific T cells in
vitro. It was observed that estrogen stimulation, especially at super-physiological concentrations,
was able to modulate Ag-specific T cell cytokine expression and secretion in response to cognate
Ag stimulation. Estrogen signaling through ER and not ER enhanced the expression and/or
secretion of TNF, IFN, and Granzyme B in Ag-specific T cells from males and females in a
dose dependent manner in response to Ag stimulation. IFN, TNF, and Granzyme B are
cytokines produced by cytotoxic CD8+ T cells and Th1 CD4+ T cells and can directly destroy
tumor cells. IFN is cytotoxic to certain malignant cells, and it enhances MHC class I expression
[406]. Granzyme B directly lyses malignant cells, and TNF promotes T cell activation, costimulation, and promotes certain cancer cell death [406]. Estrogen signaling through ER and
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not ER completely controlled the expression of IL-4 in response to Ag stimulation and, in
addition, it was shown to enhance IL-4 expression and secretion in Ag-specific T cells from
males and females in a dose dependent manner. IL-4 promotes T cell and B cell survival, induces
Ig class switch to IgE and IgG in B cells, drives long-term development of CD8+ T cell memory,
and in combination with TGF it drives Th9 T cell subset differentiation which are T cells that
augment anti-tumor responses in ACT models [387-389, 407, 408]. Overall these data
demonstrate for the first time that estrogen signaling through ER enhances the expression and
secretion of cytokines that promote stronger CD4+ and CD8+ T cell anti-tumor responses hence
estrogen signaling through ER can enhance the efficacy of ACT immunotherapy. Most
importantly, the largest effects of ER signaling enhancing cytokine expression were observed at
super-physiological estrogen concentrations which mimic the elevated estrogen concentrations in
the HCC TME. This indicates that infiltrating T cells from male and females will could be
generating stronger anti-tumor responses in response to estrogen stimulation in the TME.
EREs were found in the promoters of TNF and IFN indicating that ER ligand-bound
ERE-independent signaling could be enhancing transcription of these genes in response to
estrogen stimulation. In addition, an ERE on the promoter of T-BET, a transcription factor that
induces IFN expression, was found indicating that ER signaling could be also upregulating
transcription of T-BET. Apart from inducing IFN expression, T-BET is well known to promote
Th1 differentiation while suppressing Th2 differentiation. No ERE was found on the promoter of
IL-4 which was surprising due to the strong effects of ER signaling on IL-4 expression
observed in T cells in response to Ag stimulation. Considering IL-4 related genes, an ERE was
found on the promoter of GATA3, a transcription factor that induces IL-4 expression. This
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indicates that ER could enhance IL-4 expression by enhancing GATA3 transcription through a
ligand-bound ERE-dependent signaling. GATA3 is well known to promote Th2 differentiation.
Based on these results, estrogen signaling through ER enhances expression of prototypic Th1
and Th2 cytokines indicating that estrogen signaling does not favor differentiation towards one
subset over the other, but it most likely plays a balancing role between Th1 and Th2 T cell
responses. Estrogen signaling not only enhances expression of cytokines that generate stronger
anti-tumor immune responses and facilitate T cell survival, but it balances cytotoxic type I and
survival type II T cell responses. Type I and type II T cell responses were both shown to enhance
the anti-tumor immune response during ACT immunotherapy, especially when both CD4+ helper
Th1 and Th2 cells and cytotoxic CD8+ T cells were transferred as a mixture into patients
indicating a synergistic effect between them [82, 475]. Studies in the past have reported
contradicting evidence on the effect of estrogen on T cell cytokine production. While some
groups demonstrated an inhibitory effect of estrogen on the expression of TNF and IL-4, other
groups simultaneously reported enhancing effects of estrogen signaling on the expression of
these cytokines. The effects observed were concentration dependent, and some studies reported
that pregnancy estrogen levels (higher than physiological) induce IL-4 expression and inhibit
TNF expression, while physiological estrogen levels induce TNF and IFN expression. Based
on this evidence, it was believed that physiological estrogen signaling promotes type I T cell
responses and Th1 CD4+ T cell function while pregnancy estrogen promotes type II T cell
responses and Th2 CD4+ T cell function. The results reported in this dissertation help clarify
some of the contradicting evidence in the field and demonstrate for the first time that in the case
of human Ag-specific T cells from both sexes, the effect of estrogen is concentration and
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receptor independent and that at both physiological and super-physiological concentrations
induce Th1 and Th2 T cells responses in a dose dependent manner (Figure 38).
An attribute of genetically modified T cells that was previously correlated with enhanced
clinical outcome is their ability to express multiple functional markers simultaneously in
response to Ag stimulation, or their polyfunctionality. One clinical study in which patients with
aggressive refractory non-Hodgkin’s lymphoma were treated with CD19 CAR-T cells
demonstrated that highly polyfunctional T cells mediated stronger anti-tumor immune responses
and tumor rejection compared to those with lower polyfunctionality. Polyfunctionality of CAR-T
cells was determined immediately before CAR-T cell infusion by measuring the expression of 32
different effector, cytotoxic, helper, and chemotactic cytokines upon Ag stimulation. Cells that
expressed >2 of these markers simultaneously were considered polyfunctional. Polyfunctional
CD8+ and CD4+ CAR-T cells expressed combinations of markers including but not limited to
IFN, Granzyme B, IL-8, IL-17a, and IL-2 [428]. While T cell populations only showed
approximately 20% of polyfunctional cells, they correlated with clinical outcome significantly
more than those patients that received monofunctional CAR-T cells [428]. Polyfunctionality of
Ag-specific T cells also correlated with better disease outcome when patients were treated with
immunotherapy in combination with other cancer therapies such as chemotherapy. B cell
lymphoma challenged mice were treated with chemotherapy and then given ACT
immunotherapy with polyfunctional or monofunctional CD4+ Ag-specific T cells. Mice showed
reduced tumor burden when they were given adoptive transfer of polyfunctional Ag-specific
CD4+ T cells compared to monofunctional CD4+ T cells and compared to mice treated with
chemotherapy alone [417]. T cell polyfunctionality was also shown to correlate to clinical
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prognosis and response to immunotherapeutic interventions in solid tumors including melanoma
and breast cancer. Advanced melanoma patients that were treated with Ipilumab (anti-CTLA-4
Ab) showed better disease prognosis when polyfunctional tumor Ag-specific CD4+ and CD8+ T
cells were present infiltrating the tumor compared those patients with infiltrating monofunctional
T cells. CD4+ and CD8+ polyfunctional cells expressed combinations of markers including but
not limited to IFN, TNF, IL-2, and Granzyme B [426]. In addition, polyfunctional but not
monofunctional tumor-reactive CD8+ T cells accumulated in the peripheral lymphocyte pool of
those patients with advanced melanoma that were treated with autologous TIL immunotherapy
and showed significant tumor regression compared to non-responders [476]. These
polyfunctional CD8+ T cells persisted up to 1 year after infusion and even if they expressed PD1, they proved to be cytotoxic when re-stimulated with tumor Ag [476]. Polyfunctional CD8+
Ag-specific T cells were found infiltrating the tumors of breast cancer patients, and when
isolated, polyfunctional CD8+ TILs were shown to retain cytotoxic ability against tumor target
cells despite high PD-1 expression compared to monofunctional CD8+ TILs [477]. Overall, these
studies demonstrated that CD8+ and CD4+ Ag-specific T cell polyfunctionality not only
correlates with stronger T cell anti-tumor responses and increased tumor rejection, but also with
augmented persistence of cytotoxic T cells that can exert strong responses in response to Ag
stimulation long time after infusion. Since estrogen signaling was shown to directly enhance the
expression of several cytokines in Ag-specific T cells, it was hypothesized that estrogen
signaling increases Ag-specific T cell polyfunctionality which can result in better
immunotherapy efficacy.

Figure 38. Proposed Mechanism I: Estrogen Signaling Through ER Enhances Expression of TNF, IFN, and IL-4 and
Modulates the Balance Between Th1/Type I and Th2/Type II T Cell Responses and Differentiation. Estrogen signaling through
ER gnomically enhances the expression and secretion of Type I/Th1 cytokines IFN and TNF and the Type II/Th2 cytokine IL-4.
ER is also able to genomically enhance the expression of Th1 transcription factor T-BET and Th2 transcription factor GATA3
through the EREs on their promoters. Overall this leads to the hypothesis that estrogen signaling through ER mediates balance
between Type I and Type II, and Th1 and Th2 T cell differentiation.
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Considering these facts, the effect of estrogen signaling regulating Ag-specific T cell
polyfunctionality in response to antigen stimulation was determined by activating human male
and female HCV Ag-specific T cells with target cells expressing the HCV Ag. One of the most
striking results found in this dissertation was that estrogen signaling through ER and nor
ER enhances male and female CD8+ and CD4+ Ag-specific T cell polyfunctionality. Estrogen
signaling through ER increased the percentage of Ag-specific T cells that expressed three
markers simultaneously in response to Ag stimulation and decreased the percentage of T cells
that expressed only one marker in response to Ag stimulation. The marker combinations that
were shown to be enhanced by ER signaling when CD4+ and CD8+ T cells were analyzed
separately included CD107a+IFN+TNF+ and IFN+IL-4+TNFa+ which are combinations
including cytotoxic/effector and Th2 T cell cytokines, again known to mediate stronger antitumor immune responses and T cell survival. ER signaling reduced the percentage of T cells
expressing IFN+TNF+, and IFN+ or TNF+ in combination with no other marker. This does
not mean that expression of these markers is overall downregulated by ER, but it means that
expression of these markers in combination with other markers such as IL-4 and CD107a is
enhanced. Interestingly when the data was analyzed for the bulk Ag-specific T cell population
without dividing it into CD8+ and CD4+ subsets, additional polyfunctional marker combinations
were shown to be affected by estrogen signaling through ER and ER. Estrogen signaling
through ER was shown to increase the percentage of Ag-specific T cells expressing
polyfunctional marker combinations such as IFN+IL-4+TNFa+, IFN+IL-2+IL-4+IL-17a+TNF+,
and IL-2+IL-4+TNF+. Strikingly, inhibition of ER during estrogen stimulation enhanced the
percentage of T cells expressing these polyfunctional combinations even more than estrogen
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alone, indicating that ER signaling actually inhibits Ag-specific T cell polyfunctionality. While
these polyfunctional phenotypes were expressed by low percentage of cells, other studies
confirmed that even if there is a small percentage of polyfunctional cells in a T cell population,
stronger anti-tumor responses are still achieved compared to highly monofunctional T cell
populations [428, 433]. Estrogen signaling through ER was shown to decrease the percentage
of Ag-specific T cells expressing monofunctional marker combinations such as IFN+ and
TNF+. On the other hand, inhibition of ER during estrogen stimulation decreased the
percentage of T cells expressing these monofunctional combinations even more than estrogen
alone indicating that ER signaling actually promotes expression of monofunctional phenotypes
over polyfunctional ones. The effect of estrogen signaling on Ag-specific T cell
polyfunctionality had been never studied before and these are completely novel findings that
could help in the design of stronger immunotherapies.
T cell polyfunctionality was reported to be induced by TCR signaling and antigen
sensitivity. T cells that are stimulated with low sensitivity antigens display reduced TCR
downstream signaling activation and are less polyfunctional than those activated with high
sensitivity antigens [421, 478]. These data leaded to the hypothesis that estrogen signaling
through ER enhances TCR downstream signaling and subsequent polyfunctionality. Some TCR
downstream signaling molecules were shown to be estrogen sensitive. For example, lck, ZAP70,
and c-Fos contain EREs on their promoters indicating possible ER genomic regulation of their
expression. Also, estrogen was shown to enhance other TCR downstream pathways such as the
MAP kinase, the NFAT, and the NFB pathways [436, 437, 439]. This indicates that ER
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signaling could be enhancing TCR downstream signaling pathways which subsequently result in
polyfunctionality (Figure 39).
Another important implication of T cell polyfunctionality is that it promotes T cell
memory formation. In vaccination studies against viruses, bacteria, and parasites the
polyfunctionality of pathogen Ag-specific T cells after vaccination was not only associated with
favorable disease outcome but also with higher effector function and effector memory formation
[479-482]. Long-lasting polyfunctional memory cells are found at low frequencies in the
peripheral circulation but they can rapidly proliferate and elicit strong effector response upon
Ag-stimulation [483]. ER signaling could be promoting the development of more
polyfunctional memory Ag-specific T cells during ACT immunotherapy, indicating an
enhancement of long-lasting anti-tumor T cell responses. This is not only important to destroy
the primary tumor and possible metastatic sites but also in order to prevent relapse. The ERmediated enhancement of polyfunctional T cells could mean the generation of more long-lasting
memory Ag-specific T cells that are reactive to a specific tumor Ag and circulate the circulation
of patients surveilling for new tumor sites expressing that Ag and eliminating them. Overall, this
indicates that ER signaling could not only enhance the short-term efficacy of immunotherapy
but also enhance immunotherapy over time through the generation of highly polyfunctional
memory cells (Figure 39).
Interestingly the effect of estrogen signaling on cytokine production and
polyfunctionality was observed equally in Ag-specific T cells from male and female donors. This
indicates that estrogen signaling through ER and ER exerts the same effects on T cells no
matter on the sex of the donor. Estrogen signaling can be used as a way of enhancing ACT
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immunotherapy in both males and female patients. This is especially important for males and
post-menopausal females that have enhanced incidence rates of cancer such as HCC.
During ACT immunotherapy both cytotoxic CD8+ and CD4+ Ag-specific T cells target
tumor cells. Cytotoxic CD8+ directly lyse the tumor cells by secretion of perforin and Granzyme
B upon Ag stimulation. With the exception of Tregs which are immunosuppressive, CD4+ T cells
(Th1, Th2, and Th17 subsets) can either directly eliminate tumor cells through cytotoxic
mechanisms or indirectly by modulating other immune infiltrating cells found in the TME. For
example, CD4+ Th cells can express CD40L which interacts with CD40 on DCs and promotes
the expression of MHC and other co-stimulatory molecules [484]. Furthermore, CD4+ Th cells
can directly enhance CTL anti-tumor responses. CD4+ Th cells secrete IL-2 which is a growth
factor that enhances survival and helps recruit CTLs to the tumor site [484]. IFN production by
CD4+ Th1 cells results in the upregulation of MHC molecules on tumor cells leading to
enhanced T cell (CTL and Th) recognition [484]. In addition to being required for the generation
of optimal primary CTL responses, a number of studies have shown a critical need for CD4 + T
cells in the generation and maintenance of memory CD8 + T cells [484]. Overall these data
indicate that functional CD8+ and CD4+ T cells are required for the generation of superior antitumor responses during immunotherapy. Since estrogen signaling was showed to enhance the
function of both female and male CD8+ and CD4+ T cells, it was hypothesized that it also
enhances the CD8+ and CD4+ anti-tumor responses during immunotherapy for HCC in vivo.

Figure 39. Proposed Mechanism II: Estrogen Signaling through ER Enhances Ag-specific T Cell Polyfunctionality through
Enhancement of TCR Downstream Signaling Pathways. Estrogen signaling through ER enhances male and female Ag-specific
T cell polyfunctionality by genomically inducing the expression of TCR downstream signaling molecules like lck, ZAP70, and c-Fos
through the ERE on their promoters, and by enhancing signaling through the MAP kinase, the NFAT and the NFB pathways.
Enhancement of these pathways through ER results of the expression of polyfunctional combination of several markers
simultaneously by one T cell, which can subsequently lead to memory T cell formation.
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The role of estrogen signaling during ACT immunotherapy was then studied in vivo.
Female mice, with physiological circulating estrogen concentrations, and ovariectomized female
mice and male mice, with minimal circulating estrogen concentrations, were challenged with
HCV+HCC and given ACT with sex-matched HCV Ag-specific human T cells. First, HCC
tumor burden was assessed and, as expected, male mice showed increased tumor burden
compared to sham females. OVX females showed the most advanced tumor burden compared to
sham males and females due to loss of the protective role of estrogen against HCC. ACT
immunotherapy reduced tumor burden on sham and OVX females and males indicating
therapeutic potential. OVX females still showed very advanced tumors after ACT treatment,
indicating that loss of estrogen not only enhanced tumor burden but also decreased the T cell
anti-tumor responses generated during immunotherapy. Analysis of the phenotype of infiltrating
T cells revealed reduced tumor infiltration of Ag-specific T cells, especially CD4+ T cells, in
OVX females and males. Lack of physiological estrogen during ACT immunotherapy not only
reduced tumor infiltration but also overall CD4+ T cell survival. In addition, lack of
physiological estrogen during ACT immunotherapy hindered Ag-specific T cell activation state.
TILs isolated from sham and OVX females and sham males were then activated with target cells
expressing their cognate Ag and cytokine expression and polyfunctionality were measured.
While CD8+ T cells did not show significant differences in polyfunctionality between sham and
OVX female TILs, they showed an overall reduction on IL-4 expression in OVX females further
indicating that estrogen directly regulates IL-4 expression in Ag-specific T cells. CD4+ TILs
from OVX females showed decreased expression of IL-4, TNF, IFN, and the lytic marker
CD107a compared to sham females. Furthermore, polyfunctionality of CD4 + TILs was also
decreased in the absence of physiological estrogen with significantly lower percentages of OVX
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female TILs expressing 3 markers simultaneously compared to sham female CD4 + TILs. Overall,
these results indicated that physiological estrogen signaling during ACT immunotherapy
enhances the survival, tumor infiltration, and function of CD4+ Ag-specific T cells. Considering
the important role of CD4+ T cells both directly targeting tumor cells and enhancing CD8 + T cell
function and survival, estrogen signaling was found to be an important factor to consider into
enhancing the efficacy of ACT immunotherapy.
In summary, the results presented in this dissertation are encouraging that estrogen
signaling on Ag-specific T cells could serve as a way to enhance the efficacy of immunotherapy
for HCC. Estrogen signaling through ER was found to enhance the expression of key T cell
effector cytokines including IFN, TNF, and Granzyme B on Ag-specific T cells from male and
female donors when activated with their cognate Ag in vitro and in vivo. IFN, TNF, and
Granzyme B are required for tumor cell destruction. Estrogen signaling through ER was also
shown to completely regulate the expression of the Th2 cytokine IL-4 on male and female Agspecific T cells activated with their cognate Ag in vivo and in vitro which is not only necessary
for Th2 differentiation but promotes T cell survival and memory formation. Enhancement of
these cytokines is believed to represent the ability of ER signaling to regulate the balance
between Th1 and Th2 differentiation or type I and type II T cell responses. Estrogen signaling
through ER was shown to enhance T cell polyfunctionality on male and female Ag-specific T
cells activated with their cognate Ag. ER signaling is believed to enhance TCR downstream
signaling pathways which result on increased T cell polyfunctionality (Figure 40). Notably
estrogen effects on T cell cytokine production were observed at physiological and superphysiological concentrations in a dose dependent manner. Using an in vivo model for HCC, it
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was found that physiological estrogen not only has a protective role against HCC, but it also
enhances ACT immunotherapy. Estrogen presence during ACT immunotherapy for HCC was
found to increase the tumor infiltration, survival, activation state, cytokine production and
polyfunctionality of Ag-specific T cells. These effects were especially observed on the CD4 + T
cell subset. Reduction of CD4+ T cell survival, cytokine expression, and polyfunctionality in the
absence of physiological estrogen reduces ACT immunotherapy efficacy by not only lacking
proper CD4+ anti-tumor responses but also by the lack of support to the CD8+ subset anti-tumor
responses. Overall these results showed that estrogen signaling at physiological and superphysiological concentrations can enhance the function of male and female CD8+ and CD4+ Agspecific T cells. This regulation of T cell function is especially important during immunotherapy
in vivo, where physiological estrogen enhanced survival, tumor infiltration, and function of CD4 +
Ag-specific T cells which result on enhanced immunotherapy efficacy through the support of
CD8+ anti-tumor responses. In conclusion, estrogen signaling on Ag-specific T cells could
enhance the efficacy of ACT immunotherapy to treat cancer in male and female patients.
Future Directions
The questions posed, results observed, and findings drawn from the data generated in this
dissertation are novel and unique and provide critical information that will open the doors to new
advancements in clinical outcomes as well as new research endeavors in the field of
immunotherapy. The focus of this study was to characterize and mechanistically understand the
biology of sex and estrogen signaling on Ag-specific T cell activation, function and survival in
the context of cancer treatment.

Figure 40. Overall Proposed Mechanism: Estrogen Signaling through ER and ER Enhances Ag-specific T Cell Function
Resulting in the Enhancement of ACT Immunotherapy Efficacy. Estrogen signaling though ER results in the enhancement of
expression of key Type I/Th1 and Type II/Th2 cytokines and estrogen signaling through ER results in the enhancement of male and
female Ag-specific T cell polyfunctionality. Physiological estrogen enhances the survival, tumor infiltration, activation, and function
+
of CD4 Ag-specific T cells in vivo which results in stronger anti-tumor immune responses during ACT immunotherapy.
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My data, as presented, clearly demonstrates that although T cells are intrinsically different due to
sex, meaning T cells from male donors are intrinsically different from T cells isolated from
female donors, estrogen signaling has a profound effect on the function of T cells from both
males and female donors. Therefore, it can be concluded that estrogen signaling mediates similar
effects on the function of T cells independently of sex. Estrogen signaling occurs upon ligation
of its nuclear receptors, ER and ER and results in enhanced function of Ag-specific T cells
that can be used for immunotherapy in vitro and in vivo. These are very encouraging findings
that indicate estrogen signaling can be used as a mean of enhancing ACT immunotherapy for
both male and female cancer patients. In this dissertation, human Ag-specific T cells were
acutely treated with estrogen (2-hour treatment) which elicited an enhancement of T cell
cytokine production and polyfunctionality, especially at super-physiological concentrations.
According to these findings, genetically modified T cells from cancer patients used for ACT
immunotherapy can be assessed for function in response to Ag stimulation, and if patients’ T
cells do not express and produce important cytokines for anti-tumor function including but not
limited to, IFN, TNF, or Granzyme B, then they can be acutely treated with superphysiological estrogen concentrations prior to infusion. This estrogen treatment will enhance the
effector functions through ER ligation, and the polyfunctionality, specifically the combined
simultaneous production of anti-tumor effector and helper molecules, of T cells through
ER ligation which will result in generating stronger and more durable anti-tumor immune
responses once transferred into the patient.
Since adoptively transferred T cells will be circulating in the patients for long periods of
time, it is possible that an acute estrogen treatment will not be enough to maintain enhanced T
cell function in the long run. Because T cells benefit from estrogen presence for longer time
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periods, estrogen could be added to patient’s T cells cultures during the in vitro Ag-specific T
cell expansion performed prior to adoptive cell transfer. This approach could be first tested in
mice, where HCV Ag-specific T cells are given physiological or super-physiological estrogen
during the 3 to 5-day expansion performed prior to ACT immunotherapy. The effect of these
prolonged treatments would need to be tested on T cell subset distribution and function. Based
on the results obtained in this dissertation, prolonged estrogen treatment could affect the CD4+ T
cell subset distribution skewing it towards the Th1 and Th2 subsets. On the other hand, profound
differences in T cell function are expected after prolonged estrogen stimulation including
enhanced cytokine production and polyfunctionality. Long-term high concentration estrogen
exposure was shown to downregulate the expression of ER and ER both mRNA and protein
levels in breast cancer cells and non-reproductive estrogen target tissues [485-487]. This
estrogen-regulated feedback loop directly inhibits the transcription of the ERs through ligandbound ER genomic signaling. The suppressive effects of estrogen on ER expression were
observed after 6 hour estrogen stimulation and remained for 24 to 48 hours [485]. Decreased
expression of ERs on Ag-specific T cells would mean loss of the beneficial ER signaling
mediated enhancement of T cell cytokine production and polyfunctionality. Overall, indicating
that acute estrogen treatment of Ag-specific T cells would be a better approach than long-term
estrogen exposure.
The work of this dissertation also determined the different roles of ER compared to
ER signaling on T cell function. While ER enhanced the expression and secretion of specific
cytokines, one of the most intriguing discoveries of this study indicated that ER increases the
overall T cell polyfunctionality through mechanisms believed to enhance TCR downstream
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signaling. Knowing that ER signaling results in enhanced T cell function and polyfunctionality
which can result in enhanced T cell memory formation, ER signaling can be used to generate
polyfunctional and long-lasting Ag-specific T cell responses. In order to enhance ER signaling,
Ag-specific T cells could be treated with an ER-specific agonist prior to adoptive transfer. In
addition, the ER-specific agonist could be delivered intra-tumorally during ACT
immunotherapy to enhance the function of infiltrating Ag-specific T cells. Delivering the ER
agonist into the TME would not only affect T cells but also tumor cells and other infiltrating
immune cells. In the context of HCC, estrogen signaling was shown to inhibit tumor growth and
TAM polarization which means that delivering an ER agonist may exert anti-tumor functions as
well as inducing stronger T cell anti-tumor immune responses. While this would work when
tested in NSG-A2+ mice deficient of other infiltrating immune cells, the role of ER signaling on
the function of other immune cells in the TME including B cells, MDCSs, and DCs is unknown
and would need to be further investigated. In order to limit the beneficial effect of ER signaling
to T cells, human Ag-specific T cells can be genetically modified to overexpress ER. ER
overexpression would ensure estrogen ligand binding to and activation of ER signaling over
other estrogen receptors, including ER and GPER, present in the T cells. Enhanced ER
signaling in T cells would increase polyfunctionality, production of several anti-tumor cytokines
simultaneously by T cells, and increased T cell memory formation hence enhancing the efficacy
of ACT immunotherapy. This would be especially important for malignancies such as HCC
which can produce high concentrations of local estrogen, or malignancies located on sexual
tissues like the ovaries or the breasts.

191

In addition to providing ways to enhancing immunotherapy to treat cancer, the results
obtained in this study can enhance the treatment of other diseases such as infections and auto
immune diseases. Treatment of infections using ACT immunotherapy showed some success in
pre-clinical and clinical studies treating viral infections to which vaccines do not exist, or that
exhibit drug resistance including HIV, CMV, and Epstein-Barr virus (EBV) infections [488490]. In spite of some success, ACT immunotherapy for viral infections was sometimes rendered
unsuccessful due to large viral loads which were not able to be completely eliminated by
transferred T cells due to T cell exhaustion under to continuous Ag stimulation, and by reduced
transgenic T cell proliferation leading to reduced T cell numbers [491]. Interestingly, ACT
immunotherapy for HIV infected patients using cytotoxic CD8+ T cells was shown to require
production of high amount of Granzyme B [492], and the presence of functional helper CD4+ T
cells [493, 494]. The results of this dissertation showed that both the secretion of Granzyme B by
CD8+ Ag-specific T cells, and the persistence and anti-tumor function of CD4+ T cells were
enhanced by estrogen signaling. This indicates that ACT immunotherapy for HIV could be
enhanced by estrogen signaling enhancing the function of CD4 + and CD8+ T cells.
CD4+ T cell subsets were shown to be able to mediate several aspects of autoimmune
inflammation. While Th1 and Th17 cells drive the chronic autoimmune response, Tregs were
shown to exert immunosuppressive functions in other T cell functions during autoimmunity
[495]. In some autoimmune diseases such as RA it was shown that Tregs function is severely
impaired [495]. The results presented in this dissertation indicated that estrogen enhances T cell
function including pro-inflammatory cytokine production and polyfunctionality. Based on these
findings, removal of estrogen or inhibition of ER and ER signaling on T cells may relieve the
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pathogenesis of autoimmunity. The use of ER and ER antagonists separately and
simultaneously during autoimmunity in mouse models may reduce the secretion and expression
on pro-inflammatory cytokines and reduce the differentiation of activated T cells towards the
Th1 and Th2 subsets.
In summary, the findings of this dissertation demonstrate that estrogen signaling is an
important factor to consider in the design and optimization of T cell-based immunotherapies for
cancer and infections. In addition, characterizing the role of estrogen signaling on T cell function
may have far reaching importance in terms of regulating T cells during autoimmune disease or
even as a result of chronic inflammation due to Ag stimulation. The results in this dissertation
have provided a new foundation in which to augment T cell-based therapy efficacy for several
cancers and other further diseases.
Clinical Trial Design
The studies performed in this dissertation revealed that physiological (0.5 nM) and superphysiological (50 nM) estrogen signaling through ER enhances the expression and secretion of
specific Type 1/Th1 cytotoxic effector T cell cytokines such as IFN and Granzyme B, as well as
Type 2/Th2 helper T cell, cytokines including TNF and IL-4, on HCV Ag-specific T cells from
male and female donors. It was also shown that estrogen signaling through ER at both
physiological and super-physiological concentrations enhanced overall T cell polyfunctionality,
or the ability of HCV Ag-specific T cells from male and female donors to express more than two
functional markers upon Ag stimulation. In vivo, it was shown that physiological estrogen
enhances the infiltration, survival, activations state, cytokine expression, and polyfunctionality of
Ag-specific TILs, especially of the CD4+ subset, after ACT immunotherapy against HCC.
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Overall, these data indicate that estrogen signaling could improve the efficacy of ACT
immunotherapy against HCC by enhancing the anti-tumor function, tumor infiltration, and
survival of adoptively transferred Ag-specific T cells. Since the in vivo studies performed in
humanized mice were proven to be successful, and tumor reduction was greatly achieved in
females containing physiological estrogen (SHAM females) compare to estrogen-depleted
females (OVX females) and males in a safe manner, a clinical trial can be designed to evaluate if
estrogen could enhance Ag-specific T cell function and reduce tumor burden during ACT
immunotherapy for patients suffering from HCC.
For this clinical trial, HLA-A2+ pre-menopausal (containing physiological estrogen) and
post-menopausal (estrogen-depleted) women and age-matched men suffering from chronic HCV
infection-derived HCC will be recruited. Circulating T cells from these patients will be collected
from blood samples and transduced with the 1406 HCV TCR as described before and sorted to
obtain a > 99% pure transduced T cell population. Then, Ag-specific T cells will be expanded in
vitro using irradiated Ag-presenting cells expressing the HCV cognate Ag. Before transfer, Agspecific T cells from pre- and post-menopausal women and men will be treated with either no
estrogen, physiological (0.5 nM), or super-physiological (50 nM) estrogen overnight. According
to the data obtained in the pre-clinical studies, short-term estrogen treatment was enough to
enhance Ag-specific T cell function including cytokine expression and polyfunctionality upon
Ag stimulation. Acute estrogen treatment will also prevent the estrogen-mediated selfdownregulation of expression of ER and ER observed after long-term estrogen exposure [485487]. Patients from each respective group will be receive local liver stereotactic radiation therapy
to a total dose of 50 Gy in four 12.5 Gy fractions to control tumor burden before immunotherapy
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and to enhance tumor Ag presentation [496], then they will receive one dose of 10x106 Agspecific T cells/kg treated with either no estrogen, physiological, or super-physiological estrogen.
After adoptive transfer, patients will receive low-dose rhIL-2 (30 g/m2) every five days to
ensure Ag-specific T cell survival [497]. Tumor burden will be monitored via liver ultrasound
and serum concentration of -fetoprotein (AFP) [498]. Tumor burden will be compared on
patients from each respective group that received Ag-specific T cells treated with estrogen
compared to untreated T cells. Blood samples will be collected periodically to observe the
phenotype and counts of Ag-specific T cells remaining on the patients’ circulation. Number of
remaining CD4+ and CD8+ Ag-specific T cells and their phenotype (Type I/II, Tregs, Th1/2/17/22)
will be measured, their activation state will be assessed via flow cytometry by staining for
activation markers (CD25, CD69, CD44, and CD62L), and their function will be measured upon
Ag re-stimulation ex vivo to observe if Ag-specific T cells are under exhaustion conditions. Also,
over 3 months after ACT, survivor patients will be tested for Ag-specific T cell memory
formation by collecting blood samples and surveilling for T cell central memory markers
(CD45RO+CCR7-CD28-CD27-) as well as their ability to elicit effector responses upon HCV Ag
re-stimulation. Since estrogen signaling through ER enhances T cell polyfunctionality, which is
correlated with T cell memory formation [476], greater number of central memory T cells are
expected to be found in pre-menopausal women and post-menopausal women and men whose T
cells were estrogen treated.
According to the pre-clinical data previously observed, men and post-menopausal women
that receive untreated Ag-specific T cells will have the worse tumor burden compared to premenopausal women. Tumor burden will decrease in men and post- and pre-menopausal women
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that receive estrogen treated Ag-specific T cells in a dose dependent manner comparing
physiological to super-physiological estrogen treated T cells. Ag-specific T cells from premenopausal women will show enhanced survival, especially those in the Th1 and Th2 CD4+
subsets, as well as enhanced cytokine expression and polyfunctionality compared to those from
post-menopausal women and men. Survival and infiltration of Ag-specific T cells should
increase in a dose dependent manner with estrogen treatment in all three patient groups. If
possible, a liver biopsy will be collected after ACT immunotherapy in order to analyze the
phenotype and function of TILs (including activation state, subset differentiation, and infiltration
level), which it is predicted to be better in the presence of physiological estrogen (premenopausal women), and in patients that received estrogen-treated T cells.
If estrogen treated T cells elicit enhance anti-tumor responses and significantly reduce
tumor burden more than untreated T cells, a second clinical trial will be performed in order to
determine if signaling through ER, ER, or both receptors simultaneously is necessary for the
estrogen-mediated enhancement of the Ag-specific T cell anti-tumor immune response. In that
case, HLA-A2+ pre- and post-menopausal women and age-matched males suffering from HCVderived HCC will receive ACT immunotherapy of Ag-specific T cells that were treated with an
ER-specific agonist (PPT), and ER-specific agonist (DNP), or both simultaneously overnight
at a concentration of 100 nM. Then, treated Ag-specific T cells will be infused into the patients
of each group as described before, and tumor burden, T cell survival, phenotype, and function
will be assessed. Since it was shown that estrogen signaling through ER enhances overall Agspecific T cell polyfunctionality, it can be predicted that patients that receive Ag-specific T cells
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treated with an ER agonist will show enhanced anti-tumor immune responses and reduced
tumor burden compared to those patients that received ER agonist-treated T cells.
These clinical studies will help determine if estrogen signaling can be used to enhance the
efficacy of ACT immunotherapy. This is especially important because it will show that shortterm estrogen or ER-specific agonist treatment of Ag-specific T cells and not the whole patient,
which is safe and easy to achieve, can alone increase the T cell anti-tumor immune response. In
the case of men and post-menopausal women which show the highest incidence rates for HCC,
estrogen treatment of the Ag-specific T cells will offer a simple yet effective way to enhance a
cancer treatment that while has shown promising results, it is still inefficient in removing large
solid tumors.
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